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respiratory support, utilization of a protocol-driven respiratory management, and 
more. This book includes a chapter on noninvasive respiratory function monitoring 
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Preface
Respiratory management of the newborn is a broad field in which we are convinced it is
hard to be efficiently covered in a single book; therefore, we did not intend to cover the basic
knowledge and the day-to-day routine management of infants with respiratory distress.
Readers can easily find such information in various sources. The scope of this book is to
focus on a few specific areas of respiratory management that are often challenging. For ex‐
ample, it covers ventilator management of infants with unusually severe bronchopulmonary
dysplasia and infants with omphalocele. The book also provides an overview on new trends
in the management of fetal and transitioning lungs in infants delivered prematurely, posi‐
tioning of endotracheal tube in extremely low birth weight infants, noninvasive respiratory
support, and utilization of a strategy stems on protocol-driven respiratory management.
Neonatal resuscitation is a cornerstone skill for healthcare providers in the field of neonatol‐
ogy. The interest to ensure efficacious resuscitation and to monitor physiologic parameters
of neonates during chest compression cannot be overemphasized. This book includes a
chapter on noninvasive respiratory function monitoring during chest compression analyz‐
ing the efficacy and quality of chest compression and exhaled carbon dioxide.
Lastly, the relationship between ventilator-related lung injury and brain development is an
area of recent interest; we like to use the term “lung-brain axis,” and we believe there is a
wealth of knowledge yet to be discovered in this area of management. This book includes a
chapter on neonatal encephalopathy treated with hypothermia along with mechanical venti‐
lation. The interaction of cooling with respiration and the strategies to optimize oxygenation
and ventilation in asphyxiated newborns are discussed. This book brings new information
in a simplified structure that allows readers to enjoy as they learn. We thank contributing
authors for their valuable time and expertise that made this book possible.
Hany Aly, MD, FAAP
The George Washington University and the Children’s National Medical Center
Washington, DC, USA
Hesham Abdel-Hady, MD
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Abstract
Chest compression (CC) is an infrequent event (0.08%) in newborns delivered at near-
term and term gestation, and occurs at a higher frequency (10%) in preterm deliver‐
ies.  In  addition,  outcome  studies  of  deliveries  requiring  resuscitation  or  chest
compression have reported high rates of mortality and neurodevelopmental impair‐
ment in surviving children. A respiratory function monitor (RFM) can help guide a
resuscitator during cardiopulmonary resuscitation (CPR) in a neonate and help assess
the quality and efficacy of  chest  compression.  Utilizing a non-invasive respiratory
function  monitor  during  chest  compression  may  decrease  high  mortality  rates  in
addition to having many distinct advantages, which will benefit both the newborn and
the resuscitators. There are several different ways that a respiratory function monitor
can  assist  a  resuscitator  during  chest  compression;  these  include  confirming  and
ensuring  adequate  lung  ventilation,  analyzing  the  efficacy  and  quality  of  chest
compression and exhaled CO2 monitoring.
Keywords: infants, newborn, delivery room, neonatal resuscitation, chest compres‐
sion
1. Introduction
Fortunately, the need for chest compression (CC) or medications in the delivery room is rare.
Only about 0.1% of term infants receive these interventions, resulting in approximately 1 million
newborn deaths annually worldwide. In addition, chest compression or medications is more
frequent in the preterm population (~15%) due to birth asphyxia [1, 2]. Fortunately, the majority
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
of newborn infants successfully make the transition from fetal to neonatal life without any help
[3]. An estimated 10% of newborns need help to establish effective ventilation (e.g., positive
pressure ventilation, PPV), which remains the most critical step of neonatal resuscitation [3].
However, clinicians struggle to deliver an adequate tidal volume (VT) [4]. In addition, mask
positive pressure ventilation is often impaired by either mask leak or airway obstruction [5].
Manikin studies have further demonstrated that initiation of chest compression increases mask
leak and therefore impedes effective ventilation [6, 7]. It is imperative to give optimal ventila‐
tion during chest compression to maximize efficacy [8]. Recently, a respiratory function monitor
(RFM) has been described to be support the clinical team during simulated [9, 10] and real-
time neonatal resuscitation [11–14]. This chapter discusses how an RFM can aid during neonatal
resuscitation.
2. Respiratory function monitor
2.1. VT, gas flow, airway pressure, and exhaled CO2 monitor
Gas flow, VT, airway pressure, and exhaled CO2 (ECO2) can be measured by any respiratory
function monitor using a flow sensor placed between a ventilation device and facemask or
endotracheal tube [11, 14]. Inspiratory and expiratory tidal volume passing through the sensor
can be calculated by any flow sensor (e.g., fixed orifice pneumotach or a hot wire anemometer)
by integrating the flow signal [11, 14]. Airway pressure is measured by directly connecting a
line to the circuit, which displays peak inflation pressure and positive end expiratory pressure.
Any respiratory function monitor continuously displays waves (e.g., pressure, flow, and tidal
volume) and numerical values (e.g., airway pressure, tidal volume, and respiratory rate) [11,
14]. In addition, the percentage of mask leak or around a tracheal tube is calculated and
displayed. ECO2 is measured using a non-dispersive infrared absorption technique. According
to manufacturers, the accuracy for gas flow is ±0.125 L/min and for ECO2 is ±2 mmHg.
3. Mask leak
Mask ventilation studies in the delivery room have reported variable mask leak during positive
pressure ventilation [4], which can be significantly decreased if mask leak is displayed on an
RFM [13]. Using a manikin, Binder-Heschl et al. reported that mask leak significantly increased
from 15% during positive pressure ventilation to 32% after chest compression was started [6].
This is further supported by a study by Solevåg et al. who reported that tidal volume delivery
is significantly decreased using continuous chest compression with non-synchronized
ventilation compared to the current 3:1 cardiopulmonary resuscitation (CPR) [7]. However,
when a resuscitation used an RFM to asses mask leak, it was significantly reduced [6].
Unfortunately, the data in newborn infants are sparse and limited to a case report by Li et al.
[12]. During chest compression, mask leak was 100% and did not result in an increase in heart
rate, suggesting that adequate tidal volume was not delivered (Figure 1) [12].
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Figure 1. As CC is initiated in an extremely preterm infant, the traces indicate large mask leak. This results in ineffec‐
tive ventilation and no VT delivered, which could lead to failure of achieving ROSC.
4. Tidal volume
The purpose of inflations during chest compression is to deliver an adequate tidal volume to
facilitate gas exchange [3]. A manikin study reported that tidal volume increases once chest
compression was started compared to mask ventilation alone [7]. Interestingly, a further
manikin study examined different auditory prompts during simulated neonatal
cardiopulmonary resuscitation and reported higher tidal volumes in all groups compared to
baseline [15]. These studies suggest a change in tidal volume once chest compressions are
initiated. An increase or decrease in tidal volume could cause lung derecruitment, which could
hamper oxygenation and therefore return of spontaneous circulation (ROSV) [12]. In a porcine
model of neonatal resuscitation, Li et al. recently described that using the current
recommendation of 3:1 chest compression to ventilation ratio (Figure 2) [3], lung derecruitment
occurs [8]. The study further compared continuous chest compressions with asynchronous
ventilations and found similar results [8], however, when chest compression superimposed
by sustained inflation (CC + SI) (Figure 3) [16] improved tidal volume delivery and continuous
lung recruitment was observed, potentially leading to better alveolar oxygen delivery and lung
aeration.
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Figure 2. VT (mL/kg) changes during 3:1 chest compression:ventilation ratio (3:1 C:V) (A), continuous chest compres‐
sions and asynchronous ventilations (CCaV) (B), and continuous chest compressions superimposed by sustained infla‐
tions (CC + SI) (C). #p < 0.05 exhaled CO2 (ECO2) compared with CC + SI [8] (with permission).
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Figure 3. CC superimposed by sustained inflation; adequate lung ventilation and VT delivery are displayed: (i) ade‐
quate gas flow towards and away from the infant; (ii) average VT of 4 mL/kg is delivered without leak.
5. Exhaled carbon dioxide (ECO2)
There is increasing evidence that continuous monitoring of exhaled carbon dioxide (ECO2) can
predict rise of heart rate during neonatal transition [17], monitor lung aeration at birth [11, 18–
20], and predict return of spontaneous circulation during neonatal cardiopulmonary
resuscitation (Figure 4) [21]. Blank et al. used a Pedi-Cap during mask positive pressure
ventilation and reported a significant increase in heart rate once the Pedi-Cap turned yellow
[17]. Similar results have been described in animal models and a further delivery room study
[18]. During neonatal cardiopulmonary resuscitation ECO2 is a reliable parameter to examine
return of spontaneous circulation. Chalak et al. reported that an ECO2 of 14 mmHg was the
most reliable indicator for return of spontaneous circulation with 92% sensitivity and 81%
specificity [21]. This study suggests that monitoring ECO2 during cardiopulmonary
resuscitation would allow uninterrupted chest compression and potentially could be an
indirect indicator of the CC effectiveness. This has been further supported by a recent animal
study by Li et al., suggesting that either ECO2, rate of elimination of CO2 (VCO2) or partial
pressure of exhaled (PeCO2) could be used to monitor the return of spontaneous circulation
[12]. A recent case report of neonatal cardiopulmonary resuscitation in an extremely preterm
infant supports this hypothesis where a significant increase in ECO2 preceded an increase in
heart rate and return of spontaneous circulation [12]. ECO2 monitoring is a non-invasive tool
Respiratory Function During Chest Compressions
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that can be used to predict the return of spontaneous circulation during cardiopulmonary
resuscitation.
Figure 4. Increasing ECO2 values suggesting imminent ROSC.
5.1. Partial pressure of exhaled (PeCO2) and rate of elimination of CO2 (VCO2)
A recent animal study described VCO2 and PECO2 values as a clinical indicator during chest
compression to achieve the return of spontaneous circulation. VCO2, or the volume of expired
CO2, reflects changes in both ventilation and perfusion, and therefore ventilation/perfusion
(V/Q) matching [22]. Palme-Kilander et al. reported that low VCO2 values could be due to
residual lung fluid, very low tone, or deficient perfusion of the lungs [23]. A recent study in
preterm infants reported that higher VCO2 levels were associated with lung aeration and
successful establishment of functional residual capacity [19]. During chest compression,
increasing VCO2 values reflects adequate ventilation, perfusion, and lung aeration [22]. Thus,
VCO2 potentially provides valuable information during neonatal resuscitation.
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PeCO2 is a continuous, non-invasive measurement. Since the physiological dead space/tidal
volume (VD/VT) ratio is never zero, PeCO2 is always lower than the ETCO2 [22]. During
resuscitation, there is poor ventilation to perfusion matching, and therefore dead space/tidal
volume increases, independent of whether mismatching is either due to impaired perfusion,
impaired ventilation, or a mixture of impaired perfusion and ventilation, causing lower
PeCO2 [22]. Therefore, PeCO2 is decreased under all conditions of impaired ventilation/
perfusion. In the case of ventilation mismatch, PeCO2 is dilute relative to ETCO2, and the
PeCO2/ETCO2 ratio is reduced. In the case of reduced or maldistributed pulmonary blood flow
without airway defects, both PeCO2 and ETCO2 would be reduced, resulting in a near normal
PeCO2/ETCO2 ratio. A recent animal study described PeCO2 for the first time in the neonatal
population. Newborn piglets who successfully achieved return of spontaneous circulation had
significantly higher PeCO2 levels in the latter portion of cardiopulmonary resuscitation,
indicating sufficient gas exchange was occurring [22]. Low levels of PeCO2 can only be
attributed to poor or low quality of ventilation during cardiopulmonary resuscitation, while
decreased levels of both PeCO2 and ETCO2 may signify inadequate pulmonary perfusion due
to poor circulation [22]. These findings suggest that monitoring PeCO2 and ETCO2 continu‐
ously during cardiopulmonary resuscitation, the clinical team would be able to determine
changes in ventilation or perfusion and adjust ventilation to improve either.
6. Conclusion
Using a respiratory function monitor to assess mask leak and tidal volume delivery during
neonatal cardiopulmonary resuscitation can help improve mask ventilation. In addition, using





CC+SI  continuous chest compressions with sustained inflations
ECO2  exhaled carbon dioxide
PPV   positive pressure ventilation
ROSC  return of spontaneous circulation
VT    tidal volume
VD/VT  physiological dead space/tidal volume
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Abstract
Respiratory distress syndrome (RDS) is a disorder caused by a deficiency of surface-
active agent called pulmonary surfactant, in the pulmonary alveoli. This deficiency
leads the alveoli to collapse, impeding air entry, gas exchange, and oxygenation in
newborns.  Conventional  treatment  involves  exogenous  surfactant  administration,
ventilation, and hydroelectrolytic management.
However, there are alternative treatments to prevent RDS that can be administered to
pregnant  women  (steroids,  thyrotropin-releasing  hormone,  and  ambroxol)  or  to
newborns  in  their  first  few  hours  of  life  (continuous  positive  airway  pressure,
prophylactic surfactant in single or multiple doses, and digoxin). These approaches
may be effective and cost less than conventional treatment. Conventional treatment
requires trained medical personnel to attend to the newborn, ventilation, tempera‐
ture control, and electrolytic and nutritional support, which can cost up to USD 14,226
per event.
This chapter seeks to analyze the effectiveness of each of these alternative treatments
in preventing RDS in preterm newborns, so that it can be applied in communities with
limited resources.
Keywords: ambroxol, respiratory distress syndrome, antenatal steroids, preterm
birth, alternative therapies
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1. Introduction
The lungs are composed of different structures. The alveoli are the functional units of the lungs
that allow oxygen gas (O2) from the environment to be exchanged for carbon dioxide (CO2)
from the bloodstream.
In order for this process to take place, contact between the air-filled alveoli and the capillaries
of the lung is essential. However, certain conditions can affect this process by preventing air
from entering the alveoli, diminishing blood flow in pulmonary capillaries, or impeding
alveolus-capillary contact, which hampers gas exchange and leads to decreased O2 and
increased CO2 levels in the blood [1].
Alveoli comprise (a) type I pneumocytes, cells that provide shape and support and (b) type II
pneumocytes, cells responsible for producing the surface-active agent called pulmonary
surfactant. A surfactant is a substance made up of phospholipids (80%), proteins (12%), and
neutral lipids (8%). Surfactants decrease the surface tension inside the alveoli. When there is
insufficient surfactant, the alveoli collapse, preventing air entry and gas exchange. This is
accompanied by a decrease in O2 in the tissues and a gradual increase in respiratory effort,
leading to this disorder being known as respiratory distress syndrome (RDS) [1–3].
This disorder affects up to 30% of premature newborns (<37 weeks of gestation) and accounts
for 9.3–12% of hospital admissions to neonatal intensive care units [4–6]. Some studies have
reported that the following factors are linked to the development of RDS: birth by cesarean
section, gestational diabetes, meconium aspiration, and neonatal asphyxia [7].
Conventional treatment, which has been shown to reduce mortality rates by up to 18%,
involves the exogenous administration of natural or synthetic surfactant at a dose of 100
mg/kg, up to 2–3 times, once RDS is diagnosed. The treatment also involves the use of
mechanical ventilation, temperature control in an incubator, and electrolytic and nutritional
support. However, this treatment has multiple adverse effects, such as pneumothorax,
bronchopulmonary dysplasia, and retinopathy secondary to ventilation support and the
continuous administration of supplemental oxygen over prolonged periods, malnutrition, and
infections [2, 8].
As a consequence, many researchers have studied alternatives to prevent the development of
RDS and reduce the frequency of these complications.
2. Alternative treatments for the prevention of RDS
The following are some treatments designed to prevent the development of RDS in newborns.
2.1. Early administration of surfactant
Numerous studies have reported that the administration of surfactant in the first few hours of
life prior to the development of RDS reduces the mortality rate of preterm newborns. In 2012,
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Bahadue and Soll carried out a systematic review of six clinical trials involving 3577 preterm
newborns and analyzed the effectiveness of administering surfactant in the first 2 hours of life.
The authors found a significant reduction in the risk of death [RR 0.84 (0.74–0.95)] compared
to delayed selective surfactant administration with neonates with established RDS [9]
(Figure 1).
Figure 1. Early vs delayed administration of surfactant (risk of death).
Bahadue also analyzed adverse effects in patients that received early administration of
surfactant and reported that there was a decrease in the risk of developing chronic lung disease
[RR 0.69 (0.55–0.86)], pneumothorax [RR 0.69 (0.59–0.82)], pulmonary interstitial emphysema
[RR 0.60 (0.41–0.89)], and bronchopulmonary dysplasia [RR 0.94 (0.88–1.00)] [9] (Figures 2–5).
Figure 2. Early vs delayed selective surfactant treatment (chronic lung disease).
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Figure 3. Early vs delayed selective surfactant treatment (pneumothorax).
Figure 4. Early vs delayed selective surfactant treatment (pulmonary interstitial emphysema).
Figure 5. Early vs delayed selective surfactant treatment (bronchopulmonary dysplasia).
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2.2. Administration of multiple doses of surfactant
Some researchers have carried out clinical trials to determine the effectiveness of administering
multiple doses of surfactant to newborns to prevent RDS or reduce its complications. In 2009,
Soll and Ozek carried out a systematic review to investigate whether this alternative treatment
could decrease the risk of RDS and complications in preterm newborns. Only three clinical
trials could be included in the review, but the authors concluded from these that there was a
decrease in the risk of developing pneumothorax for neonates that received up to a maximum
of four doses of surfactant spaced 6–12 hours apart compared to those who received single
doses [RR 0.51 (0.30–0.88)]. There was a non-significant decrease in the risk of death for
newborns who received multiple doses of surfactant [RR 0.63 (0.39–1.02)]. They concluded that
the ability to give multiple doses of surfactant to infants with ongoing respiratory insufficiency
leads to improved clinical outcome and appears to be the most effective treatment policy
(Figures 6 and 7) [10].
Figure 6. Multiple vs single doses of pulmonary treatment (pneumothorax).
Figure 7. Multiple vs single doses of pulmonary surfactant (mortality).
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2.3. Early application of continuous positive airway pressure (CPAP)
CPAP is an alternative treatment for newborns with RDS that involves the application of a
type of respiratory support that applies air at low pressure in a continuous manner to keep
the airway open. This treatment increases functional residual capacity and oxygenation with
fewer secondary effects [11].
It has been observed that this type of respiratory support carries a lower risk of secondary
complications such as barotrauma, pneumothorax, and pulmonary emphysema, among
others. Recent studies of CPAP application in premature neonates in the first few minutes of
life have shown that the risk of death is lower [RR 0.68 (0.5–1.92)] than for neonates who receive
conventional ventilation. It has also been reported that the early application of CPAP in
patients who developed RDS and received conventional treatment reduced the duration of
mechanical ventilation (25 vs. 28 days) [12].
These findings were confirmed in a systematic review by Bahadue, who reported that the early
application of CPAP and the selective administration of surfactants in preterm neonates
reduced the risk of death compared to newborns who received only prophylactic surfactant
[RR 0.84 (0.74–0.95)] [9].
To study long-term outcomes, Vaucher and colleagues carried out a follow-up assessment at
22 months of 1310 neonates that had been treated with CPAP to prevent RDS and found a
decrease in the frequency of neurological and respiratory problems compared to patients
treated with conventional therapy involving mechanical ventilation [RR 0.93 (0.78–1.10)] [13],
similar findings were observed in the prospective study performed by Stevens and colleagues
in 918 infants; those who received CPAP had fewer episodes of wheezing, respiratory illnesses,
and visits to emergency room for breathing problems compared to infants who received
conventional therapy [28.9% vs. 36.5%, 47.7% vs. 55.2%, and 68% vs. 72.9% (p < 0.05), respec‐
tively] [14].
On the basis of these results, the American Academy of Pediatrics recommends the early use
of CPAP in conjunction with surfactant administration as an alternative to prevent RDS in
preterm newborns [15].
2.4. Administration of digoxin
In 1955, Lendrum suggested that cardiac insufficiency secondary to pulmonary edema was a
predisposing factor for RDS. Several clinical trials were carried out to determine whether the
administration of digoxin in the first few hours of life would improve heart contractility and
reduce the risk of developing RDS [16, 17].
As part of a systematic review in 2011, Soll and Ozek analyzed the efficacy of digoxin appli‐
cation in preventing RDS at doses of 0.01–0.06 mg/kg every 12 hours in 212 preterm newborns.
They found that, despite improvements to cardiac insufficiency, there was no significant
reduction in mortality compared to newborns who did not receive digoxin [RR 1.27 (0.78–
2.07)]. The authors concluded that although hemodynamic disturbances play a role in the
overall pathogenesis of RDS, the specific contribution of early congestive heart failure does
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not appear to be significant factor in RDS, and the treatment with digoxin has no proven value
in infants solely affected with RDS [18] (Figure 8).
Figure 8. Digoxin vs placebo for preventing or treating respiratory distress syndrome (mortality).
2.5. Administration of thyrotropin-releasing hormone and antenatal steroids
In 1972, Liggins and Howie demonstrated that the administration of steroids (betamethasone)
to pregnant women at risk of giving birth prematurely reduced the risk of their newborns
developing RDS [RR 0.69 (0.59–0.73)] because the steroid passes through the placenta, reaches
the fetal pulmonary alveoli, and stimulates the production of surfactant by type II pneumo‐
cytes. However, the use of this treatment did not become commonplace until 1987. It has since
reduced the rate of neonatal mortality and is the preventive therapy of choice for obstetricians
[19, 20].
Later, Liggins found that the administration of thyrotropin-releasing hormone (TRH) in
combination with antenatal steroids increased the production of phospholipids and the
distension of fetal sheep’ lungs [19]. In 2013, Crowther carried out a systematic review
analyzing 4600 pregnant women who were administered TRH and steroids prior to delivery.
However, no significant differences were observed in terms of reducing the risk of death for
premature newborns [RR 1.05 (0.86–1.27)] (Figure 9) or prevention of RDS compared to
neonates born to women who received antenatal betamethasone therapy [RR 1.05 (0.91–1.22)]
(Figure 10). However, it was observed that the administration of the combination of TRH and
antenatal steroids did significantly increase the risk of adverse effects such as nausea, vomiting,
and headaches [RR 3.92 (3.13–4.92), RR 2.35 (1.35–4.09), and RR 1.73 (1.36–2.22), respectively]
(Figures 11–13) [21].
Figure 9. Thyrotropin-releasing hormone + steroids vs steroids alone for RDS (mortality).
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Figure 10. Thyrotropin-releasing hormone + steroids vs steroids alone for respiratory distress syndrome.
Figure 11. Thyrotropin-releasing hormone + steroids vs steroids alone for RDS (nausea).
Figure 12. Thyrotropin-releasing hormone + steroids vs steroids alone for RDS (vomiting).
Figure 13. Thyrotropin-releasing hormone + steroids vs steroids alone for RDS (headaches).
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2.6. Administration of magnesium sulfate
The administration of magnesium sulfate to pregnant women is used by obstetricians to inhibit
labor and birth before 37 weeks of gestation by altering the union and distribution of calcium
in the muscle fibers of the uterus, thus reducing the frequency of contractions [22].
In 2015, McNamara carried out a systematic review to analyze the efficacy and safety of
magnesium sulfate (4 g loading dose and 2–5 g/h via infusion) administered to 360 pregnant
women at less than 37 weeks of gestation to inhibit preterm labor. McNamara observed that
this treatment reduces the risk of developing RDS [RR 0.31 (0.11–0.88)] and decreases the time
that neonates spend in intensive care [MD −3.10 (0–5.48 to −0.72 days)]. However, there is too
little evidence available to recommend the regular use of this treatment (Figures 14 and 15) [23].
Figure 14. Magnesium sulfate for respiratory distress syndrome.
Figure 15. Magnesium sulfate for RDS (days of stay neonatal intensive care unit).
2.7. Administration of ambroxol
Ambroxol is a metabolite derived from bromhexine that increases the movement of cilia in the
cells of the respiratory tract, facilitating the transport of mucus in the airway and inhibiting
the activity of lysosomal phospholipase, the enzyme responsible for the degradation of
pulmonary surfactant [24].
Laoag-Fernandez and Seifart carried out several clinical studies to analyze the effectiveness of
ambroxol as an alternative treatment in the prevention of RDS because it allows easily reaching
the fetus through placental circulation. These studies allowed Gonzalez to carry out a system‐
atic review in 2014 [25].
The systematic review included 14 clinical trials analyzing 1047 pregnant women at risk of
preterm birth who were administered a daily 1 g dose of ambroxol for a week.
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The results of the review showed a reduction in the risk of neonates developing RDS compared
to treatments in which women were administered antenatal steroids (betamethasone) or a
placebo [RR 0.79 (0.59–1.07) and RR 0.74 (0.46–1.20), respectively] (Figures 16 and 17) [25].
Figure 16. Ambroxol vs betamethasone for respiratory distress syndrome.
Figure 17. Ambroxol vs placebo or no treatment for respiratory distress syndrome.
3. Conclusions
We can see that although there are multiple alternative treatment options to prevent preterm
newborns from developing RDS, their effectiveness has not yet been proven (with the
exception of prenatal steroid administration) with evidence that is strong enough due to a lack
of studies with larger numbers of participants and sound methodology. Nevertheless, it is
possible that these might be viable treatments in communities that do not have the financial
resources or the medical care required to attend to these patients. Conventional treatments
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require trained medical personnel who can attend deliveries and care for premature neonates
in hospital units that have the necessary infrastructure as well as mechanical ventilators,
temperature control systems, antibiotics for infection control, and intravenous solutions to
maintain nutritional and hydroelectrolytic homeostasis.
In 2014, Martínez-Valverde and colleagues carried out a study to estimate the costs of provid‐
ing care to newborns with RDS in public hospitals in Mexico and found that, on average, the
cost per patient per event can reach USD 14,226, without accounting for the cost of treating
secondary conditions [26].
Undoubtedly, more studies need to be carried out to strengthen the evidence supporting the
use of these alternative treatments. However, they could be a sustainable option in commun‐
ities with limited financial resources because they are more readily available and have fewer
adverse effects and lower costs than conventional treatment.
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Abstract
Despite advances in neonatal care,  infants with omphalocele have a mortality rate
ranging between 5% and 25%. Respiratory insufficiency is a common clinical chal‐
lenge  and  an  independent  predictor  of  mortality  in  these  infants.  The  causes  of
respiratory failure are diverse and are not well understood. This chapter discusses the
unique aspects of respiratory management in omphalocele infants. The authors have
chosen references in this chapter with appropriate sample size, variable comparisons,
regression analyses, and documented median follow-up times. Omphalocele is rare;
therefore, the case reports of chapter references have important information.
Omphalocele infants are sometimes born with inadequate lung volume to support
survival. Prenatal predictors of pulmonary hypoplasia are discussed in the context of
fetal magnetic resonance imaging (MRI) and postnatal clinical-radiologic correlation
studies.  Two recent retrospective articles explain the unique aspects of pulmonary
hypertension in omphalocele infants and distinguish it from pulmonary hypoplasia.
The avoidance of abdominal compartment syndrome at the time of omphalocele closure
is discussed. Clinical strategies that improve the respiratory care of these infants, based
on Specific definitions and diagnoses, may reduce the high mortality rate.
Keywords: respiratory insufficiency, pulmonary hypoplasia, pulmonary hyperten‐
sion, abdominal compartment syndrome, extracorporeal membrane oxygenator, de‐
layed repair
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1. Introduction
Omphalocele is a congenital ventral defect of the umbilical ring with herniation of the
abdominal viscera. The reported incidence is 1 in 6000 live births [1]. If omphalocele is
diagnosed in the first trimester, over 30% of fetuses die in utero [2, 3]. Despite advances in
neonatal care, for live-born infants, the mortality rate remains between 5% and 25% [4].
Postnatal management includes protection of the herniated viscera, prevention of hypother‐
mia, gastric decompression, and maintenance of cardiopulmonary stability [5].
Respiratory insufficiency at birth is reported as an independent predictor of mortality for
infants with omphalocele, but the causes are diverse [1]. Respiratory insufficiency in neonates
is generally defined as hypoxemia in room air with progressive respiratory and metabolic
acidosis and the need for mechanical ventilation within 24 hours of birth [1].
In this chapter, giant and nongiant omphaloceles are compared, as giant omphalocele infants
have a more complex postnatal course and more respiratory difficulties.
Prenatal predictors of postnatal respiratory failure and unique clinical care strategies are
discussed. Pulmonary hypoplasia is defined. Historically, fetuses and infants with omphalo‐
cele are reported to have markedly reduced chest capacities. Recently, fetal magnetic resonance
imaging (MRI) has expanded the understanding of decreased congenital lung volume in
infants with omphaloceles. Clinical-radiologic correlation studies support the use of prenatal
MRI to predict the degree of respiratory insufficiency observed in the postnatal period.
The contribution of major anomalies to respiratory difficulties is discussed.
Infants with omphalocele may have increased pulmonary vascular reactivity and pulmonary
hypertension that increases the postnatal mortality risk. In this chapter, pulmonary hypoplasia
and pulmonary hypertension are defined as distinct entities. The chapter emphasizes that the
two diagnoses must be distinguished from each other in the clinical setting. Each has different
clinical implications and care strategies.
The implications of congenital heart defects in omphalocele infants are explained. The roles
and goals of assisted ventilation for respiratory insufficiency in omphalocele infants are
expanded.
Since 2011, a small number of infants with omphalocele and respiratory insufficiency have
required the extra-corporeal membrane oxygenator (ECMO) for respiratory failure. This
chapter provides the first review of the Extra-corporeal Life Support Organization (ELSO, Ann
Arbor, MI, USA) database for the causes of respiratory failure and outcomes in omphalocele
infants place on ECMO.
The timing of surgical repair and postoperative complications, such as compartment syn‐
drome, delayed surgical closure techniques, and the implications of a ruptured omphalocele,
are explained.
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Pulmonary function abnormalities, chronic lung disease, the role of tracheostomy, the
influence of gastroesophageal reflux disease (GERD), prematurity, and strategies to improve
outcomes, are discussed.
2. Giant omphalocele
Giant omphalocele represents an important subset of omphalocele infants. Giant omphalocele
is defined as an omphalocele defect containing greater than 75% liver in the sac, and/or a
diameter greater than 5 cm [4, 6]. A nongiant omphalocele is generally defined as a defect with
diameter less than 5 cm. Previous definitions that measured the defect in centimeters do not
account for the differences in size and gestational age of infants.
The definition that giant omphalocele is a defect that contains greater than 75% liver in the sac
is preferable and uniform [4]. Giant omphalocele is associated with poor prognosis in many
studies. Giant omphalocele is often associated with a greater incidence of respiratory insuffi‐
ciency, longer ventilator requirements, and an increased incidence of pulmonary hypoplasia
and pulmonary hypertension [6, 7].
Infants with giant omphaloceles have significantly more neonatal morbidity. When large and
small omphaloceles are compared, the median length of stay (47 vs. 10 days), median age at
full enteral feeds (23 vs. 5 days), median duration of mechanical ventilation (23 vs.7 days), and
requirement of supplemental oxygen at 30 days of life (88% vs. 27%) are significantly longer
for infants with giant omphaloceles [7].
Respiratory failure is the major cause of mortality in infants with giant omphaloceles [8]. In
the neonatal period, these infants have significantly more pulmonary hypoplasia and pulmo‐
nary hypertension and therefore, more respiratory difficulties [4, 7, 9]. Lung preservation
ventilation strategies are emphasized in infants with giant omphaloceles. The overall in-
hospital mortality for infants with giant omphaloceles approaches 20% [6].
After the neonatal period, giant omphalocele infants have more chronic lung disease and
gastroesophageal reflux. In contrast, small omphaloceles generally have a good prognosis
when they are not associated with lethal malformations or congenital syndromes [5].
Most minor defects are closed primarily. Because of the preponderance for respiratory
insufficiency in infants with giant omphaloceles, however, there is more controversy regarding
closure techniques.
Infants with giant omphaloceles have suboptimal neurodevelopmental outcomes. Their
difficult early course frequently includes hypoxia, acidosis, hypotension during delivery, a
long duration of mechanical ventilation, infection, and prolonged hospitalization. These
factors all compound and play a role in determining neurologic outcomes.
Giant omphalocele survivors tend to have more significant neurodevelopmental delay than
children with other congenital anomalies such as congenital diaphragmatic hernia or congen‐
ital heart defects. They appear similar in their neurocognitive outcomes to preterm newborns
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that develop severe bronchopulmonary dysplasia. This further emphasizes the importance of
optimal respiratory management and an understanding of the goals of assisted ventilation for
infants with giant omphaloceles [6].
3. Pulmonary hypoplasia and the role of fetal magnetic resonance
imaging
Lung hypoplasia is defined as insufficient development of pulmonary airways, alveoli, and
vessels [10]. Historically, plain chest radiographs of omphalocele infants revealed a narrow
thorax and curved ribs. Measures of chest width and lung area were significantly smaller in
giant omphalocele infants. Such abnormalities of lung growth may be the result of a defor‐
mation sequence in utero. The liver is displaced in giant omphaloceles and so does not mold
the thoracic cage [11–13].
Subsequently, prenatal ultrasound was used to calculate observed/expected lung volumes for
fetuses. Two-dimensional ultrasound measured the lung-to-thorax ratio and predicted
pulmonary hypoplasia. However, some report the assessment as inaccurate [14]. Three-
dimensional ultrasound has improved sensitivity in normal amniotic fluid volume but not
oligohydramnios [15, 16].
Presently, fetal magnetic resonance imaging studies have established a curve of normal fetal
lung volume values plotted against gestational age [17]. The measured fetal lung volume is
divided by the expected mean fetal lung volume for a given gestational age or fetal body
volume to obtain the observed/expected total fetal lung volume (O/E-TFLV) ratio [17].
Accurate measurement of fetal lung volume has important clinical applications. Fetal magnetic
resonance imaging has shown that lung volumes are only 50% of the predicted values in some
prematurely born omphalocele infants with large defects. Such infants have lower Apgar
scores and require prolonged ventilator support [18].
When infants with congenital lung malformations (CLMs), congenital diaphragmatic hernias
(CDHs), or omphaloceles and an O/E-TFLV of 40% to 60% are compared, the need for ECMO,
the use of supplemental oxygen at 30 days of life, and the 6-month mortality are similar among








Length of intubation, days
median (IQR)
9.0 (7–17) 0 (0–6)* 0 (0–1.3)* <0.001
Length of hospital stay, days
median (IQR)
29.0 (22–55) 30.5 (15–47) 8.0 (3–20)*# 0.009
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11/27 (40.7%) 0/13 (0%)* 0/16 (0%)* 0.001
Treatment of pulmonary HTN
n (%)
7/27 (25.9%) 0/13 (0%) 0/16 (0%)* 0.014
iNO utilization
n (%)
4/27 (14.8%) 0/13 (0%) 0/16 (0%) 0.099
ECMO
n (%)
1/27 (3.7%) 0/13 (0%) 0/16 (0%) 0.579
Supplemental oxygen at 30 DOL
n (%)
7/27 (25.9%) 3/13 (23.1%) 1/16 (6.3%) 0.274
Mortality at 6 months
n (%)
0/27 (0%) 1/13 (7.7%) 0/16 (0%) 0.234
IQR: interquartile range; HTN: hypertension; iNO: inhaled nitric oxide; ECMO: extra-corporeal membrane
oxygenation; supplemental O2 at 30 DOL: supplemental oxygen at 30 days of life
*p < 0.05 vs. CDH.
#p < 0.05 vs. OM.
Table 1. Outcomes of congenital diaphragmatic hernia (CDH), omphalocele (OM), and congenital lung malformation
(CLM) in infants with fetal lung volumes between 40% and 60% of predicted values [19].
In fetuses with CLM, an O/E-TFLV of less than 75% after 26 weeks predicts a difficult postnatal
course that includes increased respiratory distress, a need for intubation, and lung mass
excision [20].
Infants with CDH generally have O/E-TFLV measurements ranging from less than 25% to 45%.
They require more pulmonary support than omphalocele and congenital lung malformation
infants. Clinical-radiologic correlation studies support the use of prenatal MRI to predict the
perinatal and postnatal courses in neonates with CDH. The measurements have also been used
to guide the fetal therapy with improved postnatal results. Ratios less than 35% are associated
with an increased use of ECMO and a higher mortality [21].
A series of infants with giant omphaloceles compare those with less than 50% to infants with
greater than 50% O/E-TFLV at 26 to 31 weeks gestational age. Infants with less than 50% O/E-
TFLV have significantly lower Apgar scores at birth, prolonged ventilation, and a longer
hospitalization. MRI-based O/E-TFLV of less than 50% is considered predictive of increased
postnatal morbidity in giant omphalocele infants [18].
A precise quantification of compromised fetal lung development in omphalocele infants may
improve perinatal and postnatal management. Fetal magnetic resonance imaging after 26
weeks gestational age and calculation of the O/E-TFLV is recommended.
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Similar to CDH and CLM, this calculation reflects pulmonary hypoplasia and allows clinicians
to prepare for increased respiratory distress, a need for intubation after birth, and chronic
ventilator support. Similar to CDH, further studies may prove that it prognosticates for ECMO
use and for mortality. Detailed prenatal counseling and realistic expectations can be provided.
For infants that do not survive, lung-volume-to-body-weight ratios have been established for
term and preterm infants [10]. Assessment of lung growth is a critical component of perinatal
autopsy. One single series review reports lung biopsy or autopsy pathologic diagnosis of
pulmonary hypoplasia or pulmonary hypertension in five omphalocele cases but does not
expand on the precise histology details [7].
Fetal magnetic resonance lung volume curves and pathologic lung-volume-to-body-weight
ratios for gestational age exist, but clinical-pathologic correlation studies are needed to further
characterize pulmonary hypoplasia in infants with omphaloceles.
4. The contribution of major anomalies
Infants with major anomalies and omphaloceles have a longer duration of mechanical
ventilation, hospital stay and a need for oxygen at 30 days of life. In a single-institution series
of 82 live-born infants, 26% had chromosomal and 30% had major associated anomalies. None
of the 19 live-born infants with an isolated defect died. Mortality, however, was 41% and 17%
for those with major and minor anomalies, respectively [22].
The presence of associated anomalies is a strong predictor of morbidity and mortality, and
anomalies are also linked to respiratory status [5, 16, 23].
Beckwith-Wiedemann syndrome is characterized by omphalocele, macroglossia, macrosomia,
hypoglycemia, and embryonic tumors. It is a growth disorder due to dysregulation of the
growth regulatory gene on chromosome 11p15 [23]. The presence of hypoglycemia in the
perinatal period should alert the clinician to the possibility of Beckwith-Wiedemann syn‐
drome.
The finding of omphalocele on a prenatal ultrasound should prompt a search for associated
anomalies and possible further prenatal testing. In a large prenatal study of 445 fetuses with
omphalocele, diagnosed in the first trimester, only 55 were live born. Over 85% died in utero
due to the presence of fatal chromosomal anomalies [2, 3].
The presence of omphalocele indicates an increased risk of aneuploidy. In a recent first
trimester study, fetuses with an omphalocele were found to carry a chromosomal abnormality
in 55% of cases [16]. The most frequent abnormal karyotypes in omphalocele infants are
Trisomy 18 and 13 [24]. Both have almost 100% incidence of congenital heart defects, including
ventricular septal defect, atrial septal defect, and double outlet right ventricle. Infants with
omphaloceles, in the setting of Trisomy 13 or 18 and a congenital heart defect, tend to have
severe hemodynamic compromise.
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In the setting of omphalocele and major anomalies, the cardiopulmonary support provided
by the clinician is intensified [25].
Congenital diaphragmatic hernia is sporadically reported in conjunction with an omphalocele.
Careful review of fetal MRI of the diaphragm may identify congenital diaphragmatic hernia.
Conflicting reports exist, but generally pulmonary hypertension is profound and the outcome
is poor [7, 26]. Elevated hemidiaphragms, diaphragmatic eventration, and congenital dia‐
phragmatic hernia have been described in infants with giant omphaloceles, and could
contribute to impaired lung development and postnatal distress [8, 11, 27].
5. Pulmonary hypertension
Previously, nonspecific respiratory insufficiency at birth was reported as an independent
predictor of mortality for infants with omphaloceles. Older reports do not distinguish between
pulmonary hypertension and pulmonary hypoplasia in their contribution to ventilation
difficulties.
Pulmonary hypertension is now established as an independent predictor of mortality in infants
with omphaloceles [28]. One recent series found that mortality was highest for live-born infants
with omphaloceles diagnosed with pulmonary hypertension (45%), considerably higher than
mortality in a cohort of infants with omphaloceles alone (18%) [29]. The contribution of
pulmonary hypertension to respiratory insufficiency was previously unappreciated [28].
Pulmonary hypertension is diagnosed using echocardiography performed after the second
day of life. Changes in the transitional circulation on the first day of life preclude evaluation
for pulmonary hypertension by echocardiography. Directionality of flow through the ductus
arteriosus is not considered in the diagnosis of pulmonary hypertension on the first day of life.
Pulmonary hypertension is defined on echocardiography as flattening of the interventricular
septum during systole and/or a tricuspid regurgitant jet (TR) with an estimated right ventric‐
ular pressure greater than 40 mmHg when observed in the setting of hypoxemia [28, 30].
Qualitative measures of right-sided stress, as determined by the cardiologist interpreting the
study, contribute to the assessment. These are right ventricular dilation, right atrial enlarge‐
ment, right ventricular hypertrophy, septal flattening, and pulmonary artery dilation [28, 30,
31].
The incidence of pulmonary hypertension is reported in 37 to 55% of infants with giant
omphaloceles. It is more prevalent in infants with additional anomalies [28, 31]. The explana‐
tion, whether structural, oxygen tension related, genetic, or some other cause, remains
unknown.
Pulmonary hypertension correlates to endpoints of pulmonary insufficiency, including
duration of mechanical ventilation, requirement for high-frequency oscillator ventilation, need
for tracheostomy, and reliance on oxygen at the time of discharge from neonatal intensive care
unit [31].
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Conflicting reports exist regarding the prognosis of infants with giant omphaloceles. Some
have mild respiratory distress, achieve early feeding and undergo delayed fascial closure with
good results [28]. In contrast, others report a high mortality rate in giant omphalocele infants,
relating to the predominance of respiratory insufficiency and pulmonary hypertension.
Several retrospective studies suggest that there may be a direct relationship between giant
defects and abnormal pulmonary vascular tone. Clinicians should not focus on the defect
diameter, but recognize that respiratory insufficiency and pulmonary hypertension are the
prognosticators to identify [8, 18, 32].
A recent multicenter retrospective review illustrates the distribution of respiratory insuffi‐
ciency and pulmonary hypertension in 51 infants with omphalocele (Figure 1). All 51 had
echocardiography performed between the day of life 2 and 7 [28].
Sixteen infants (31%) had no pulmonary hypertension and no respiratory insufficiency at birth.
Of these, 15 survived (94%) and 1 died (6%).
Of the 51 infants (55%), 28 had pulmonary hypertension, and of these, 13 had respiratory
insufficiency (46%) while 15 did not (54%).
Of the 51 (39%), 20 infants had respiratory insufficiency at birth without detectable pulmonary
hypertension. Six of twenty (30%) were premature infants with a mean gestational age of 31.7
weeks.
Ninety-two percent of mortalities in the cohort were distributed among the infants with
pulmonary hypertension, with or without respiratory failure, or respiratory failure without
pulmonary hypertension. Of 38 survivors, one that initially presented with respiratory
insufficiency, without pulmonary hypertension, progressed to chronic lung disease and
required a tracheostomy and a long-term ventilator support. Of the 15 infants with isolated
Figure 1. The distribution of respiratory failure and pulmonary hypertension in 51 infants with omphaloceles.
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pulmonary hypertension and no evidence of respiratory insufficiency, 13 survived (87%), and
none required long-term ventilation (Figure 1).
Giant omphalocele defects containing 75% liver were closely associated with mortality. The
distribution of 17 giant defects is illustrated among the cohort in Figure 1. Eight of seventeen
(47%) died, and the eight deaths with giant defects were all distributed in the nine infant deaths
that had a combination of pulmonary hypertension and respiratory failure at birth (89%). The
distribution of the remaining giant defects is illustrated among the survivors (Figure 1) [28].
Logistic regression analysis further revealed that both respiratory insufficiency at birth (OR:
14.8; 95% CI: 2.5–85.0) and pulmonary hypertension diagnosed between days 2 and 7 of life
(OR: 6.4; 95% CI: 1.1–39.0) were independently associated with mortality in infants with
omphaloceles. This is a new and previously unappreciated finding.
A clinical care strategy that screens for pulmonary hypertension in omphalocele infants is
recommended. Echocardiography is best performed between the second and seventh day of
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We report one case of giant omphalocele treated with sildenafil and Bosentan. Echo performed
at age 4 years shows that the pulmonary hypertension has completely resolved. Bosentan is
an oral endothelin receptor antagonist that inhibits vascular remodeling and muscular
thickening. Endothelin-1 is believed to play a role in the pathogenesis of neonatal pulmonary
hypertension, and endothelin blockade augments pulmonary vasodilation in the perinatal
lung. Several reports have shown that Bosentan provides benefit in the treatment of pulmonary
hypertension in infants [33].
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Selected fetuses may benefit from a maternal hyperoxia study prenatally to predict who will
be at risk for elevated pulmonary vascular resistance and pulmonary hypertension, similar to
prenatal evaluation in congenital diaphragmatic hernia [25, 35, 36].
The biology of neonatal pulmonary hypertension is linked to lung vascular growth modified
by prenatal and early postnatal factors. The use of medical therapy to modify pulmonary
hypertension in omphalocele infants is an important area of future study [37].
6. Congenital heart defects
The anterior abdominal wall develops between weeks 3 and 10 of fetal development. The
process involves folding of the embryonic disk in cranio-caudal and lateral directions. By week
6 of fetal development, the elongated midgut herniates into the base of the umbilical cord due
to lack of space in the abdominal cavity. By the tenth week, it rotates and returns to the
abdomen. During this period, the cardiac tubes, which lie on the ventral surface of the embryo,
are incorporated into the chest by the lateral folds. Errors in these critical steps of fetal
development result in simultaneous anterior abdominal wall defects, such as omphalocele,
and structural cardiac defects [25].
In general, a single- or multiinstitutional series of live-born infants with omphaloceles report
a 30% incidence of structural congenital heart defects. Neonates with patent ductus arteriosus
or patent foramen ovale are not considered to have a congenital heart defect.
A single-center retrospective series found that of 22 live-born omphalocele infants, 7 had
evidence of a structural congenital heart defect, 4 of which developed pulmonary hyperten‐
sion, and 1 of the 4 also had a dysplastic tricuspid valve. Only one infant required a surgical
repair, and that infant presented with coarctation of the aorta [25]. The incidence of structural
cardiac defects was lower than expected, and this was attributed to the low incidence of
abnormal karyotypes.
Another recent multicenter series reports a congenital heart defect incidence in omphalocele
infants of 30%, but all were nonductal-dependent lesions without hemodynamic compromise.
None had cardiac failure [28].
Although structural cardiac defects should be specifically sought by echo in the first week of
life, the influence of congenital heart defects on the outcome for omphalocele infants may be
lower than expected, in particular if the cohort has normal karyotypes.
Although clinicians previously evaluated for congenital heart defects, they did not evaluate
for pulmonary hypertension. Recent reports clarify that pulmonary hypertension likely has a
greater influence on the outcome and mortality in omphalocele infants than congenital heart
defects, unless Trisomy 13 or 18 is diagnosed.
In the setting of Trisomy 13 or 18, the incidence of congenital heart defects is over 90%. The
most common defects are ventricular septal defect, atrial septal defect, and double outlet right
ventricle.
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The congenital heart defects of these chromosomal anomalies tend to present with hemody‐
namic compromise [25, 28, 38]. The establishment of regional and national databases for
omphalocele would enhance the statistical understanding of the true incidence of congenital
heart defects and hemodynamic compromise in omphalocele infants as few detailed reports
with large sample size exist.
7. Respiratory insufficiency and assisted ventilation
Assisted ventilation may be necessary in neonates with omphalocele due to respiratory
insufficiency from pulmonary hypoplasia, increased abdominal pressure following surgical
repair, diaphragm dysfunction, and pulmonary hypertension [39]. The need for assisted
ventilation may occur at delivery or may be confined to the immediate postoperative period
related to increased intraabdominal pressure and upward displacement of the diaphragm
following closure.
7.1. Goals of assisted ventilation
The goal of assisted ventilation in neonates with respiratory insufficiency due to omphalocele
is to achieve adequate functional residual capacity to facilitate gas exchange. Assisted venti‐
lation should be applied to maintain adequate lung volume with even distribution of tidal
volume to avoid trauma from atelectasis and lung injury. If lungs with partial atelectasis are
ventilated, the tidal volume entering only the open alveoli will lead to overexpansion of the
relatively healthy portion of the lung with subsequent trauma due to overexpansion.
Additionally, atelectasis leads to vascular protein leak with increased surfactant inactivation
and release of inflammatory mediators. Maintaining adequate lung volume is achieved by
applying adequate positive end expiratory pressure (PEEP). There is no single optimal PEEP,
and the level must be tailored to the degree of lung injury. For infants with healthy lungs and
normal lung compliance, PEEP of 3–4 cm H2O may be appropriate. Excessive PEEP may lead
to overexpansion of normal lungs with circulatory impairment and elevated cerebral venous
pressure. However, poorly compliant lungs with atelectasis may transiently require higher
PEEP, as high as 8–10 cm H20 or more, to achieve adequate alveolar recruitment and optimize
ventilation/perfusion ratios [40].
For small omphaloceles, if primary abdominal closure has been accomplished, the majority of
neonates will require mechanical ventilation for a few days postoperatively. During this time,
the abdominal wall and bowel wall edema will improve, and the intraabdominal pressure will
decrease.
The elective, routine use of mechanical ventilation to ensure primary closure in every instance
is unwarranted. Short-term ventilator support, however, has been a welcomed adjunct to
postoperative care and certainly has improved the outlook for these infants [41].




Little information exists regarding the use of continuous positive airway pressure (CPAP) or
positive end expiratory pressure (PEEP) in stabilizing the lungs of infants with omphaloceles.
Positive end expiratory pressure has been used in premature infants to minimize the effect of
excessively compliant chest wall and surfactant deficiency by stabilizing alveoli during the
expiratory phase, and has been shown to help establish functional residual capacity.
Traditional management in neonates with omphalocele and respiratory insufficiency involves
intubation and mechanical ventilation in the delivery room to presumably avoid further
distention of bowel from air swallowing. However, nasal CPAP and/or nasal intermittent
positive pressure ventilation may be a preferable approach to improve inadequate respiratory
effort in these neonates, while avoiding the complications associated with endotracheal
intubation [42].
The noninvasive approach offers the benefit of avoiding an endotracheal tube; therefore,
reducing the incidence of ventilator-associated pneumonia and avoiding the contribution of
postnatal inflammatory response to the development of bronchopulmonary dysplasia.
Noninvasive ventilation reduces iatrogenic lung injury.
7.3. Conventional mechanical ventilation
Several modes of mechanical ventilation have been applied to neonates with omphalocele, but
there is little evidence to guide clinicians in selecting the best method. Historically, pressure-
controlled ventilation is the standard mode of ventilation in neonates with respiratory failure
because of its wide availability, simplicity, ability to ventilate despite large endotracheal tube
leak, and improved intrapulmonary gas distribution. However, pressure-controlled ventila‐
tion is limited, in that tidal volume varies with changes in lung compliance.
A rapid improvement in compliance may occur in the immediate postnatal period as a result
of resorption of lung fluid, recruitment of optimal lung volume, and surfactant replacement
therapy, leading to hyperventilation and trauma from excessive lung hyperexpansion [40].
Insufficient tidal volume may develop because of decreasing lung compliance, increasing
airway resistance, airway obstruction, air trapping, and/or decreased spontaneous respiratory
effort. Inadequate lung volume leads to hypercapnia, increased work of breathing and oxygen
consumption, agitation, fatigue and atelectasis/atelectrauma. Low tidal volume leads to
inefficient gas exchange due to increased dead space: tidal-volume ratio. Mechanical ventila‐
tion goals should include weaning toward extubation, as well as weaning supplemental FiO2,
in order to avoid oxygen toxicity that may contribute to chronic lung disease.
7.4. High-frequency ventilation
In selected infants with respiratory failure due to pulmonary hypoplasia and/or severe
pulmonary hypertension, high-frequency ventilation may optimize lung inflation and
improve gas exchange. High-frequency ventilation is beneficial as it reduces pressure and
volume swings transmitted to the periphery of the lungs, and promotes gentle ventilation. For
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optimal effectiveness, alveoli must be recruited and stabilized with the lowest possible mean
airway pressure.
There is little information in the literature describing the effectiveness of high-frequency
ventilation in neonates with omphalocele. In a large single-center series of giant omphalocele
infants, mechanical ventilation maintains preductal oxygen saturation above 85% and high-
frequency oscillatory ventilation is reserved for patients with refractory hypercapnia [41].
One report examines the use of high-frequency ventilation in 15 omphalocele infants after
surgical closure. Of 15 infants, 11 had not required ventilation and were breathing room air
prior to operation. High-frequency ventilation is reported as required in six infants (61%)
within the first week in the intensive care unit after omphalocele closure. The remainder were
managed with conventional ventilation. In half of the 15 infants, lung expansion on chest
radiograph was reported at 50%.
The average mean airway pressure at days 5–7 for both the conventional ventilation group
and the high-frequency group was 14 mmHg ± 3.0. Weaning from ventilation was achieved
on day 7 in only five of the omphalocele infants. Six required ventilation until day 28. Four
infants required tracheostomy and prolonged respiratory support between 330 and 1065 days
[38]. Prolonged duration of mechanical ventilation and use of parenteral nutrition during this
time period likely also contribute to an increased risk of infection.
Primary closure was the procedure of choice in this series. Despite the use of high-frequency
ventilation, this series reports a slightly lower survival rate of 73%, compared to the studies
with an emphasis on delayed closure that report survival rates of 80% or higher. They note
that tension was described by the surgeon in three closures and may have contributed to
postoperative difficulties. They note closure of the abdominal wall defect compromised
pulmonary mechanics when increased intraabdominal pressure inhibited diaphragmatic
movements as the viscera was reduced [38].
This study supports the existence of a degree of pulmonary hypoplasia and decreased
pulmonary reserve in omphalocele infants that could only be overcome to a degree by high-
frequency ventilation in some but not all of the infants that underwent early closure. It supports
the use of delayed closure techniques and careful evaluation of abdominal-visceral dispro‐
portion and cardiopulmonary status prior to proceeding with operation [38].
8. Extra-corporeal membrane oxygenation (ECMO)
Despite improvements in the management of respiratory insufficiency and pulmonary
hypertension in infants, a number of infants with inadequate gas exchange are treated with
extra-corporeal membrane oxygenation (ECMO). This includes infants with omphaloceles.
The authors retrospectively analyzed the Extra-corporeal Life Support Organization (ELSO,
Ann Arbor, MI, USA) database between 1992 and 2015 for extra-corporeal membrane oxy‐
genator (ECMO) use and omphalocele. ELSO membership consists of many major medical
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centers worldwide, with the capability of placing infants on ECMO. This database would
capture the majority of infants with omphaloceles, managed with ECMO, during the time
period and provide the most of the information about the use of ECMO in these infants. The
first infant with an omphalocele was placed on ECMO in 2011.
The specific diagnoses for respiratory insufficiency listed in the database are pulmonary
hypertension, congenital heart defects, congenital diaphragmatic hernia, and sepsis. The
recorded diagnoses for respiratory insufficiency in the 11 infants were isolated pulmonary
hypertension in three; congenital heart defect and pulmonary hypertension in five (one of the
five also had capillary alveolar dysplasia); congenital diaphragmatic hernia, congenital heart
defect, sepsis, and pulmonary hypertension in one; and congenital diaphragmatic hernia and
pulmonary hypertension in two infants.
The six congenital heart defects were double outlet right ventricle in two, Tetralogy of Fallot
in one, ventricular septal defect in one, cor triatriatum in one, and aortic atresia/stenosis in one.
Table 2 presents the demographic details and outcomes of 11 infants with omphaloceles placed
on ECMO between 2011 and 2015.
Omphalocele
N = 11
First recorded ECMO run 2011
ECMO after day of life 3 8 (73%)
Gender (male) 7 (64%)
Weight at ECMO (kg)a 3.27 (2.5–10)
Age at ECMO (days)a 10 (0–351)
Run length (hours)a 193 (11–589)
A diagnosis of PHN 11 (100%)
Veno-arterial ECMO 10 (91%)
Discontinued from ECMO alive 7 (64%)
Discharged from hospital alive 2 (18%)
Data are expressed in number (%) except with (a) data are expressed in median (range).
Table 2. Omphalocele infants that underwent ECMO (2011–2015).
This is a small but significant series as it provides the only data available at present for
omphalocele infants and the use of ECMO. The incidence of abnormal karyotypes is not
reported with the database, so any association with Trisomy 13 or 18 is unknown.
For infants with omphaloceles that underwent ECMO, between 2011 and 2015 and reported
in the ELSO database, the overall mortality was 80%. This high mortality rate contrasts to the
reports from a large multicenter series of infants that underwent ECMO for pulmonary
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hypertension and other conditions such as congenital diaphragmatic hernia between 2000 and
2010, where the mortality rate is 20% or better. These data support the need to better under‐
stand the underlying pathophysiology of pulmonary hypertension, so therapy can target its
causes in omphalocele infants. There is overlap in the diagnoses of respiratory insufficiency
in almost all cases of omphalocele placed on ECMO. Only a large study with multivariate
analysis could determine the contribution of each diagnosis to respiratory failure and mortality
in omphalocele infants.
One term infant with omphalocele, and respiratory insufficiency attributable to congenital
heart defect and pulmonary hypertension, underwent lung biopsy after 10 days of ECMO
support. The lung biopsy revealed capillary alveolar dysplasia. Extra-corporeal membrane
oxygenation was withdrawn due to the fatal prognosis.
This solitary report raises questions about the etiology of persistent pulmonary hypertension
in some omphalocele infants. More autopsy studies and published reports after examination
of omphalocele infant lungs may expand the understanding of the contribution of this disorder
to pulmonary hypertension and mortality.
Clinically, capillary alveolar dysplasia cannot be distinguished from other syndromes that
cause pulmonary hypertension. Histologically, it is characterized by paucity of capillaries
adjacent to alveolar epithelium, immature alveolar development, and muscularization of
arterioles. The distribution can be diffuse or patchy. The etiology and incidence of capillary
alveolar dysplasia are unknown [43].
9. Surgical considerations
The aim of surgical management in infants with omphaloceles is to avoid an abrupt increase
in the abdominal pressure that may impair ventilation. An omphalocele which is less than 4
cm in size may be suitable for primary repair after cardiopulmonary stabilization and assess‐
ment of anomalies. In contrast, if a giant omphalocele is closed too early, the intraabdominal
volume may be insufficient to contain the organs [4, 5].
Immediate postoperative complications are compromise of venous return from a sudden
increase in intra-abdominal pressure and cardiopulmonary instability from decreased
diaphragmatic excursion. The result is abdominal compartment syndrome (ACS) [38, 39].
Compartment syndrome due to increased intraabdominal pressure is a serious complication
after a difficult omphalocele reduction. Early series report a 12% incidence of complications,
including acute hepatic congestion, renal failure, and bowel infarction [5, 6].
Before the impact of viscero-abdominal disproportion (VAD) and abdominal compartment
syndrome was understood, surgeons placed emphasis on operative closure. Between 1980 and
1995, in a series of 30 operative closures, about half were small defects and were closed
primarily without complications [44].
The remainder were giant omphaloceles. Three underwent skin closure due to viscero-
abdominal disproportion. Thirteen underwent silo placement and were closed between 11 and
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137 days. There were 14 serious complications in 13 infants. All were due to initial tight closure,
and all were opened postoperatively. There was one postoperative death (Table 3).
No randomized studies show that intraabdominal pressure monitoring is beneficial, and
therefore it is not used to guide closure in the operating room, but may have a role in the
postoperative period. Continuous bladder pressure monitoring in the postoperative period
does not prevent necrotizing enterocolitis, but maintaining abdominal pressure below 20
mmHg prevents renal failure [45].
Various closure techniques for giant omphalocele exist, including alloderm patch, vacuum-
assisted closure, tissue expanders, silos, and other types of mesh materials [46, 47]. If the sac
is intact, application of topical agents and dressing changes for initial nonoperative manage‐
ment of a giant omphalocele is recommended. This technique transitions to delayed closure
[26]. Tension and intraabdominal compression increase morbidity and must be avoided during
closure. If tension exists, then a silo or mesh must be used for coverage [38].
In two recent series, infants with giant omphaloceles underwent treatment of the sac with
topical agents and delayed closure. The median age of repair was 10 months (range: 3.4–23.6
months) in one series and 215 days in the other. No repairs were opened postoperatively [4,
22]. Six-month survival was 80% in both the series, despite the fact that half of the delayed
closure infants in one series met the criteria for pulmonary hypoplasia on fetal magnetic
resonance imaging [22].
A recent series of 16 infants with giant omphaloceles achieved discharge and returned for
delayed closure during an elective admission at a median of 14 months (range: 2–28 months).
The median length of hospital stay for this elective admission was 4 days (range: 2–21 days).
One of sixteen (6%) required unexpected prolonged ventilation and stayed in hospital for 21
days. Four (25%) required mesh as viscero-abdominal disproportion had not resolved [26].
When compared to the reports obtained from previous decades, surgeons wait 7–24 months
longer before attempting closure of a giant omphalocele. Although no comparative studies
exist, the concept of giant omphalocele closure has evolved over the last two decades [38, 39].
Most surgeons promote application of topical agents to the sac, followed by delayed closure.
This approach allows improved respiratory status, fewer complications, and better outcomes
Complication N (%)
Wound dehiscence 7 (24%)
Gastroesophageal reflux 5 (17%)
Hepatic hematoma 3 (10%)
Hepatic congestion 2 (6%)
Enterocutaneous fistula 2 (6%)
Bowel infarction 1 (3%)
Renal failure 1 (3%)
Table 3. Operative complications [44].
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[1, 4, 22, 26]. The emphasis on closure has been replaced by a better appreciation of viscero-
abdominal disproportion, abdominal compartment syndrome, and the connection between
stable cardiopulmonary status and survival.
Clinicians should be aware, however, that even if closure succeeds, a 40–50% reduction in
respiratory system compliance on the first and second postoperative days after closure of
abdominal wall defects has been demonstrated, as well as a 38% reduction in forced vital
capacity.
Mechanical ventilation, including high-frequency ventilation, may be required after delayed
omphalocele closure [9, 26, 27].
9.1. Technique of delayed repair
After birth, the application of topical povidone-iodine, silver sulfadiazine or bacitracin
ointment and xeroform gauze to the omphalocele sac allows epithelialization. Epithelialization
often occurs within 10 weeks [16]. During this time, the infant can begin intestinal feeding.
As the giant omphalocele infant grows, the viscero-abdominal disproportion gradually
resolves, but the infant must be clinically monitored. Giant omphalocele infants with respira‐
tory distress, pulmonary hypoplasia, pulmonary hypertension, or sepsis will require specific
care strategies, until they meet the criteria for extubation. Surgical closure of the abdominal
fascia is not a priority during this time period.
The respiratory status of some giant omphalocele infants improves to the point that they can
be discharged, followed as an outpatient, and can return for elective closure [26]. When the
omphalocele contents reduce manually into the abdominal cavity with ease, the body cavity
is considered large enough to proceed with operative closure.
If the contents fit, the impact on venous return, renal perfusion, and diaphragmatic excursion
is decreased. After operative closure, the majority of infants are extubated postoperatively,
and the average length of hospital stay is 4 days. A minority of infants may have a longer
ventilator time after closure (up to 21 days), and this can be difficult to predict [4, 26]. Parents
should be informed of this possibility.
9.2. Ruptured omphalocele
A ruptured omphalocele is defined as any disruption of the omphalocele sac membrane [48].
Rupture of the omphalocele sac is frequently reported as a poor prognosticator associated with
sepsis and mortality. The goal of the pediatric surgeon is to cover the eviscerated organs.
Although disrupted, if enough sac exists, it can be successfully sutured together with absorb‐
able sutures.
Successful reduction and coverage of a giant ruptured omphalocele are reported after silo
placement and coverage with an absorbable mesh, followed by split thickness skin grafting
[49]. Despite coverage, many infants die of respiratory insufficiency and infection [28].
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A ruptured sac requires urgent surgical intervention, but only sporadic case reports exist that
pertain to specific surgical management of a ruptured omphalocele.
Hemodynamic instability dominates the clinical course in infants with ruptured omphalocele.
The majority of infants with ruptured omphalocele require at least 80 ml–1 kg–1 volume
expansion in the first 7 days of life [38]. Intestinal exposure results in increased water and heat
loss. Manipulation and closure can result in losses into a third space that exacerbates hypo‐
volemia.
Volume expansion to achieve a mean arterial pressure of 45 mmHg increases blood pressure
and urine output. The use of renal dose dopamine is controversial, and benefits have not been
confirmed in recent meta-analyses. High-dose norepinephrine should be avoided as it can
exacerbate bowel ischemia and necrosis [38].
An infant with ruptured omphalocele requires surgical consultation to obtain organ coverage,
but intensive cardiopulmonary support with features of sepsis and a high mortality rate will
dominate the clinical course. The association between ruptured omphalocele, sepsis, and
mortality is not well understood.
10. Long-term respiratory support
There is a potential need for ongoing mechanical ventilatory support after the neonatal period
in neonates born with a giant omphalocele. Partridge observed high rates of reactive airways
disease in giant omphalocele survivors that was significantly associated with pulmonary
hypertension [31]. Neonates with giant omphalocele and pulmonary hypertension required
increased respiratory support based on the significant increases in the duration of mechanical
ventilation, requirement for high-frequency oscillatory ventilation and tracheostomy, with
dependence on home oxygen therapy following hospital discharge [31].
Whether reactive airways disease is an innate characteristic of the airways of infants with
pulmonary hypoplasia associated with giant omphalocele versus increased respiratory
support requirements and sequelae of mechanical ventilation remains unclear.
Pulmonary function abnormalities have been described in giant omphalocele survivors, and
include reduced mean forced vital capacity and forced expiratory volume on pulmonary
function testing with significant bronchodilator responsiveness in almost half of all patients
studied [31]. Long-term respiratory issues in infants with giant omphaloceles include asthma,
recurrent infections, chronic lung disease, and bronchomalacia.
Prolonged respiratory insufficiency is a frequent complication of giant omphalocele and the
major prognostic factor for infants without life-threatening malformations. Infants with giant
omphaloceles may require support for respiratory insufficiency into their second year of life.
This possibility should be discussed with their families.
Of 22 long-term survivors with giant omphaloceles in a prospective follow-up series, chronic
lung disease exists in 40%, and 16% have a tracheostomy for prolonged ventilation at a mean
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day of life 154 (median: 156 days; range: 100–204 days) [6]. Of six long-term survivors in a
single retrospective series at 33.2 months (range: 20–70 months), three have asthma requiring
medical therapy, two have recurrent infections, and one requires overnight continuous
positive airway pressure (CPAP) at 20 months for bronchomalacia [4].
Not much data are reported about the indications of tracheostomy in neonates with giant
omphalocele, although most retrospective series report a subset that required prolonged
ventilation and tracheostomy placement, in general, 5–10% of infants in a series. In general,
tracheostomies are placed to secure a safe airway for infants with protracted mechanical
ventilation. The optimal timing for tracheostomy placement in these babies is unknown;
however, severity of lung disease and problems of airway that preclude extubation are the
most common indications.
There is no good evidence for deferring tracheostomy because infants are receiving high
ventilator pressures. While high ventilator settings may be a concern that discourages
consideration of tracheostomy placement, appropriate developmental interventions are nearly
impossible to implement without placement of a tracheostomy in infants with an unstable
artificial airway [50].
11. Gastroesophageal reflux disease (GERD)
In infants with omphaloceles, the incidence of gastroesophageal reflux disease (GERD) with
associated esophagitis approaches 45% [51]. Gastroesophageal reflux disease is diagnosed at
a median age of 7 months and is more prevalent in infants with giant defects. Infants with
omphalocele and a large defect have a high incidence of GERD complicated by esophagitis
during the first few years of life [51].
Frequently, the retrospective series reports infants with omphaloceles and GERD that fail
medical therapy and undergo Nissen fundoplication [6].
Pulmonary function studies were performed on follow-up of 30 giant omphalocele infants at
a median of 19 months. The studies performed were spirometry, fractional lung volume
measurements, assessment of bronchodilator responsiveness and passive respiratory mechan‐
ics, to evaluate the nature and degree of pulmonary dysfunction in these survivors. The series
reports lung volume restriction without obstruction, an increased likelihood of airway
hyperresponsiveness and reduced compliance in almost 50% of the infants studied [31, 52].
Early recognition of pulmonary functional impairment may help develop targeted treatment
strategies for these infants, and this may include evaluation and treatment for GERD.
Partridge reports similar high rates of reactive airways disease in giant omphalocele survivors.
Follow-up pulmonary function study results are similar to those obtained for infants with
congenital diaphragmatic hernia and bronchopulmonary dysplasia. There may be a common
etiology between pulmonary hypoplasia and reactive airways disease. The same series of
omphalocele infants also reports a 10% rate of Nissen fundoplication for symptomatic GERD.
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Targeted treatment strategies are not well established, but GERD will exacerbate hyperactive
airways and asthma. Evidence for GERD should be sought by pH probe studies or endoscopy
to diagnose esophagitis in infants with omphaloceles. Contrast radiographs may also add
information regarding the esophageal-gastric anatomy and the presence of GERD. Any
contribution of GERD to airway responsiveness should decrease with appropriate medical
and/or surgical therapy.
12. Prematurity
In the majority of series that examine outcomes in omphalocele infants and factors associated
with mortality, when factors such as respiratory insufficiency, pulmonary hypertension, and
measures of pulmonary hypoplasia are examined, the influence of prematurity (defined as an
infant born before 37 weeks gestation) is rarely as preponderant as other respiratory comor‐
bidities. In the first series that reported respiratory insufficiency as an independent predictor
of mortality in omphalocele infants, respiratory insufficiency at birth was found to be inde‐
pendent of gestational age [1].
In a recent multicenter series of 51 infants that found pulmonary hypertension and respiratory
insufficiency at birth were associated with mortality in omphalocele infants, the median
gestational age was 38.2 weeks (range: 28.0–40.0 weeks) for survivors and 34.6 weeks (range:
29.0–40.4 weeks) for mortalities [28]. There was no significant difference in gestational age
between survivors and nonsurvivors. Respiratory insufficiency and pulmonary hypertension
were associated with mortality, independent of gestational age. Of seven infants with respi‐
ratory insufficiency at birth, but without evidence of pulmonary hypertension, six survived.
None of the remaining 44 infants in the series were premature. There was no significant
association between prematurity, respiratory insufficiency, and mortality that could be
identified in these infants with omphaloceles [28].
In contrast, in one study from Porter, preterm birth complicated more than a third of ompha‐
locele cases, and the only neonatal deaths occurred because of complications of prematurity
[53]. This is an isolated report.
Another series reports that the presence of major anomalies was the most significant factor
associated with pulmonary morbidity, independent of gestational age [19].
For the majority of series that examine the influence of various factors on respiratory insuffi‐
ciency, morbidity, and mortality in omphalocele infants, the influence of prematurity is not as
predominant as other factors. This is likely because the median gestational age for most series
is closer to term as modern prenatal care and monitoring of high-risk pregnancies may prevent
preterm birth. For infants that are premature, if there is no pulmonary hypertension or
pulmonary hypoplasia, the modern neonatal care of premature infant lungs is now sophisti‐
cated to the point that an influence on mortality cannot be consistently identified in the
retrospective series.
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13. Conclusions
Despite advances in neonatal care, mortality rates for infants with omphaloceles remain
between 5% and 25% [4]. In this chapter, the unique aspects of respiratory management in
omphalocele infants and care strategies are discussed. The chapter emphasizes pulmonary
hypoplasia as distinct from pulmonary hypertension. Pulmonary hypoplasia is defined as
insufficient development of pulmonary airways, alveoli, and vessels. Fetal MRI after 26 weeks
gestational age with calculation of the O/E-TFLV is recommended. A prenatal O/E-TFLV of
less than 50% predicts lower Apgar scores and a longer duration of mechanical ventilation. It
may eventually prognosticate for mortality.
Pulmonary hypertension is an independent predictor of mortality in omphalocele infants [28].
A relationship may exist between giant defects and abnormal pulmonary vascular tone.
Respiratory insufficiency and pulmonary hypertension, not the defect diameter, are the
prognosticators to identify [8, 18, 32]. We recommend echocardiography between days 2 and
7 of life to evaluate for pulmonary hypertension. After diagnosis, echocardiography should
be performed at regular intervals, until stabilization is demonstrated [28, 30].
Assisted-ventilation concepts in omphalocele infants are similar for all neonates with respira‐
tory compromise. Gentle ventilation, adequate gas exchange, and early extubation minimize
adverse outcomes. A longer duration of ventilation is associated with chronic lung disease,
sepsis, and neurodevelopmental impairment [6]. Infants with giant omphaloceles represent a
subgroup that benefit from these concepts. They frequently have several comorbidities and a
longer period of respiratory insufficiency after birth.
Review of the ELSO database reveals that for infants with omphaloceles requiring ECMO,
between 2011 and 2015, the mortality is estimated at 80%. Clinicians should consider these
results before recommending ECMO. The surgical approach for infants with omphaloceles has
evolved over the last two decades. The emphasis on primary closure is now replaced by an
appreciation of viscero-abdominal disproportion and abdominal compartment syndrome [1,
4, 22, 26].
Respiratory management for infants with omphaloceles may be arduous. Application of
specific definitions allows targeting of therapy and clinical strategies. A multidisciplinary
approach by perinatology, pediatric surgery, and neonatology may allow comprehensive
evaluation of respiratory status. Analysis of prenatal information followed by postnatal clinical
correlation may improve the outcomes for infants with omphaloceles.
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Abstract
Neonatal  respiratory  care  involves  physicians  with  variable  backgrounds  treating
multiple respiratory problems and populations with a number of invasive and non-
invasive devices and strategies. Unfortunately, there is a lack of strong evidence to guide
the  most  adequate  management  for  several  specific  situations.  Altogether,  this
complexity leads to significant practice variability that can affect patient and health care
outcomes. Respiratory care protocols, guided by evidence and/or consensus, are an
attractive solution to promote standardization of care and reduction of unnecessary
practice  variations.  Indeed,  despite  the  limited  evidence  supporting  the  use  of
respiratory protocols in neonates, a significant number of units have already devel‐
oped and implemented them into clinical practice. Respiratory care protocols appear to
promote evidence-based practices,  discourage outdated approaches and ultimately
improve patient safety.
Keywords: neonates, protocols, respiratory support, mechanical ventilation, intensive
care
1. Introduction
The hallmark of neonatology relies on adequate provision of respiratory care, most common‐
ly in the form of  noninvasive respiratory support  or  mechanical  ventilation (MV).  Also,
adjunctive therapies such as surfactant, caffeine, postnatal steroids and inhaled nitric oxide
play important roles. In the past decade, a large number of strategies to guide respiratory care
practices have been investigated in an attempt to improve neonatal short- and long-term
outcomes, including length of MV, extubation failure rates, bronchopulmonary dysplasia
(BPD) and neurodevelopment. Unfortunately, there is often limited or conflicting evidence to
guide clinicians, leading to highly variable practices and a wide display of outcomes across
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neonatal intensive care units (NICUs). One way to decrease unnecessary variations in practice
is through the use of clinical protocols. The objective of this chapter is to (1) describe the
variability of respiratory care practices in neonatology; (2) evaluate the impact of practice
variability on patient and health care outcomes; (3) review the evidence for using respirato‐
ry care protocols in neonates; and (4) provide an overview on how to develop and imple‐
ment these protocols in the NICU.
2. Variability of respiratory care practices in neonatology
In the modern era of neonatology, with the introduction of many new technologies and
adjunctive therapies, the provision of adequate respiratory care has become very complex and
challenging. Several local, national and international surveys have been undertaken to describe
how these therapies are utilized across NICUs, consistently revealing wide intra- and inter-
center variability.
2.1. Respiratory care management in the delivery room
Approximately 10% of neonates require some degree of respiratory assistance after birth [1].
As an inadequate delivery of respiratory support may have serious repercussions, it is crucial
for health care providers to have a solid foundation in neonatal resuscitation while staying up-
to-date with recent advances in the field. A number of national and international expert
consortiums regularly publish evidence-based guidelines to help providers during this critical
period [1]. Despite these recommendations, surveys from around the world continue to
demonstrate wide variations in many aspects of respiratory care management in the delivery
room.
The most striking illustration of variability is ventilation during neonatal resuscitation. Units
provide positive pressure ventilation using various methods, including the flow-inflating bag
(2–63%), self-inflating bag (6–96%), T-piece/Neopuff (1–79%) and ventilator (16–49%) [2–9].
These can be delivered via face mask, binasal prongs, single nasal prong or a nasopharyngeal
tube. Many institutions have more than one device at their disposal. Although positive-end-
expiratory pressure (PEEP) is now commonly used during positive pressure ventilation, many
centers that use the self-inflating bag do not apply it with a PEEP valve or manometer [6]. In
addition, delivered peak inflation pressures vary with regard to the maximal level and
duration of the inflation [5, 8]. Continuous positive airway pressure (CPAP) in the delivery
room has gained popularity over the past years, particularly for the preterm population. But
its use varies between 50 and 85% across countries, with units setting different gestational age
thresholds (anywhere from 24–32 weeks) above which they would attempt CPAP [2, 3, 5, 9].
For those infants who get intubated, 3–45% of units have reported using CO2 detectors [4, 6–
9]. Moreover, there are variations in the preferred routes of intubation (oral vs. nasal) and types
of endotracheal tubes used (straight vs. shouldered) [5].
The second most prominent source of variability in the delivery room relates to oxygenation.
Despite evidence-based recommendations on the use of pulse oximetry (PO), oxygen blenders
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and resuscitation of term infants with room air [1], some units have not yet adopted these
practices. Routine use of PO and O2 blenders ranges from 30 to 100% and 36 to 100% across
units, respectively [2, 5–10]. Although guidelines recommend preductal saturation measure‐
ments, one survey showed that only 37% of units placed their saturation probes correctly [3].
Similarly, 7–56% of units have been reported to initiate resuscitation in 100% oxygen [3, 4, 7,
10]. In the case of preterm infants, the starting concentration of oxygen varies considerably
(between 21 and 100%), with some providers starting high and tapering down and others doing
the contrary [8]. Oxygen is commonly titrated based on predefined oxygen saturation targets,
but some units still adjust according to color and heart rate [6].
2.2. Invasive mechanical ventilation
With the rapid advent of technology, clinicians can now choose from a wide range of
ventilators and modalities for invasive MV. Some surveys have reported as many as 12
different brands of ventilators for delivering conventional MV and at least 4 different types
of machines for providing high-frequency oscillatory ventilation (HFOV), with many units
having more than one type at their disposal [11–13]. There are currently over 10 different MV
modes available, including assist control (pressure or volume controlled), intermittent
mandatory ventilation (with or without synchronization, with or without pressure sup‐
port), HFOV (with or without volume control), high-frequency jet ventilation and neurally
adjusted ventilatory assist (NAVA). Use of all these ventilators and modalities is rarely
guided by patient disease or best evidence, but rather by availability, familiarity and personal
preferences [11–16].
A noticeable observation from recent surveys reveals that volume-targeted ventilation has yet
to gain widespread adoption during MV, despite established evidence for its use as a lung-
protective strategy [17]. There are significant geographical variations in volume-targeted
ventilation use, ranging from 5 to 60% [12–14, 16, 18, 19]. With regard to the preset tidal volume
(VT), the recommended target is generally 4–7ml/kg. However, surveys have demonstrated
that some units use VT targets as low as 3–4ml/kg and as high as 10ml/kg [18, 19]. Another
prospective observational study showed that as many as 18% of units used VT levels higher
than 7ml/kg [12]. These extremes of low and excessive VT may predispose to inadequate
ventilation and volutrauma, respectively.
Furthermore, tools used for monitoring and titrating MV settings are quite heterogeneous. For
instance, gas exchange can be monitored using PaCO2 levels in the blood, transcutaneous
CO2, end tidal CO2 or near-infrared spectroscopy [16, 20]. There is generally no consensus on
the blood gas route (venous, arterial or capillary), frequency of sampling and thresholds for
titrating. Although some evidence suggests that permissive hypercapnia may be a lung-
protective strategy during MV, a recent survey in the USA showed that clinicians aimed for
various target PCO2 levels, anywhere between 45 and 65 mmHg [21]. Ventilator settings are
also titrated in many different ways. In one Canadian survey, PEEP could be titrated on the
basis of oxygen saturation, pulse oximetry, blood gas, fraction of inspired oxygen (FiO2) or
chest x-ray findings [16]. The indications and frequency of performing chest x-rays in intubated
neonates are also rarely delineated and subject to individual preferences.
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There are many other aspects of MV that lend themselves to practice inconsistencies. Endo‐
tracheal tubes (ETTs) are secured using various taping methods. Infants are suctioned via the
ETT at different frequencies and techniques. Practices relating to infant positioning (supine vs.
prone) or the ability to do kangaroo care during MV are also nurse or clinician dependent.
Most importantly, the use of sedation during MV is so controversial that it has led to very
changeable practices; some clinicians always provide opiates and/or sedatives to intubated
patients, while others sometimes or never use it [14, 15].
2.3. Peri-extubation practices
In order to limit complications associated with MV, infants are often extubated as early as
possible. The process of extubation is quite complex and consists of three important steps:
weaning from MV, assessment of extubation readiness and provision of post-extubation
respiratory support. Significant variations in practice exist for all components of this process,
with decisions often being physician dependent and not always evidence based. For instance,
synchronized intermittent mandatory ventilation (SIMV) appears to be the most commonly
used weaning mode across surveys [13, 14, 16], despite the evidence that assist control
ventilation confers more homogeneous VT and faster weaning when compared to SIMV [22].
Furthermore, in a recent international survey focused on extremely preterm infants, extubation
readiness was primarily assessed based on the subjective interpretation of ventilator settings,
blood gases and overall clinical stability [23]. In addition, 16% of infants were extubated infants
on the basis of passing a spontaneous breathing trial, although the trial was often conducted
in variable ways. The timing of extubation was extremely variable, with some units removing
the ETT immediately after surfactant administration while others only after 2 weeks of MV.
Finally, 10% of the centers still reported extubating extremely preterm infants to low-flow nasal
cannula, oxyhood or no respiratory support despite the undisputed evidence favoring the use
of noninvasive ventilation in this population [24].
2.4. Noninvasive ventilation
Continuous positive airway pressure—Since its discovery in the late 1970s, CPAP has been
extensively studied in neonates. Consequently, it is by far the most widely used noninvasive
mode across the world. Although CPAP has been well established and widely adopted for the
treatment of apnea of prematurity and following extubation of preterm infants, its use as a
primary therapy for respiratory distress syndrome (RDS) has only recently gained attraction.
A recent study comparing epidemiological data from the Vermont Oxford and Italian Neonatal
Networks revealed significantly high coefficients of variation in the use of CPAP as a primary
therapy, ranging from 0 to 80% [25]. To provide CPAP, a variety of devices (ventilator, infant
flow SiPAP or bubble) and interfaces (nasal prongs, nasal mask, nasopharyngeal tubes, nasal
cannula) are used [11, 26]. There is no clear consensus on the level of CPAP to be applied as
well as on how to wean and discontinue CPAP therapy. For instance, cycling off CPAP and
transitioning from CPAP to high-flow nasal cannula (HFNC) therapy are common non-
evidence-based practices.
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Nasal intermittent positive pressure ventilation (NIPPV) —This has also gained popularity, with
rates of use varying from 18 to 88% in different parts of the world [25–28]. It is most commonly
applied as a rescue mode for infants who fail CPAP, to prevent intubation in infants with RDS
or immediately after extubation. This variability in usage mainly stems from conflicting
evidence on its effectiveness as well as limited understanding of its mechanisms of action,
clinical indications and optimal means of delivering the pressures. Similar to CPAP, units may
have at their disposal up to five different devices and interfaces for delivering NIPPV [26–28].
Synchronized NIPPV is still used by some units, but for the majority it is no longer commer‐
cially available [27, 28]. This is particularly important because the only studies demonstrating
physiological and clinical benefits have used synchronized NIPPV [28].Furthermore, there is
no consensus on what constitutes best settings (peak inflation pressure, PEEP and rate) and
how to optimally wean NIPPV.
High-flow nasal cannula—Well before any clinical trials had established its safety and effective‐
ness, high-flow nasal cannula (HFNC) had been widely used across units. Surveys revealed
that between 50 and 77% of units were using it [25, 29, 30]. The most common indication was
in the immediate post-extubation period. In two surveys, 33% of extremely preterm infants
(≤28 weeks) and 12% of infants with birth weight ≤1kg were extubated directly to HFNC,
respectively [23, 30]. This is particularly concerning, given the lack of evidence for infants
below 26 weeks and experts cautioning against its routine use in this population [31]. Another
popular application for HFNC is as an alternative to CPAP or as a weaning step between CPAP
and no respiratory support. However, no evidence currently exists to support any of those
practices [32]. With regard to the actual delivery of HFNC, current evidence (from the literature
and manufacturers) recommends using no more than 8 L of flow and a nasal cannula that allow
some degree of leakage around the nares (around 50%). In spite of this, there is wide variability
in HFNC delivery; one survey reported that as many as 15% use maximal flows greater than
8 L, over half of the respondents apply nasal cannula that exactly fits the nostrils and 23% apply
measures to keep the mouth closed [29]. All these actions have the potential to deliver
unreliable and dangerously high levels of pressure.
Other modes of noninvasive ventilation—More novel noninvasive modes have recently made their
way into clinical practice despite the lack of evidence to support their use. Two such examples
include noninvasive HFOV and noninvasive NAVA. A recent European survey reported that
17% were using noninvasive HFOV for diverse indications, mainly for CPAP failure or as
primary therapy. There were significant variations in the types of equipment, interfaces and
settings used for its delivery, with little information about its safety profile [33]. Similarly,
noninvasive NAVA is increasingly applied in many NICUs across North America using
evidence mainly based from animal data, retrospective clinical studies and case series [34].
2.5. Adjuvant therapies
Caffeine—A succession of animal, pharmacological and clinical evidence over the years has led
to widespread caffeine use in neonates. The most influential publication of all was the large,
multicenter Caffeine for Apnea of Prematurity (CAP) trial, which showed that caffeine
significantly reduced incidence of bronchopulmonary dysplasia and cerebral palsy in preterm
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infants [35, 36]. Nonetheless, in the real world, caffeine practices continue to be highly variable
and not always reflective of current evidence. For example, two recent surveys that reported
54 and 77% of units ensured that extremely preterm infants were loaded with caffeine prior to
extubation [14, 23]. This is contrary to recommendations advocating for caffeine use in order
to improve chances of successful extubations in preterm infants [37]. As another example, the
use of prophylactic caffeine for the prevention of apnea has been heavily debated. The latest
Cochrane review in 2010 [38] did not support routine use of prophylactic caffeine, but a series
of recent retrospective studies have shown that early administration of caffeine (in the first 48
h of life) significantly reduced length of MV and improved short-term respiratory outcomes
in preterm infants [39, 40]. As a result, the off-label use of prophylactic caffeine has risen from
22% (at the time of the CAP trial) to 60–75% [39, 41, 42]. The first dose is given anytime between
days 1 to 25 of life and for a duration ranging from 2 to 119 days [42]. There are also noticeable
differences in practices related to monitoring and discontinuation of caffeine. Ten percent of
units still routinely measure caffeine levels [41]. The timing of caffeine cessation often depends
on the unit’s prespecified gestational age cutoff (anywhere from 32 weeks to greater than 35
weeks). A significant proportion of units also discontinue caffeine once the infant has become
apnea-free for 5–7 days (81%), ≤4 days (11%) or ≥8 days (8%) [41].
Surfactant—The introduction of surfactant is probably one of the most important and life-
saving discoveries in the history of neonatology. It improved survival and reduced important
morbidities associated with MV, especially for the extremely preterm population. However,
the role of surfactant in everyday practice has markedly evolved over time. Originally,
surfactant was mainly recommended as prophylaxis for all extremely preterm infants and was
preferably administered in the first 2 hours of life [43]. Nowadays, clinicians are trying to avoid
MV all together and are therefore looking for alternative ways to administer it using less
invasive routes [44]. As such, use of prophylactic surfactant varies anywhere between 0 and
90% [10, 11, 14, 25, 45]. Most units use the intubation-surfactant-extubation method, but other
strategies are increasingly tried [46]. When surfactant is provided as rescue therapy, clinicians
use different clinical indications (e.g., FiO2 thresholds), number of doses and methods of
administration (e.g. infant’s position, rate of infusion, pressures and lung recruitment maneu‐
vers used pre- and post-administration) [14, 45, 46].
Inhaled nitric oxide—The use of iNO for persistent pulmonary hypertension and acute hypoxic
respiratory failure has been comprehensively studied in late preterm and term infants. In spite
of this, there exists wide practice variations related to iNO administration in this population.
Clinicians assess illness severity in a variety of ways (e.g., oxygenation index, pre-post ductal
saturation difference, O2 requirements and echocardiographic findings) and have different
thresholds or indications to start iNO and use variable starting doses (5–20 ppm) and maximal
doses (20–40 ppm) [47, 48]. Moreover, there is no standard approach for monitoring and
weaning iNO (blood gases, oxygenation index, oxygen saturation and/or O2 needs), especially
in patients who are non-responders to the therapy. The most striking observation of all is the
rising off-label use of iNO in preterm infants less than 34 weeks gestation, despite firm position
statements and consensus guidelines recommending against it. In fact, a number of surveys
and large epidemiological studies have documented wide regional and inter-hospital varia‐
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tions in iNO use, indications, age of initiation, dosage and duration of therapy for this group
[48–50]. This raises great concern, especially when iNO is associated with staggering health
costs and has not been demonstrated to improve short- or long-term outcomes in this popu‐
lation, with potential to cause harm in the subset of extremely preterm infants less than 1000
g [51].
3. The impact of respiratory care practice variability
For the many reasons explained in the first session of this chapter, variability in respiratory
care practices is extremely prevalent. The NICU is a fast-paced environment where decisions
are often made on the go and clinicians do not always have the time or sufficient knowledge
to make the most informed decisions. In addition, units are often restrained in their ability to
adopt a certain practice by its cost, ease of use or resource requirements (space, personnel, etc.).
Most importantly though, despite the abundant existing literature, the evidence to justify most
respiratory care practices is often limited or conflicting, leading clinicians to interpret study
results in various ways, or shape their practices according to different background experiences
and personal beliefs.
There are many implications of practice variability on patient outcomes (Box 1). In cases where
high-grade evidence exists to guide respiratory care practices, it is easy to perceive how
deviations (e.g., evidence-based therapies are introduced too late, too soon or are misused for
certain populations and conditions) can negatively affect patients. But, even in cases where
the evidence is unclear, the mere presence of variability has been linked to marked differences
in pulmonary morbidities across NICUs. For example, rates of extubation failure range from
20 to 70% in preterm infants [52, 53]; this means that units with low extubation failure rates
may perhaps be exposing infants to prolonged periods of MV while units with high failure
rates may be disconnecting infants from the ventilator too soon. Both prolonged MV and the
need for reintubation have been associated with serious, preventable morbidities [54, 55]. In a
similar way, rates of unplanned extubation vary between 1 and 80% depending on unit MV
practices and ETT fixation methods [56]. These accidental extubations also expose infants to
unnecessary complications, including hemodynamic instability, need for reintubation and
prolonged MV [56]. Moreover, several benchmarking studies have demonstrated important
variations in the incidence of BPD across centers, which persist even after adjusting for
variables known to affect this outcome [57, 58]. Authors of these studies have suggested that
differences in clinical practice may actually be affecting this clustering effect. Similar obser‐
vations have been made for non-respiratory related outcomes, including survival and neonatal
sepsis [59–61].
Box 1.
Impact of respiratory care practice variability.
On patients
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- Potential for using non-evidence-based practices
- Potential for increased errors and morbidities
- Unpredictable management





- Confusion of health care team
- Inconsistent learning environment for trainees
- Reduced potential for quality control initiatives
Practice variability has potentially negative consequences that go even beyond patient
outcomes (Box 1). It is not uncommon for a single patient to be exposed to several ventilation
modes or therapies throughout hospitalization, or for a family to receive conflicting opinions
regarding their child’s respiratory management. This could be a great source of anxiety for the
parents and may weaken their alliance with the health care team. Besides, this could create a
lot of confusion among nurses, respiratory therapists and trainees, leading to lesser opportu‐
nities for productive teaching or learning. Finally, with little continuity or predictability of
management, it becomes quasi impossible to effectively audit respiratory care practices or
perform any quality control studies in the unit.
4. The role of respiratory care protocols in neonates
One way of harmonizing practices is through the use of respiratory care protocols. Protocols
are a set of guidelines or rules to follow for a prespecified population with a prespecified
condition. They have been extensively studied in critically ill adult and pediatric patients,
namely for sepsis, sedation, hyperglycemia and MV. In these patients, MV protocols have
consistently been demonstrated to improve outcomes by reducing costs, decreasing MV
duration and shortening length of stay [62, 63]. They also have been shown to reduce rates of
extubation failure as well as unplanned extubations [64, 65]. As such, MV protocols have been
considered standard of care and have been developed and implemented by over two-thirds
of adult ICUs [66, 67].
In contrast, the evidence for using respiratory care protocols in neonates is still limited. Studies
are small, single center and retrospective or observational in nature. In one Canadian study,
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nities for productive teaching or learning. Finally, with little continuity or predictability of
management, it becomes quasi impossible to effectively audit respiratory care practices or
perform any quality control studies in the unit.
4. The role of respiratory care protocols in neonates
One way of harmonizing practices is through the use of respiratory care protocols. Protocols
are a set of guidelines or rules to follow for a prespecified population with a prespecified
condition. They have been extensively studied in critically ill adult and pediatric patients,
namely for sepsis, sedation, hyperglycemia and MV. In these patients, MV protocols have
consistently been demonstrated to improve outcomes by reducing costs, decreasing MV
duration and shortening length of stay [62, 63]. They also have been shown to reduce rates of
extubation failure as well as unplanned extubations [64, 65]. As such, MV protocols have been
considered standard of care and have been developed and implemented by over two-thirds
of adult ICUs [66, 67].
In contrast, the evidence for using respiratory care protocols in neonates is still limited. Studies
are small, single center and retrospective or observational in nature. In one Canadian study,
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the implementation of a respiratory therapist-driven MV protocol for premature infants with
birth weight <1250 g resulted in earlier extubation, greater number of successful extubations
and shorter duration of MV [68]. In another study, the implementation of a standardized SBT
protocol for extubation of extremely preterm infants resulted in faster weaning times with no
impact on extubation failure rates [69]. In a further study, the implementation of a nurse-driven
comfort protocol in ventilated preterm infants significantly reduced the amount of morphine
used which translated in fewer days on MV and a shorter course of hospitalization [70]. Lastly,
the use of a standardized surfactant protocol allowed clinicians to audit their practice and
identify strategies to reduce adverse events associated with surfactant administration [71]. The
results of this quality control initiative led to later modifications of the surfactant protocol,
which has recently been published [72].
Despite the lack of strong evidence, it is interesting to observe that many units have already
developed and implemented respiratory care protocols. In a recent Canadian survey, we
showed that 38% of NICUs had at least one MV protocol, while 29% had a protocol for NIV
[16]. In another international survey, 36% of units reported having a guideline or written
protocol for ventilator weaning [23]. Protocols for CPAP and NIPPV are available in approx‐
imately 20% of units [16, 27, 28], while guidelines for HFNC are present in 25–50% of units [16,
29, 30].
The most striking trend is the increasing use of iNO protocols in practice. With the rising costs
of iNO treatment, there have been many incentives from clinical managers and hospital
administrators to audit iNO practices within their respective units. As a result, it is no surprise
that almost two-thirds of units have developed and implemented iNO protocols [16]. To our
knowledge, there have been no studies directly evaluating the impact of implementing iNO
protocols in neonates, but there is some evidence from the pediatric literature that iNO
protocols reduce practice variability, decrease iNO usage and thus lower costs without
affecting mortality [73, 74]. As such, several local, national and international committees have
published evidence-based guidelines to assist NICUs in developing their own institutional
protocol.
Finally, there is a rising body of evidence recommending the development and implementation
of clinical protocols for other specific neonatal practices or conditions. Some of these include
pain control, sedation, feeding and delivery room management of extremely preterm infants
(i.e., the golden hour) [75–77]. But the area in which protocols have been most well studied
remains the respiratory management of neonates with congenital diaphragmatic hernia
(CDH). In this population, implementation of a standardized, evidence-based protocol for
respiratory care (e.g., using gentle ventilatory approaches, and permissive hypercapnia) has
reliably led to lesser practice variations, improved survival and decreased morbidities [78–80].
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5. Development and implementation of respiratory care protocols in the
NICU
From the above sections, there is no doubt that respiratory care protocols confer many benefits.
But, under some circumstances, they may also have some disadvantages (Box 2). Developing
and implementing a respiratory care protocol is not an easy task. It requires mobilization of
many collaborators, careful scrutiny of a large body of evidence and ongoing monitoring to
ensure adequate application of the protocol in practice. This section will outline the key
principles for effectively developing and implementing respiratory care protocols in clinical
practice (also summarized in Box 3).
Box 2.
Pros and cons of respiratory care protocols.
Pros
- Reduces unnecessary variability in care
- Quick adoption of new information at the bedside




- Improves patient safety
Cons
- Inappropriately used for certain patients or conditions
- Oversimplified or too prescriptive
- Designed around low-quality evidence
- Potential loss of individualization of care
- Potential to be outdated if not kept current
Box 3.
General principles for effectively developing and implementing respiratory care protocols.
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Preconception
- Obtain support from all team members
- Form a multidisciplinary working group
- Take into account that developing and implementing protocols require ample time, organization and
resources
Development
- Easy to use
- Patient and disease specific
- Not too prescriptive
- Does not replace clinical judgment
Implementation
- Readily available
- Regular educational sessions
- Regular monitoring of adherence and compliance
- Periodical revision to accommodate for new evidence or clinical practice patterns
5.1. Preconception
Well before any protocol is drafted, it is important to take the time to get buy-in from all
members of the team who will eventually be using the protocol. This includes nurses, nurse
practitioners, respiratory therapists, neonatologists and their respective professional leader‐
ship. Many providers are often unaware of the negative impacts of variability on health care
outcomes. Others may feel skeptical about the benefits of protocols, potentially fearing that it
will take away from their ability to individualize patient care. Thus, it is of utmost importance
to provide a clear rationale for using a certain protocol in the unit. Showing unit-specific data
that highlight practice variations and compare outcomes with other centers may be a useful
step to further justify the need for a protocol. Thus, by involving all stakeholders as early as
the preconception phase, all team members will feel included and invested in the realization
of the project. This will further aid in improving later rates of adherence and compliance to
the protocol.
Once buy-in is obtained, the next crucial step is to create a working group that will be in charge
of preparing the protocol. A member from each discipline involved in providing respiratory
care (e.g., neonatologist, respiratory therapist, nurse, pharmacist and respirologist) should be
encouraged to participate in this group. By using such approach, all key disciplines are
represented and given the opportunity to share their perspectives. This multidisciplinary
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endeavor should lead to a stronger, more comprehensive and especially more inclusive
protocol.
5.2. Preparation of the protocol
The development of a sound protocol depends heavily on the accuracy of its content. If a
protocol is based on outdated or low quality evidence, it may actually lead to undesirable or
even harmful effects. For that reason, it is essential to perform a thorough review looking for
the best available evidence in the literature. Ideally, protocols should be based on results from
randomized controlled trials, systematic reviews and meta-analysis. In the absence of such
high-quality evidence, other studies should be carefully scrutinized with a critical mind.
Additional information should be sought out from expert opinion or from other units who
already have had some experience with that specific protocol. Furthermore, epidemiological
databases can be a useful resource to identify centers that have better outcomes in a certain
aspect of respiratory care and collaborate with them in order to identify potentially better
practices responsible for these positive outcomes.
With regard to the information contained in the protocol, it should preferably be patient
specific, disease specific and easy to follow. A protocol that is too flexible or unclear may lead
to variable interpretations and misuses. In contrast, a protocol that is too rigid, detailed or
overly specific may become inapplicable for most patients. Thus, careful attention should be
placed on developing a protocol that englobes most targeted patients but that also leaves some
room for individualized decision making.
5.3. Implementation and monitoring
Once the protocol is completed and approved by the necessary regulatory authorities, a
number of steps need to be undertaken in order to ensure its adequate implementation. First,
the protocol needs to be made readily available to all health care providers who will use it.
Different channels can be used to disseminate the protocol, including the hospital intranet,
monthly newsletters, posters in the unit, printed copies at the bedside and small laminated
cards for staff to carry. Second, the protocol should be formally presented at educational
sessions, in-services and special rounds with the aim to raise awareness, answer people’s
questions and clarify their concerns.
Following implementation, an effort should be made to monitor adherence to the protocol in
an ongoing manner. In the absence of monitoring, it is not uncommon for protocol compliance
rates to decrease with time. Thus, it is important to regularly monitor protocol usage in the
unit in order to identify any major issues and promptly correct them. Regular refresher sessions
may also be useful to reinforce the protocol. Finally, it is plausible that with time, new evidence-
based recommendations will be made available, and hence the protocol might become
outdated. As such, protocols should be revised periodically and resubmitted for approval.
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6. Conclusion
Neonatal respiratory care involves prompt lung recruitment and adequate ventilation and
oxygenation during the transition period immediately after birth to management of a variety
of respiratory conditions. For this, a number of different technologies and adjunctive therapies
are available with lack of high-level evidence for several of them. Thus, it is not surprising that
practice variability is a reality. Respiratory care protocols are an attractive tool to promote
practice standardization and reduce unnecessary variations and health care-related costs.
Despite the limited evidence supporting their use in neonates, a significant number of NICUs
have already developed and implemented clinical protocols into practice. Overall, respiratory
care protocols appear to promote evidence-based practices, discourage outdated approaches
and ultimately improve patient safety.
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Abstract
Birth asphyxia and the resulting neonatal encephalopathy are a significant cause of
mortality  and long-term morbidity in children.  Hypothermia is  currently the only
neuroprotective treatment to have been clinically tested in large trials to prevent the
development of brain injury in some term asphyxiated newborns. Most of the asphyxi‐
ated newborns treated with hypothermia are intubated at birth as per resuscitation
measures and remain on mechanical ventilation during some part of the hypothermia
treatment or during the whole length of the treatment. They also may present with
oxygenation problems. Very often, they present with hypocapnia that can be worsened
with the use of mechanical ventilation during the first days of life. When taking care of
these newborns, a few important points should be remembered about the impact of
asphyxia and therapeutic hypothermia on oxygenation and ventilation. In this article, we
review some of the physiopathology behind neonatal encephalopathy and the implica‐
tions of brain cooling from a respiratory point of view. Strategies to optimize oxygena‐
tion and ventilation for these newborns, as well as to prevent further brain injury, are also
discussed based on a current literature review.
Keywords: brain, hypocapnia, neonatal encephalopathy, persistent pulmonary hyper‐
tension, ventilation
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1. Introduction
Birth asphyxia and the resulting neonatal encephalopathy are significant causes of infant
morbidity and mortality. Every year, three to five newborns per 1000 live births suffer from
birth asphyxia and have an increased risk to die or to develop long-term neurodevelopmental
sequelae [1, 2]. The sequelae may range from mild traits such as language impairments, attention
deficits, and hyperactivity to more severe traits such as cerebral palsy, global developmental
delay, and epilepsy [3].
Brain injury secondary to birth asphyxia and neonatal encephalopathy is a dynamic two-step
process. Initially, the asphyxial insult leads to decreased blood flow to the brain (primary
lesions), and this oxygen and blood deprivation around the time of birth may cause direct
neuronal cell injury and cell death (necrosis) within minutes [4]. Then, as the blood flow is
restored in an injured brain, a cascade of secondary pathways is initiated within the first hours
and days of life that can lead to further worsening of neuronal cell injury and cell death
(apoptosis) (“reperfusion injury”). Several mechanisms have been involved in these reperfu‐
sion injuries, that is, excitotoxicity from glutamate and aspartate release, disruption of calcium
homeostasis, generation of oxygen-free radicals, and inflammation [2].
In the past, asphyxiated newborns were managed with supportive care only (avoidance of
hypotension, avoidance of hypoglycemia, correction of blood gas parameters, and seizure
control), with the goal to maintain homeostasis to limit brain injury [5]. In recent years, a
number of large trials have demonstrated the efficacy of therapeutic hypothermia for the
treatment of neonatal encephalopathy [6–12]. Therapeutic hypothermia is currently the only
neuroprotective treatment demonstrated to be effective for preventing the development of
brain injury in some term asphyxiated newborns by preventing reperfusion injuries [8] and
for decreasing the risk of death and disability [1, 13, 14]. Therapeutic hypothermia involves
systemic or selective head cooling of the asphyxiated newborns to an esophageal temperature
of 33.5°C. Based on animal studies, the treatment has been shown to be efficient when started
within 6 hours of life and continued for 72 hours, followed by progressive rewarming [6–12].
The exact therapeutic window in humans is yet to be determined.
Despite hypothermia treatment, a significant number of asphyxiated newborns still develop
brain injury, and maintenance of homeostasis within the first hours and days of life is of the
utmost importance.
2. Impact of birth asphyxia on oxygenation and ventilation
Brain oxygenation occurs normally through the glycolytic pathway where glucose is converted
to pyruvate. This step produces the formation of the acetyl coenzyme, which enters the Krebs
cycle to generate energy in the form of adenosine triphosphate through mitochondrial
oxidative phosphorylation [15]. Thus, oxygen delivery to the brain cells is critical for oxidative
phosphorylation to occur and for the cell to produce energy. In contrast, excessive oxygen
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delivery to this powerful cellular machinery will result in the generation of oxygen-free
radicals leading to hyperoxia-related brain and lung injury [16]. The delivery of oxygen to the
different organs, especially the brain, requires several key steps. First, oxygen is delivered from
the air to the lungs. The second step occurs in the lungs at the alveolar level where the delivered
oxygen is exchanged with tissue-produced carbon dioxide; this step requires adequately
functioning alveoli and pulmonary vessels around these alveoli. The third step requires an
adequate circulating blood flow generated by the heart to deliver the oxygen to the tissues,
but also an adequate cerebral perfusion for oxygen delivery to occur in the brain. The fourth
step is the extraction of the hemoglobin-bound oxygen by the tissues and its delivery to the
cells.
Birth asphyxia affects the oxygenation process through several mechanisms. At the cellular
level, the asphyxial event deprives cells from oxygen, and thus, pyruvate is converted to lactate
through the lactate dehydrogenase enzyme. In addition, this anaerobic condition blocks the
oxidative phosphorylation in the mitochondria, which leads to energy production failure, since
adenosine triphosphate production is reduced [15]. In the lungs, asphyxia increases pulmo‐
nary vascular resistance, and thus the risk of persistent pulmonary hypertension, and therefore
contributes to oxygenation failure, since persistent pulmonary hypertension often leads to a
right-to-left shunting of deoxygenated blood, and thus a decreased delivery of oxygen to the
brain [17]. This right-to-left shunting could be either intracardiac through the patent foramen
ovale or through the ductus arteriosus, or intrapulmonary shunting. Also, high pulmonary
vascular resistance may impair oxygenation in the absence of shunting by causing right
ventricular dysfunction. Asphyxia also has a direct negative impact on cardiac function [18],
and this cardiac dysfunction may contribute to oxygenation failure, since an adequate cardiac
output is important for oxygen delivery to all tissues, particularly the brain. An impairment
of the oxygen process has the potential to worsen brain injury in asphyxiated newborns.
Birth asphyxia leads to metabolic acidosis, mainly because the cells switch to an anaerobic
metabolism as oxygen gets depleted, which leads to lactate accumulation [19]. This metabolic
acidosis may lead to hyperventilation, hypocapnia, and the development of a respiratory
alkalosis. Hypocapnia has been shown to exacerbate brain injury and lead to negative
outcomes. Hypocapnia alters pH, reduces cerebral blood flow (through vasoconstriction and
a release of vasoactive factors), alters potassium channels, and affects calcium homeostasis, all
of which contribute to further damaging the brain. Hypocapnia has been associated with
periventricular leukomalacia, intraventricular hemorrhage, cerebral palsy, cognition devel‐
opmental disorder, and auditory deficits [20]. Thus, it may also worsen brain injury in
asphyxiated newborns.
Clinical manifestations of neonatal encephalopathy include an initially altered level of
consciousness, tone and reflexes, and seizures may happen [9, 21]. Respiratory difficulties are
very often associated with the initial neonatal encephalopathy [21]. Most asphyxiated new‐
borns are intubated at birth as per resuscitation measures and remain on mechanical ventila‐
tion during some part of the hypothermia treatment or during the whole length of the
treatment [22].
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3. Impact of hypothermia on oxygenation and ventilation
Mild hypothermia achieves neuroprotection mainly by decreasing metabolic demand and
minimizing secondary energy failure. A reduction of 2–4°C of the body temperature of
asphyxiated newborns can decrease their rate of cell death, delay metabolic changes, and even
delay secondary brain injury [23]. The metabolic rate decreases by 5–8% with every 1°C
reduction in core temperature, which in turn reduces glucose and oxygen utilization, and
therefore mitigates energy failure following the initial asphyxial event [24].
Overall, hypothermia has a direct and favorable effect on oxygenation parameters (Table 1).
Hypothermia shifts the oxygen-dissociation curve to the left, and thus, a lower partial pressure
of oxygen is needed to achieve the same level of hemoglobin saturation. This left shift prevents
some of the oxygen release to the tissues, which should be considered an appropriate phys‐
iological adaptation, since hypothermia also decreases the demand for oxygen. Although
hypothermia has been suspected to worsen the existing pulmonary hypertension caused by
asphyxia [25], larger randomized studies of asphyxiated newborns that have tested hypother‐
mia as a treatment did not report an increased incidence of persistent pulmonary hypertension
[1, 26]. In addition, hypothermia also may have an impact on lung mechanisms [27]. Asphyxi‐
ated newborns treated with hypothermia tend to have an increased compliance and a de‐
creased mean airway pressure, and these changes tend to reverse during the rewarming
process [27], and may thus predispose the newborn to a worsening of the underlying persistent
pulmonary hypertension during that phase of treatment [27]. Further impairment of persistent
pulmonary hypertension, and thus of oxygenation, has the potential to worsen the brain injury
of asphyxiated newborns treated with hypothermia.
Parameters Changes during hypothermia treatment Management Strategies
Oxygen (FiO2 and pO2) Lower temperature shifts the oxygen-
dissociation curve to the left. Lower
pO2 are thus needed to achieve same
level of hemoglobin saturation
Avoid hyperoxia (lower PO2 may be




lung compliance and decreases mean airway
pressure
Optimize lung recruitment and avoid
overdistension (lower MAP may be
needed). Carefully monitor changes in
lung compliance during rewarming
Ventilatory rate Lower temperature decreases metabolic
rate, and thus CO2 production
Avoid hyperventilation by adjusting
ventilatory settings
Pulmonary pressure Lower temperature may worsen
persistent pulmonary hypertension (?)
Use O2 and NO as needed to avoid further
hypoxia. Maintain adequate systemic blood
pressure. ECMO to be considered when
optimized treatment fails. Avoid hyperoxia
Blood gas analysis Lower temperature decreases pCO2
and increases pH
“pH-stat” strategy (correction of pH and
pCO2 to the body temperature) suggested
as the most cautious approach
Abbreviations: ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; NO, nitric oxide;
pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen.
Table 1. Ventilation in asphyxiated newborns treated with hypothermia.
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Another important factor to take into account is the variations in oxygen utilization and
demand that occur during hypothermia treatment, in particular during the first few hours of
life. In a previous study on asphyxiated newborns treated with hypothermia, the regional
cerebral oxygen saturation measured by near-infrared spectroscopy (NIRS) increased from
day 1 to 2 of life in all newborns regardless of whether they did or did not develop brain injury.
However, newborns who later develop brain injury had higher regional cerebral oxygen
saturation, which may reflect either more severe neuronal injury, and thus less utilization of
oxygen by dead tissues, or the phenomenon of luxury perfusion that occurs when increased
brain perfusion exceeds the metabolic demand [28].
As previously mentioned, hypothermia decreases metabolic rate and therefore leads to a
decrease in carbon dioxide production. With respect to an asphyxiated newborn treated with
hypothermia, who is breathing spontaneously, this means that any drop in the partial pressure
of carbon dioxide (by a decrease in carbon dioxide production) will correlate with decreased
ventilation via chemoreceptor inhibitory input into the respiratory center, in an effort to
maintain a stable partial pressure of carbon dioxide. However, regarding an asphyxiated
newborn treated with hypothermia, who is intubated, a risk of hyperventilation and respira‐
tory alkalosis exits if the ventilator parameters are not adjusted to the decreased carbon dioxide
production [22]. Further worsening of the hypocapnia by hypothermia may further worsen
brain injury in asphyxiated newborns treated with hypothermia.
4. Evidence for best practices for ventilation in asphyxiated newborns
treated with hypothermia
Most asphyxiated newborns are intubated at birth as per resuscitation measures and remain
on mechanical ventilation during some part of the hypothermia treatment or during the whole
length of the treatment. Past studies have reported that the ventilatory management of
asphyxiated newborns treated with hypothermia is very complex [29], since it has to take into
account all the previously discussed issues. The adjustment of ventilator settings should be
closely fine-tuned to optimize oxygenation and limit hypocapnia in asphyxiated newborns
treated with hypothermia (Table 1).
Mechanical ventilation in asphyxiated newborns treated with hypothermia should aim for
optimal lung recruitment and avoidance of overdistension. Optimal lung recruitment should
decrease atelectasis, which may reduce the effective gas exchange area in the lungs and
contribute to the hypoxic pulmonary vasoconstriction [25]. In contrast, overdistension should
be avoided, since it may lead to systemic hypotension by decreasing venous return, exacerbate
persistent pulmonary hypertension, worsen the oxygen delivery, and thus decrease the organs’
perfusion, particularly the brain [30]. No evidence from randomized controlled trials has
suggested the superiority of high-frequency oscillatory ventilation over conventional me‐
chanical ventilation in near-term and term newborns [31]. In addition, no available studies
have explored which mode is the most suitable among the different possible modes of
mechanical ventilation for these newborns.
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After optimal lung recruitment, optimizing oxygenation consists mainly in limiting persistent
pulmonary hypertension. Wide variations in the management of persistent pulmonary
hypertension persist among neonatologists, which probably reflect the lack of an evidence-
based approach for the treatment of neonatal persistent pulmonary hypertension [32]. In
addition, the most optimal values for oxygenation parameters for asphyxiated newborns
during hypothermia treatment are currently not known and probably vary according to the
day of life, as has been demonstrated by the previously discussed variations in oxygen
utilization and demand that occur during hypothermia treatment. Increasing the fraction of
inspired oxygen has a known pulmonary vasodilator effect and should thus improve oxygen
delivery and decrease the risk of further brain injury. However, this increase in the fraction of
inspired oxygen should be carefully monitored, since hyperoxia or an excessive delivery of
oxygen relative to the demand may lead to a worsening of brain injury through the formation
of oxygen-free radicals that could at the same time worsen pulmonary hypertension [33].
Although current evidence does not support the early use of inhaled nitric oxide in preterm
infants, it has been shown to decrease the need for extracorporeal membrane oxygenation in
near-term and term infants with hypoxic respiratory failure [34]. Given the potential-added
beneficial effect on neuroprotection and the possible impact of persistent pulmonary
hypertension on brain injury, the use of nitric oxide should be considered early in the course
of treatment [35]. In addition, it is important to consider cardiopulmonary interactions and
optimize blood pressure in these newborns to limit the right-to-left shunting. As a last
treatment resort, extracorporeal membrane oxygenation should be considered to optimize
oxygenation and has been demonstrated to be feasible for asphyxiated newborns treated with
hypothermia [17]. Further studies are needed to determine the most optimal values for
oxygenation parameters and the best methods to reach them with respect to asphyxiated
newborns treated with hypothermia.
Limiting hypocapnia is the next important step. Several studies have highlighted the impor‐
tance of preventing hypocapnia in ventilated asphyxiated newborns during hypothermia [29,
36]. It remains to be established what has the worst impact on brain perfusion—a single
hypocapnic episode, cumulative hypocapnia, and/or fluctuations in the partial pressure of
carbon dioxide [29]. Moreover, it may be the combination of hypocapnia with hyperoxia that
could lead to more adverse outcomes [36]. Alternatively, hypercapnia also should be avoided,
since it has been shown to alter cerebral blood flow by causing cerebral vasodilatation and
impairing cerebral autoregulation [37]. Currently, conflicting evidence exists with respect to
the efficacy of permissive hypercapnia on brain protection. Although some studies have
argued that it helps to avoid ventilation-induced brain injury [20], a recent study on extremely
low-birth weight infants has found no significant decrease in lung injury nor mortality in
newborns managed with permissive hypercapnia [38]. Permissive hypercapnia has yet to be
further studied in asphyxiated newborns receiving therapeutic hypothermia. Further studies
that continuously monitor the partial pressure of carbon dioxide levels and quickly adjust the
ventilator settings would be necessary to improve the ventilatory management of these
newborns.
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oxygenation parameters and the best methods to reach them with respect to asphyxiated
newborns treated with hypothermia.
Limiting hypocapnia is the next important step. Several studies have highlighted the impor‐
tance of preventing hypocapnia in ventilated asphyxiated newborns during hypothermia [29,
36]. It remains to be established what has the worst impact on brain perfusion—a single
hypocapnic episode, cumulative hypocapnia, and/or fluctuations in the partial pressure of
carbon dioxide [29]. Moreover, it may be the combination of hypocapnia with hyperoxia that
could lead to more adverse outcomes [36]. Alternatively, hypercapnia also should be avoided,
since it has been shown to alter cerebral blood flow by causing cerebral vasodilatation and
impairing cerebral autoregulation [37]. Currently, conflicting evidence exists with respect to
the efficacy of permissive hypercapnia on brain protection. Although some studies have
argued that it helps to avoid ventilation-induced brain injury [20], a recent study on extremely
low-birth weight infants has found no significant decrease in lung injury nor mortality in
newborns managed with permissive hypercapnia [38]. Permissive hypercapnia has yet to be
further studied in asphyxiated newborns receiving therapeutic hypothermia. Further studies
that continuously monitor the partial pressure of carbon dioxide levels and quickly adjust the
ventilator settings would be necessary to improve the ventilatory management of these
newborns.
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To monitor the changes in the partial pressure of carbon dioxide and pH during hypothermia
treatment and the adjustment of ventilatory settings, two strategies are available, depending
on whether the partial pressure of carbon dioxide and pH are corrected or not for temperature.
The “α-stat” strategy does not correct the partial pressure of carbon dioxide and pH for body
temperature; rather, it measures them at normal body temperature (37°C) as is usually done
for lab measurements of blood gas parameters if not specified otherwise. Alternatively, the
“pH-stat” strategy adjusts the partial pressure of carbon dioxide and pH values to the actual
body temperature of the newborn. At hypothermia temperature (33.5°C), the partial pressure
of carbon dioxide will decrease and pH will increase compared to normal body temperature
(37°C) [22, 39], since the solubility of a gas within a liquid (such as blood) decreases with lower
temperature due to physical laws. A review of 16 studies comparing the efficacy of these two
strategies in managing acid-base disturbances in the context of deep hypothermic circulatory
arrest have suggested that the pH-stat strategy should be preferred for the pediatric population
[40–44]. Such a study has not yet been performed in asphyxiated newborns treated with
cooling. In the large randomized controlled trials of therapeutic hypothermia following
asphyxia [9, 10], the pH-stat strategy was used, since it was considered to be the most cautious
approach for maintaining the physiologic partial pressure of carbon dioxide and pH levels.
With this strategy, ventilator settings need to be decreased more aggressively.
5. Conclusions
The respiratory management of asphyxiated newborns treated with hypothermia is complex.
Many factors specifically related to asphyxia and hypothermia must be considered when
dealing with the ventilatory management of these newborns, so to offer them the best possible
level of care. Evidence is currently lacking regarding the best practices to use to optimize
oxygenation and ventilation in these newborns and prevent the development of further brain
injury. Further studies should be performed to determine what is the optimal mode of
ventilation and what are the most optimal values for oxygenation parameters for these
newborns during hypothermia treatment. Until then, the treating team should keep a very
close eye on them to maintain, as much as possible, homeostasis, and to avoid hypoxemia,
hyperventilation, and hypocapnia.
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Abstract
Bronchopulmonary dysplasia (BPD) is the chronic lung disease of prematurity, and is
the most common morbidity associated with preterm birth. Severe BPD is defined
currently as a supplemental oxygen requirement at 28 days of age and a need for >30%
oxygen and/or positive pressure at 36 weeks of corrected gestational age (CGA) in an
infant  born  at  <32  weeks  of  gestational  age.  The  vast  majority  of  severe  BPD  is
characterized by high lung resistance, such that ventilation approaches must consider
the relatively long time constants needed to adequately ventilate all portions of the lung
to maximize ventilation-perfusion (V/Q) matching. At the same time, any ventilation
strategy  must  take  into  account  the  vulnerable  neurodevelopmental  stage  that
characterizes the preterm infant with severe BPD. To maximize neurodevelopmental
outcomes the ventilation strategy must avoid chronic use of sedation. In this chapter,
we present the physiology underlying a low-rate, high-volume ventilation approach
that maximizes V/Q matching, while optimizing neurodevelopment in patients with
severe BPD.
Keywords: lung resistance, time constant, neurodevelopment, preterm infant
1. Introduction
Bronchopulmonary dysplasia (BPD) was first characterized by Northway and colleagues in
1967 as a chronic lung disease afflicting premature infants after neonatal intensive care unit
(NICU) treatment that included administration of oxygen and mechanical ventilation [1]. Early
descriptions of BPD noted profound airway inflammation, fibrosis, areas of emphysema, and
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
a heterogeneous physiology. At that time BPD typically affected babies greater than 30 weeks
of gestation at birth who weighed more than 1000 g, as few babies born earlier or smaller survived.
As neonatal care has advanced, with widespread use of prenatal, antenatal, and postnatal
treatments that have markedly improved survival, there has been a notable change in the
epidemiology of BPD [2–4]. Such improvements in care include but are not limited to nearly
universal administration of prenatal steroids to high risk infants, aggressive resuscitation
practices,  gentle  forms of  ventilation,  improvements  in  parenteral  and enteral  nutrition,
surfactant administration, and widespread use of nasal continuous positive airway pressure
(nCPAP). The result of all these improvements in care has been marked increases in NICU
survival of extremely low birth weight (ELBW) infants. While NICU survival has improved and
BPD has become uncommon in infants greater than 30 weeks of gestation, rates of BPD have
not changed for ELBW infants and thus the absolute number of infants diagnosed with BPD is
likely increasing [5–7].
BPD is a phenotypically diverse disease with a variety of causes and consequences [8]. While
previous definitions of BPD focused on a single diagnostic criteria (i.e., X-ray changes, a
supplemental oxygen requirement at 28 days of age, or, more recently, a supplemental oxygen
requirement at 36 weeks of corrected gestational age (CGA)) the most widely used current
classifications divide BPD into mild, moderate, and severe based on the degree of support
required at critical junctures. Mild BPD is defined as any supplemental oxygen requirement
at 28 days of life, moderate BPD is defined as any supplemental oxygen requirement less than
0.3 FiO2 at 36 weeks, while severe BPD is defined as a supplemental oxygen requirement with
a FiO2 greater than 0.3 and/or the need for positive pressure respiratory support at 36 weeks
of CGA [9]. These changes in classification have been helpful in better defining BPD. However
there remains a population of infants with the most severe forms of BPD who are not well
characterized by the current classification and who represent the most difficult clinical cases
typically cared for within neonatology (the severest of the severe). Such infants typically
require chronic and extreme ventilator support with high peak inspiratory pressures (PIPs)
and mean airway pressures (MAPs). They are often treated with high doses of neuroactive
medications including narcotics, sedatives, and systemic corticosteroids. With a few notable
exceptions [10], their neurodevelopmental outcomes are typically grim [11, 12]. The clinical
management of patients with this degree of illness (informally known as “super-severe BPD”)
will be the focus of this chapter.
2. Disease progression and physiology
To understand the keys to clinical management of super-severe BPD as shown in the chest X-
ray in Figure 1, it is critical to understand the underlying disease progression and physiology.
ELBW infants are typically born at the intersection of the canalicular and saccular stages of
lung embryogenesis whereas more mature infants in previous cohorts were born well after
the saccular stage had commenced. This is a critical issue to understand modern, severe BPD
because the stage of lung development during which lung damage occurs heavily influences
both the pathological findings associated with the diagnosis and the clinical care required to
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manage infants with evolving BPD. Whereas older descriptions of BPD (referred to as “old
BPD”) typically emphasized classic progressive stages including prominent fibroproliferative
changes, recent descriptions (referred to as “new BPD”) have noted disruptions of distal lung
growth [13, 14]. A key insight for the clinical management of the most severe forms of BPD,
however, is the prominence of airway injury and dysfunction resulting from disruption of
normal canalicular development.
Figure 1. A typical chest X-ray for a patient with severe BPD demonstrating areas of overinflation interspersed with
areas of consolidation.
Most current lung-protective strategies in neonatology are directed towards surfactant
deficiency, for which extremely preterm infants are at high risk early in their NICU course [15].
Surfactant deficiency is characterized by low lung compliance (CL, defined as change in volume
for a given change in pressure or ΔV/ΔP expressed as ml/cmH2O) and normal lung resistance
(RL, defined as change in pressure for a given flow rate of the gas or ΔP/flow expressed as
cmH2O/ml/s). For infants in the early, acute stages of neonatal intensive care this is a very
reasonable assumption, and the point of the lung protective strategy is to prevent BPD.
However, this chapter discusses the mechanical ventilation of the patient with severe BPD, a
relatively long time after admission to the NICU for initial respiratory care using appropriate
lung protective strategies.
Let us consider how the lung fills and more importantly how the lung empties. The time needed
to fill or empty is indicated by the product of CL and RL, termed the time constant (τ, measured
in seconds). One time constant describes the time required to achieve 63% of maximal inhaled
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or exhaled volume, and 5 time constants are needed for 99% of maximal inhaled or exhaled
volume. Since compliance is low and resistance is normal in early, acute lung disease afflicting
extremely premature infants, the time required for full inflation or deflation of the lung is very
short. Thus, in order to avoid overdistention and atelectasis and consequent injury, “gentle
ventilation” emphasizes high-rate, low-tidal volume ventilation administered with short
inspiratory times (Ti) with adequate positive end-expiratory pressure (PEEP) via either
conventional mechanical ventilation (CMV) or high-frequency oscillatory ventilation (HFOV).
Typical “lung protective” strategies suggest CMV rates of 40–60 breaths per minute (bpm), Ti
of 0.2–0.3 s and tidal volumes (Vt) of 4–6 ml/kg, and for HFOV use of the minimum MAP and
amplitude (ΔP) required to achieve clinical goals. Successful application of “gentle ventilation”
strategies has been associated with improvements in a number of clinical outcomes including
reductions in BPD, earlier extubation, and improved survival, among others. Indeed, gentle
ventilation is clearly the standard of care in early, acute lung disease in extremely preterm
infants.
While it may be safe to assume that early lung disease is associated with low compliance and
normal resistance and can thus be adequately managed with a high-rate, low-tidal volume
approach, are these assumptions valid in well-established BPD, particularly in the most severe
forms? Severe BPD is often perceived to have reduced pulmonary compliance, however the
predominant findings in established BPD are complex and measurement of pulmonary
physiology in infants is technically difficult. The following is a summary of the current
knowledge of pulmonary function in infants with the most severe forms of BPD.
3. Pulmonary function in severe BPD
While a variety of methods have been used to assess pulmonary function in infants during
tidal breathing, it is critical to understand that each method has specific limitations and the
results of such measurements must be understood within this context [16]. Measurements of
CL, for instance, may be variable as they are typically determined over a limited tidal volume
range and depend heavily on the lung volume at which they are obtained. Further, increased
airway resistance can impact measurements of CL during tidal breathing depending on the
respiratory rate. This is termed “frequency dependence” and can lead to reductions in
measured compliance even in the absence of actual changes in true compliance. Other methods
of assessing resistance and compliance present different problems; the single breath occlusion
technique, for instance, assumes a linear, “one-compartment” model, however evidence
strongly suggests that the curvilinearity of the passive expiratory flow-volume relationship in
infants with severe BPD is much better described by a “two-compartment” model. Therefore,
the one-compartment analysis available in ventilator software may substantially underesti‐
mate the time constant for the damaged portions of the lungs [17–19].
Despite the limitations described above, our own data combined with those of other advanced
pulmonary centers describe a fairly consistent picture. In summary, infants with the most
severe forms of BPD are overwhelmingly likely to have pulmonary function that is dominated
by marked increases in resistance to airflow, as demonstrated by reductions in forced expira‐
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tory volume in the first 0.5 s (FEV 0.5) and in other forced expiratory flows (FEFs), with
relatively normal compliance when normalized for the infant’s size [20–23]. This type of
pulmonary function is, in many ways, similar to that found in asthma and severe bronchiolitis
and is likely the result of injury to the developing airways predominant in ELBW infants.
Figure 2. Volume-time curve for one breath for typical patient with severe BPD showing the fast space and the slow
space. In this example, the inspiratory time is 0.5 s and the rate is 17 breaths per minute. The fast compartment (black
circles) has CL = 0.5 ml/cmH2O, RL = 0.2 cmH2O/(ml/s), and τ = 0.1 s, while the slow space (gray circles) has CL = 0.8
ml/cmH2O, RL = 0.75 cmH2O/(ml/s), and τ = 0.6 s. The open triangles are the total Vt and is the sum of the volumes in
the fast space and slow space. In this example the total Vt is 31.4 ml, the Vt of the fast space is 11.9 ml, and the Vt of the
slow space is 19.5 ml. Clearly demonstrated is that exhalation depends entirely on the slow space as the fast space has
completely emptied by 1 s, while the slow space has only completely emptied by 3.5 s, the total time for 1 breath.
The injuries to the lungs of infants with severe BPD are not regionally uniform and thus the
pulmonary function of the respiratory system is heterogeneous, with some portion of the lung
functioning well and other portions that are severely affected. Because of this nonuniformity,
the best way to describe this heterogeneity is a “two-compartment” model with two separate
and distinct sets of pulmonary mechanics [17–19]. The healthy compartment (sometimes
referred to as the fast compartment) has normal or near-normal compliance and resistance,
and thus a near-normal time constant. Conversely the damaged compartment (sometimes
referred to as the slow compartment) is often severely injured with extremely high resistance
but normal or near-normal compliance (Figure 2). This creates a situation in which the optimal
clinical strategies necessary to achieve adequate oxygenation and ventilation will be deter‐
mined by the clinician’s assessment of the relative proportion of the lung that each compart‐
ment represents. Infants with relatively minimal disease, for instance, have lungs that are
mostly composed of the fast compartment, while those with the most severe BPD are almost
entirely slow compartment. Our own data suggest that on average 67% of the tidal volume is
from the slow compartment in patients with severe BPD following bronchodilator treatment
[17, 19]. This is a critical distinction as the most effective ventilatory strategy for patients with
Mechanical Ventilation of the Infant with Severe Bronchopulmonary Dysplasia
http://dx.doi.org/10.5772/63691
87
severe BPD must take into account the slow space, and the approach to ventilating the slow
space is vastly different from the approach to ventilating the normal or fast space.
In addition, infants with severe BPD have significant areas of ongoing ventilation/perfusion
(V/Q) mismatch and other areas of tenuous V/Q matching which lead to ongoing hypoxia and
occasional “blue spells” as the tenuous area becomes intermittently poorly ventilated.
4. Physical exam, radiological, and laboratory findings in severe BPD
Physical examination findings in infants with evolving or established severe BPD are predict‐
able but nonspecific as they represent typical findings of respiratory distress from any cause.
Patients with severe BPD are typically tachypneic and will often have retractions, grunting,
and nasal flaring. On auscultation wheezing and/or rales are common findings. In addition,
infants with severe BPD will often be relatively hypoxic with substantial intermittent hypoxic
spells that are unpredictable and often associated with movement, coughing, gagging, or
bronchospasm [18]. Such infants may further appear stressed with varying degrees of hyper-
or hypotonia depending on the scale of their respiratory insufficiency. On palpation, the
abdomen is typically normal; however, the liver may be displaced by pulmonary hyperinfla‐
tion into the abdomen and may be easily palpable.
Radiological findings in severe BPD are typically dependent on the progression of the disease.
Infants in the early stages of BPD may have diffusely hazy lungs, with marked edema, and
may be underinflated. As the disease evolves and becomes dominated by resistance, however,
the typical chest X-ray will demonstrate hyperinflation, with relatively little direct correlation
to ventilator pressures. This more likely results from breath-stacking due to prolonged
expiratory time constants rather than the set ventilator pressures. Further, as the disease
progresses the chest X-ray typically becomes much more heterogeneous with areas of patchy
atelectasis intermixed with areas of hyperinflation (Figure 1).
Laboratory findings for infants with severe BPD are typically no different than for any infant
with chronic respiratory insufficiency. Most notably, many such patients will have a chronic
respiratory acidosis with an elevated pCO2 and consequently an elevated serum bicarbonate.
They may have a compensatory metabolic alkalosis and if blood gases are obtained they may
have a substantial base excess. In addition, infants with severe BPD are at extreme risk for
growth failure and osteopenia of prematurity, and thus may have associated laboratory
abnormalities including elevated alkaline phosphatase, low total protein, and low albumin
levels.
5. Approach to mechanical ventilation in severe BPD
There are three critical components to successfully ventilating infants with BPD. The first is
that the physician must come to terms with the fact that infants with severe BPD have
significantly damaged lungs that are physiologically relatively static, in other words they have
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a chronic illness and not an acute illness. It is simply impossible for the lung function of such
infants to change substantially over short periods of time (days to weeks) and it is therefore
unreasonable to expect that the required respiratory support can be weaned relatively rapidly.
Second, severe BPD is evolving in infants during periods of incredibly rapid neurodevelop‐
ment. Overall growth during the first few months of an extremely preterm infant’s life is
geometric and represents their most rapid period of growth; consequently, missed opportu‐
nities for developmental gains may be irrecoverable. Thus it is imperative that the respiratory
support provided such infants be adequate to support normal interactions with their parents,
family, and environment, even if requiring mechanical ventilation. Finally, the modes of
ventilation used in these patients must be optimized to address the pulmonary function
present in the damaged part of the lung, which likely represents the majority of the lung.
Strategies that are not aimed at the diseased compartment of the lung will by definition be
focused on the little remaining healthy tissue which then must compensate by absorbing the
entire ventilatory load.
Since pulmonary function in infants with severe BPD is dominated by increased resistance,
the expiratory time constant is very long. In infants with the most severe forms of BPD, this
time constant may be as long as 0.5–0.75 s [19]. Complete exhalation, by definition, requires 5
time constants and thus may require as long as four or five seconds (5 x 0.5 = 2.5 s; 5 x 0.75 =
3.5 s). Thus, the respiratory rate must be set to allow for 5 expiratory time constants in patients
with severe BPD. For if too high a respiratory rate is set on the ventilator, then there will be
inadequate time for exhalation, and the subsequent breath will begin with the lung already
partially inflated (breath stacking). This cycle will occur with every breath; the damaged
portion of the lung will rapidly become hyperinflated, and will not be able to contribute
meaningfully to overall minute ventilation (MV). Therefore the primary goal of ventilation in
infants with severe BPD is to allow adequate time, in absolute terms, for complete emptying.
If we take an example assuming an inspiratory time of 0.5 s and an expiratory time constant
of 0.6 s, the minimum inhalation/exhalation cycle length consistent with full exhalation is 3.5
s (inhalation = 0.5 s, exhalation = 3 s), and the maximum rate that can be used on the ventilator
would be 60 seconds divided by 3.5 seconds per cycle, or 17 bpm (see Figure 2). Any respiratory
rate greater than 17, in this example, will result in breath stacking, hyperinflation, and
insufficient ventilation of the bulk of the lung. This will lead to V/Q mismatch and hypoxemia
which will manifest as an increasing oxygen requirement.
Carbon dioxide removal however depends on MV. MV is equal to the rate times the tidal
volume (MV = rate x Vt). If the MV is 200–300 ml/kg/min, and we need to limit the set rate on
the ventilator to 17 bpm to avoid hyperinflation and hypoxemia, then the only variable that
we can impact is Vt. The equation can be rearranged to determine the necessary Vt as follows:
Vt = MV/rate, and substituting our MV and rate gives 200–300/17 which equals a Vt of 12–18
ml necessary to provide an adequate MV at a rate of 17. A lower Vt than this will, by definition,
results in inadequate MV. Furthermore, keep in mind that increasing the rate will prevent
adequate emptying, leading to hyperinflation which will make the lung less compliant and
thereby lead to a decrease in Vt. Essentially then, the practitioner has no alternative that is
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consistent with both full emptying and adequate MV other than to utilize a low-rate, high-
tidal volume ventilation strategy in the patient with severe BPD.
The patient with severe BPD who is ventilated with a faster rate usually manifests air hunger
demonstrated by tachypnea, retractions, and “fighting” the ventilator. These patients are often
given sedatives and sometimes even paralyzed to facilitate ventilation. However in patients
with severe BPD on mechanical ventilation, once a physiological slow-rate, high-tidal volume
ventilation strategy is employed, the patient begins breathing more normally without air
hunger. These patients usually do not require sedation and should be awake and active, such
that they can interact with their environment and with therapies. Thus, this physiological
ventilation strategy not only improves V/Q matching in the lung but also allows the patient to
maximally benefit from neurodevelopmental therapy. Using this approach we have found that
neurodevelopmental outcomes for patients with severe BPD are no longer grim, but rather are
quite good [10, 24].
A small number of patients with severe BPD will not respond to this mechanical ventilation
strategy. When a patient with severe BPD does not respond to slow-rate, high Vt ventilation,
then the practitioner must consider rare but important causes of hypoxemia and V/Q mis‐
match. We recommend structure-function studies in these patients because a very small
percentage of patients diagnosed with severe BPD will actually have a predominantly
restrictive lung disease, and therefore will respond better to lower tidal volumes and/or PEEP.
Also, there are some patients who will have tracheobronchomalacia as the predominant
pathology. These patients will often benefit from relatively high PEEP to “stent” open airways
on expiration. Another important cause of V/Q mismatch in this population, particularly those
with severe degrees of hypoxia, is pulmonary hypertension [25]. Thus, we recommend an
echocardiogram in patients who do not respond to the slow-rate, high Vt strategy with a
decrease in FiO2, or in those patients who fail to subsequently wean on the mechanical
ventilator. For patients with severe BPD it is prudent to follow echocardiograms while the
patients are on mechanical ventilation, since they are at high risk of developing pulmonary
hypertension [26].
Once adequate MV is achieved in infants with severe BPD, it is imperative to avoid the usual
acute care mentality of rapid weaning, as the underlying pathophysiology will change only
with growth. In other words, once adequate MV and V/Q matching is established in the patient
with severe BPD, the focus should change from weaning the ventilator to providing optimal
nutrition [27]. Furthermore, the infant with severe BPD at this stage must be adequately
supported at all times to allow proper neurodevelopment. In fact, attempts to wean support
rapidly are highly unlikely to succeed and can impede neurodevelopmental progress putting
the patient at higher risk for adverse neurodevelopmental outcomes. Our approach is to
determine the most optimal ventilator settings as quickly as possible and then to delay attempts
at weaning until the oxygen requirement has steadily declined to less than 40%. Optimal
ventilator settings are those settings that allow for weaning of FiO2 and allow the patient to
breath comfortably without evidence of air hunger. Even when these criteria are met, it is
critical to assess each infant’s developmental response to therapy. If therapies are well tolerated
and FiO2 is <40% then it is reasonable to try slowly weaning the ventilator. Although we are
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often successful extubating patients without any pressure weaning at all, if weaning is
considered necessary then we recommend weaning Vt, either by decreasing PIP (for pressure-
targeted ventilation) or decreasing set Vt (for volume-targeted ventilation). Each wean should
be evaluated in terms of oxygen requirement and tolerance of therapies. If the wean does not
result in an increase in oxygen need or a decreased tolerance of therapies then that wean was
tolerated by the patient. If, on the other hand, the wean results in an increase in FiO2 or poor
tolerance of therapies then that wean was not tolerated and the ventilator should be turned
up again to the previous settings. Once extubation criteria are met (Table 1) and the patient is
successfully extubated, infants with severe BPD will often need prolonged noninvasive
positive pressure via nCPAP, which should only be weaned once the infant is thriving on
relatively low amounts of supplemental oxygen (25–30%). Obviously, these patients will likely
need supplemental oxygen therapy for a relatively long time. Although it is rare in our practice
to discharge patients home on mechanical ventilation or positive pressure, the majority of our
patients are, i.e. patients are discharged home on supplemental discharged home on supple‐
mental oxygen.
No airway anomalies
Thriving with FiO2 ≤0.4 for at least 48 h
No recent escalation in respiratory support
Positive weight trend and good linear growth
Full enteral feeds
No surgery planned for at least 72 h
No ROP examination on day of extubation
No active infections
All needed extubation medications ordered
No recent extubation failures
Team consensus that the patient is ready
Table 1. Extubation criteria for infants with severe BPD.
6. Conclusions
Infants with severe BPD are at extreme risk for morbidity and mortality. The vast majority of
these infants, however, has fairly predictable pulmonary mechanics, characterized by high
resistance. Once these pulmonary mechanics are understood, it is usually possible to ade‐
quately ventilate these babies using a physiological, low-rate, high-tidal volume approach
aimed at supporting ongoing neurodevelopment. It is imperative to adequately support these
patients for a relatively long time to allow for lung growth and neurodevelopment. The
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temptation to wean these patients rapidly, as we do for acutely ill patients, must be avoided
to allow for optimal outcomes.
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Chapter 7
Respiratory Distress and Management Strategies in the
Newborn
Begüm Atasay, İlke Mungan Akın and Serdar Alan
Additional information is available at the end of the chapter
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Abstract
Approximately 10% of neonates require respiratory support immediately after delivery
due to transitional problems or respiratory disorders, and up to 1% of neonates are in
need  of  resuscitation.  Respiratory  distress  is  the  most  frequent  cause  of  neonatal
intensive care unit (NICU) admission, and the individual management strategies should
be the main task in NICUs for these infants. Regardless of the cause, if not recognized
and managed in advance, respiratory distress can escalate to respiratory failure and
cardiopulmonary arrest. This chapter explores the evaluation and differential diagno‐
sis of respiratory distress in neonates and presents an update on management strategies
according to the protocol of Ankara University Children’s Hospital Neonatal Inten‐
sive Care Unit.
Keywords: respiratory distress, newborn, transient tachypnea, respiratory distress
syndrome, neonatal pneumonia, management
1. Introduction
Approximately 10% of neonates require respiratory support immediately after delivery due
to transitional problems or respiratory disorders, and up to 1% of neonates are in need of
resuscitation. Respiratory distress is the most frequent cause of neonatal intensive care unit
(NICU) admission, and the individual management strategies should be the main task in
NICUs for these infants. Fifteen percent of term infants and twenty-nine percent of late preterm
infants admitted to the NICU develop significant respiratory morbidity; this is even higher
for infants born before 34 weeks’ gestation.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Regardless of the cause, if not recognized and managed in advance, respiratory distress can
escalate to respiratory failure and cardiopulmonary arrest. Therefore, it is imperative that any
health care practitioner caring for newborn infants can readily recognize the signs and
symptoms of respiratory distress, differentiate various causes, and initiate management
strategies to prevent significant complications or death. [1]
2. Evaluation of the newborn infant’s respiratory status
Respiratory distress is recognized as any signs of labored breathing in the neonate. Recognition
of these signs and symptoms is important for both diagnosis and evaluation of the response
to treatment [2].
A thorough history may guide in identifying risk factors associated with common causes of
neonatal respiratory distress. Together with former and present obstetric history, gestational
age, birth weight, presence of fetal distress, maternal diseases, medications, exposure to
antenatal steroid, mode and duration of delivery, need for resuscitation, timing, and severity
of signs and symptoms are all important for initial evaluation and decision making.
A detailed physical examination should focus beyond the lungs to identify non-pulmonary
causes, such as airway obstruction, abnormalities of the chest wall, and cardiovascular or
neuromuscular disease that may initially present as respiratory distress in a newborn [1].
Careful inspection and auscultation are important. Signs of increased work of breathing (WOB)
[1], such as tachypnea, nasal flaring, retractions, bilateral and equal aeration of the lung and
breath sounds, and the presence of cyanosis, should be evaluated. Noisy breathing may
Figure 1. Etiologies of respiratory distress in the newborns.
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indicate increased airway resistance, and the type of noise auscultation such as grunting,
stridor, and wheezing may help to localize airway obstruction [1].
Non-invasive pulse oximetry is recommended by the American Heart Association (AHA)
guideline for neonatal resuscitation in 2015 [3] and the American Academy of Pediatrics (AAP)
to screen infants for hypoxemia, and saturation oxygen (SpO2) values less than 85% are
considered normal before 5 minutes of age [3, 4]. The partial pressure of transcutaneous CO2
(PtCO2) is considered as an accurate estimate of both arterial and venous CO2 tension in
newborn [5]. Blood pressure, heart rate follow, and frequent assessment of capillary refill time
also give clues about the infants’ well being.
Chest X-ray can reveal congenital malformations, and intrathoracic space-occupying lesions,
such as pneumothorax, mediastinal mass, and congenital diaphragmatic hernia (CDH), can
compromise lung expansion [1].
Blood gas analysis may vary according to gestational age and underlying disease of the
newborns. Targeted arterial blood gas values are shown in Table 1 [6].
Gestational age Arterial blood gas values
pH PaO2 (mm Hg) PaCO2 (mm Hg) HCO3 (mEq/L) BE
<30 weeks 7.27–7.32 45–60 45–60 19–22 ±4
30–36 weeks 7.30–7.35 50–70 45–55 22–25 ±3
>36 weeks 7.32–7.38 60–80 35–45 24–26 ±3
Term with PPHT 7.35–7.45 80–100 30–45 24–26 ±3
BPD 7.35–7.45 50–80 55–65 22–25 ±3
Table 1. Range of acceptable arterial blood gas values according to gestational age. Adapted from Ref. [4].
Neonatal respiratory distress is not due to respiratory origin. Thus, after initial resuscitation
and stabilization, it is important to attain a detailed history, physical examination, and
radiographic and laboratory analyses to determine a more specific diagnosis and tailor an
appropriate individual management as soon as possible (Figure 1).
Significant tachypnea without increased work of breathing (WOB) should prompt additional
laboratory investigation to identify metabolic acidosis or sepsis [1].
Most of the time it may be difficult to distinguish cardiovascular diseases from pulmonary
causes of respiratory distress. Most congenital heart defects present with cyanosis, tachypnea,
or respiratory distress from cardiac failure. Timing of the symptoms is an important clue for
most of the conditions as very few congenital heart defects present immediately after birth [1].
Cardiac pathology should be suspected especially when there is persistent cardiomegaly,
abnormal pulses, or a postductal SaO2 drop.
Regardless of the cause, it is vital to recognize symptoms and act quickly. Non-specific
treatment and respiratory support started even before the specific underlying diagnosis. If the
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newborn cannot sustain the extra WOB to meet its respiratory needs, respiratory failure
follows. This failure may manifest as impaired oxygenation (cyanosis) or ventilation (respira‐
tory acidosis). Without prompt intervention, respiratory arrest is imminent.
3. Common diseases causing neonatal respiratory distress
3.1. Transient tachypnea of neonate
Transient tachypnea of neonate (TTN) is a benign self-limited, common respiratory disease of
term and late preterm infants due to impaired clearance of lung liquid. Rapid clearance of fetal
lung fluid is a key aspect of the transitional period in the delivery room [7]. Hooper et al. [8],
who used phase contrast X-ray imaging to observe the rate and spatial pattern of lung aeration
at birth in rabbit pups delivered by cesarean section, found the close association of residual
liquid clearance from the airways with the present inspiratory activity. They detected no
significant distal movement of the air/liquid interface between breaths. These findings indicate
that the transpulmonary pressure generated by inspiratory effort also plays a critical role in
the airway fluid clearance [8]. The clearance of fetal lung fluid mainly depends on two
mechanisms: amiloride-sensitive sodium transport through epithelial sodium channels in lung
and mechanical forces created during vaginal delivery. Actually, lungs of preterm infants are
less responsive to this sodium reabsorption, leading to less efficient lung fluid clearance [9].
Pathophysiology of TTN and RDS is assumed to be related to the disruption of this process [7].
In our study, we suggested the possible relationship of lower cord levels of cortisol, adreno‐
corticotrophic hormone, and free triiodothyronine in TTN group with fetal lung fluid clearance
and hormonal modulatory effect on postnatal pulmonary adaptation [10]. Thus, interruption
of this process at any step such as delivery before onset of labor or delay in the first breath may
result in transition problems including TTN.
Delivery following elective cesarean section (C/S) is the main risk factor for TTN. The usual
mechanisms present with the onset of labor for the clearance of lung fluid in vaginal delivery
are often inadequate after elective C/S, resulting in TTN [11]. Other risk factors are delivery
prior to 39 weeks of gestation, precipitous delivery, fetal distress, male sex, low birth weight
and macrosomia [12], multiple gestations and maternal sedation, and maternal diseases such
as gestational diabetes and asthma [13].
Incidence of TTN requiring ventilation is significantly reduced to each extra week in utero
decreasing from 34% at 37 weeks to 0.5% at 41 weeks of gestation [14]. In European Consensus
Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants
– Update 2013 [15], antenatal steroids are also considered for women undergoing a C/S prior
to labor up to term. As the long-term effects are currently unknown, at present, the best course
is to avoid elective C/S prior to 39 weeks wherever possible.
The infant is usually term, near term or large, and premature, and shortly after delivery or
within the first 6 hours of delivery has tachypnea. It usually presents with grunting and other
mild signs of respiratory distress because lung liquid inhibits gas exchange, which persists for
up to 48 hours.
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Continuous pulse oximetry follow-up is needed. Blood gases often reveal some degree of mild
to moderate hypoxemia. Partial CO2 pressure is usually normal due to tachypnea but some‐
times either hypocarbia or mild hypercarbia may exist resulting in mild respiratory acidosis
[16].
Complete blood count (CBC) is needed for differentiation of sepsis, neonatal pneumonia, and
polycythemia because CBC is normal in TTN.
Chest radiographs reveal hyperinflation, which is a hallmark of TTN. There are excess diffuse
parenchymal infiltrates due to fluid in the interstitium, fluid in the interlobar fissure, and
occasionally pleural effusions. Mild to moderate cardiomegaly with flattened diaphragm and
prominent pulmonary vascular markings may also be present (Figure 2a).
Figure 2. Chest X-ray of a newborn with (a) transient tachypnea of the newborn, (b) respiratory distress syndrome, (c)
meconium aspiration syndrome, and (d) pneumothorax.
3.2. Neonatal pneumonia
Among newborns with respiratory distress, the third most likely cause after RDS (46%) and
TTN (37%) is pneumonia. The incidence of pneumonia/sepsis in preterm infants with birth
weight 1500–2500 g is only 0.28%, whereas in patients with birth weight <1000 g, the incidence
is severalfold higher at 1.9% [17].
Respiratory infections in the newborn may be bacterial, viral, fungal, spirochetal, or protozoan
in origin. Infants may acquire pneumonia transplacentally (congenital pneumonia), through
infected amniotic fluid, through colonization at the time of birth, from the community or
nosocomially [18]. Perinatal pneumonia is the most common form of neonatal pneumonia and
is acquired at birth. Common pathogens include Group B streptococcus (GBS), gram-positive
bacteria, Streptococcus pneumonia, Staphylococcus aureus, Listeria, and gram-negative enteric
rods (e.g. E. coli); and viruses, such as herpes simplex virus, respiratory syncytial virus, and
influenza A & B viruses; atypical organisms, such as chlamydia; and fungi [19]. Risk factors
for perinatal pneumonia include prolonged rupture of membranes (PROMs), maternal
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infection (maternal fever or raised white cell count), and prematurity [19]. Birth weight and
age of onset are both strongly associated with the mortality risk from pneumonia. Pneumonia
can occur secondary to invasive mechanical ventilation but is largely confined to preterm
infants who receive prolonged ventilation. Prevention of neonatal pneumonia and its compli‐
cations focuses on maternal GBS screening, intrapartum antibiotic prophylaxis, and appro‐
priate follow-up of newborns at high risk after delivery [20, 21]. On the other hand, the most
important and easiest method of preventing nosocomial pneumonia is hand washing to
prevent cross-infection and avoiding invasive ventilation [19–21].
Pneumonia in newborn infants is often difficult to diagnose and distinguish from other causes
of respiratory distress including RDS and TTN. Infants present with increased WOB and
oxygen requirement. In contrast to older infants and children, neonatal pneumonia is part of
a generalized sepsis illness; thus, obtaining investigations including blood white cell counts,
CRP even though they lack the necessary sensitivity and specificity to accurately diagnose
pneumonia, blood, and cerebrospinal fluid cultures and initiating broad-spectrum antibiotic
therapy is recommended for any symptomatic infant [19, 20]. Unlike TTN, RDS, and MAS,
bacterial infection takes time to develop with respiratory consequences occurring hours to
days after birth.
Chest radiography helps in the diagnosis with bilateral diffuse parenchymal infiltrates with
air bronchograms or lobar consolidation suggesting in utero infection. Pleural effusions are
present in two thirds of cases [22].
3.3. Respiratory distress syndrome
Respiratory distress syndrome (RDS), formerly called hyaline membrane disease, is caused by
a deficiency of surfactant and is often, which strictly speaking, a histological diagnosis. The
Vermont Oxford Network definition for RDS requires an arterial oxygen tension (PaO2) <50
mmHg and central cyanosis in room air, a requirement for supplemental oxygen to maintain
PaO2 >50 mmHg, or a requirement for supplemental oxygen to maintain a pulse oximeter
saturation over 85% and a characteristic chest radiographic appearance within the first 24
hours of life [23].
The EuroNeoNet figures for 2010 show an incidence of 92% at 24–25 weeks’ gestation, 88% at
26–27 weeks, 76% at 28–29 weeks, and 57% at 30–31 weeks [24]. However, published data have
shown that infants with a birth weight of >2500 g account for 9.9–11.5% of infants with RDS,
and those with gestational age of 37 weeks’ gestation account for 7.8% [12].
Pathophysiologic mechanisms include as follows:
A- Surfactant deficiency increases surface tension in alveoli, resulting in microatelectasis and
widespread alveolar collapse. In the absence of surfactant, the small airspaces collapse; each
expiration results in progressive atelectasis. Exudative proteinaceous material and epithelial
debris, resulting from progressive cellular damage, accumulate in the airway and directly
decrease total lung capacity.
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B- In the presence of a weak, compliant chest wall secondary to prematurity, the large negative
pressures generated to open the collapsed airways cause retraction and floppy chest wall
instead of proper inflation and stability [23].
C- The presence or absence of a cardiovascular shunt through a patent ductus arteriosus (PDA)
may change the presentation or course of the disease.
Decreasing gestational age is inversely related to the RDS risk. Dani et al. reported the main
risk factors for RDS as gestational age, low birth weight, maternal age, elective and emergency
C/S, and male sex [12]. Type II cells responsible for surfactant synthesis are sensitive to
asphyxia. Their maturation can be delayed with the presence of fetal hyperinsulinemia. On
the contrary, administration of antenatal corticosteroids, chronic intrauterine stress due to
pregnancy-induced hypertension, intrauterine growth restriction, or twin gestation enhances
their maturity [23].
Preventing premature birth will lower the incidence of RDS. Prenatal steroids decrease the risk
of RDS and additionally decrease the risk of intraventricular hemorrhage and NEC [24].
Twenty-four milligrams of betamethasone therapy is recommended in all pregnancies with
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3.4. Persistent pulmonary hypertension of the neonate
Persistent pulmonary hypertension (PPHN) is a condition characterized by marked pulmo‐
nary hypertension resulting from elevated pulmonary vascular resistance (PVR) and altered
pulmonary vasoreactivity, leading to right-to-left shunting of blood through intra or extrap‐
ulmonary shunts (foramen ovale or PDA) [29]. It can be either primary or secondary due to
conditions leading to hypoxemia such as RDS, congenital diaphragmatic hernia (CDH), MAS,
and pneumonia. Events such as perinatal stress, hemorrhage, aspiration, hypoxia, and
hypoglycemia may lead to PPHN. On the other hand, PPHN may be the result of underde‐
velopment of the lung together with its vascular bed (e.g., CDH and hypoplastic lungs) [19,
29]. Right-to-left shunting of blood through foramen ovale or PDA due to high PVR further
contributes to systemic hypoxemia and metabolic acidemia, both of which contribute to
ongoing increased PVR. Ventilation perfusion mismatching is also likely to be present
compounded by conditions such as MAS [19]. Risk factors can be classified as conditions
related to lungs such as MAS, RDS, pneumonia, pulmonary hypoplasia, and CDH and
conditions related to other systemic disorders (such as polycythemia, hypoglycemia, hypoxia,
acidosis, hypocalcemia, hypothermia, and sepsis) or some of the congenital heart diseases
(total anomalous venous return and hypoplastic left heart). Perinatal asphyxia, CNS disorders,
and neuromuscular diseases can also result in PPHN [29]. Resuscitation and support from
birth may presumably prevent or ameliorate, to some degree, PPHN when it may occur
superimposed on a preexisting condition.
Pulmonary hypertension needs to be considered in any infants with respiratory distress and
cyanosis. This may occur despite adequate ventilation. It is often challenging to manage and
usually presents in the first few hours of life but may present later especially when secondary
to the other conditions. It is also associated with significant mortality especially if associated
with CDH [30]. When PPHN occurs without concurrent pulmonary disease, differentiating
from cyanotic heart disease is difficult. In an infant with pulmonary disease, PPHN should be
suspected as a complicating factor when there is marked hypoxemia and liability in oxygen‐
ation. These infants may have significant decrease in pulse oximetry readings with routine
nursing care or minor stress [29]. The response to ventilation with 100% oxygen (hyperoxia
test) can help distinguish the two conditions. In some neonates with PPHN, the PaO2 will
increase above 100 mmHg, whereas it will not increase above 45 mmHg in infants with cyanotic
heart defects that have circulatory mixing [29].
Physical findings may include a prominent right ventricular impulse, a single second heart
sound, and a murmur of tricuspid insufficiency. In extreme cases, there may be hepatomegaly
and signs of heart failure [29].
In the presence of right-to-left shunting of blood through the PDA, a difference >10–15 mmHg
of the PaO2 is present between the preductal blood (from the right radial artery) and the
postductal blood (obtained from other extremities or umbilical artery).
The chest X-ray differs according to the cardiac functions and the presence of pulmonary
disease. Normal or decreased pulmonary vascularity and normal-sized heart or cardiomegaly
can be observed [29].
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Echocardiography is essential in distinguishing cyanotic congenital heart disease from PPHN
because the latter frequently is a diagnosis of exclusion.
3.5. Meconium aspiration syndrome
Meconium is composed of lanugo, bile, vernix, pancreatic enzymes, desquamated epithelia,
amniotic fluid, and mucus. Meconium is present in the gastrointestinal tract as early as 16
weeks’ gestation but is not present in the lower descending colon until 34 weeks’ gestation;
therefore, meconium stained amnion fluid (MSAF) is seldom seen in infants younger than 37
weeks’ gestation [31]. In the compromised fetus, hypoxia or acidosis may result in a peristaltic
wave and relaxation of the anal sphincter, resulting in meconium passage in utero. The passage
of meconium in utero results in MSAF, which may be aspirated by the fetus especially if already
compromised, during gasping [19]. Any infant who is born through MSAF and develops
respiratory distress after delivery, which cannot be attributed to another cause, is diagnosed
as having MAS. Meconium aspiration syndrome is essentially a disease of term and post-term
born infants, but an infective etiology especially from Listeria should be suspected in preterm
deliveries associated with MSAF [19]. Meconium can cause mechanical obstruction of the
airways leading to mismatched ventilation/perfusion. Meconium is toxic to the newborn lung,
causing inflammation and epithelial injury as it migrates distally. The pH of meconium is 7.1–
7.2. The acidity causes airway inflammation, chemical pneumonitis, and infection, which
inhibits surfactant function and leads to inflammation and swelling, which also can block small
airways with release of cytokines [1, 31]. As meconium reaches the small airways, partial
obstruction occurs, which results in air trapping and hyperaeration. Thick MSAF, post-term
gestational age, fetal distress, male sex, APGAR score <7 at 5 minutes, and oligohydramnios
are the main risk factors. Previously, many post-term infants (>42 weeks’ gestation) developed
MAS. Reducing post-term deliveries has been shown to reduce the incidence of MAS [32]. In
addition, advances in fetal heart rate monitoring have identified compromised fetuses,
allowing for timely obstetric intervention that may help to prevent in utero aspiration of
meconium. Amnioinfusion or transcervical infusion of saline into the amniotic cavity has been
proposed, but best evidence does not indicate a reduced risk of moderate to severe MAS or
perinatal death [33].
Endotracheal suctioning immediately after birth was a routine practice for all meconium-
stained infants until a large randomized controlled trial found that intubating and suctioning
vigorous infants born through MSAF had no benefit and increased the rate of complications
[34]. This finding has been confirmed by additional, well-designed studies [35], prompting a
change in practice guidelines in 2000. And recently, in the last quarter of 2015, ILCOR changed
the ongoing practice of immediate endotracheal suctioning of the depressed infant (<100 beats
per minute), poor muscle tone, and no spontaneous respiratory effort before positive pressure
ventilation with prompt initiation of ventilation support. Intubation is considered when there
is airway obstruction with no special relevance to MSAF [3].
Most of the infants with MSAF do not exhibit any sign of respiratory distress, but MAS can
result in respiratory distress of varying severity immediately after birth or in the transition
period. Umbilical cord staining takes 15 minutes with thick meconium and 1 hour with light
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meconium. Four-to-six-hour exposure leads to staining of nails, while nearly 12 hours are
needed for vernix caseosa staining [36].
Large amounts of thick meconium can result in airway obstruction, which results in apneic or
gasping respirations at first, and then as it is driven down to distal airways, respiratory distress
secondary to increased resistance, decreased compliance, and air trapping develop [36].
Arterial blood gas is hypoxemic. In mild cases, hyperventilation may result in respiratory
alkalosis, while in severe ones, just the opposite is true with respiratory acidosis progressing
into mixed acidosis.
The typical chest radiograph initially appears streaky with diffuse parenchymal infiltrates
(Figure 2c). In time, lungs become hyperinflated with patchy areas of atelectasis, due to
inactivated surfactant by the bile acids within the meconium, and alveolar distension.
Pneumomediastinum, pneumothorax, and PPHN are common in MAS [1].
Pulmonary hypertension commonly develops in severe cases and should be aggressively
treated. Echocardiography helps confirm PPHN.
3.6. Pneumothorax
Pneumothorax is an abnormal accumulation of air or gas between the visceral and parietal
pleura. It develops secondary to an underlying disease process such as pneumonia, meconium
aspiration, ventilation, or congenital abnormalities of the lungs. It can also occur spontane‐
ously in 1% of newborns around the perinatal period, although only about 10% of these are
symptomatic [37]. On the other hand, traumatic pneumothorax can occur due to either positive
pressure ventilation (PPV) or accidental insult during a central line placement [38]. Tension
pneumothorax is the life-threatening condition, requiring immediate medical attention and
intervention. When the air is trapped in the pleural cavity and lung volume is decreased and
increased pleural pressure causes a mediastinal shift [38].
Patients with TTN, RDS, MAS, pneumonia, pulmonary hypoplasia, urinary tract anomalies,
perinatal asphyxia, and infants who were resuscitated at birth or infants receiving CPAP, PPV
cardiopulmonary resuscitation, and male infants are under risk [38].
The clinical presentation may vary from mild or severe signs of respiratory distress to a gradual
decline in respiratory function. In non-tension pneumothorax, signs can be variable in severity
such as mild-to-moderate tachypnea, apnea, irritability, grunting, pallor, and cyanosis. In
tension pneumothorax, clinical findings are very severe with definite cyanosis, hypoxia,
tachypnea, a sudden decrease in heart rate with bradycardia, a sudden increase in systolic
blood pressure followed by narrowing pulse pressure and hypotension, an asymmetric chest,
decreased breath sounds, and shift of the cardiac apical pulse away from the affected side [38].
Blood gas can reveal hypercarbia and hypoxia with respiratory acidosis and metabolic
acidosis, which may accompany in tension pneumothorax.
Anteroposterior chest radiography may show shift of the mediastinum away from the affected
side, depression of the diaphragm on the same side, and displacement of the lung on the
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affected side away from the chest wall by a radiolucent band of air (Figure 2d). In cases of
confusion, lateral decubitus view will detect even a small pneumothorax. The infant should
be positioned so the side of the suspected pneumothorax is up [38].
4. Management of respiratory distress
4.1. Stepwise approach for newborn infants with respiratory distress in the delivery room
AHA guideline for neonatal resuscitation should be followed for newborns who need
resuscitation in the delivery room [3]. In 2015 update, there were major management differ‐
ences and new recommendations compared to 2010 guideline [3].
Spontaneously, breathing preterm infants with respiratory distress may be supported with
CPAP initially rather than with routine intubation for administering PPV.
Figure 3. Practical AUCH approach for newborns in the delivery room. CS: cesarean section; AUCH: Ankara Universi‐
ty Children’s Hospital.
Practical approach for spontaneously breathing infants who do not need resuscitation but have
respiratory distress signs—that is to say labored breathing (tachypnea, apnea, grunting, flaring
of the nostrils, retractions) or persistent cyanosis in relevance with ILCOR 2015—in the
delivery room at Ankara University Children Hospital (AUCH) is summarized in Figures 3
and 4 . Delivered oxygen concentration to reach the targeted saturation and gestational age is
a key point for practical approach to newborns with respiratory distress in our delivery room
(Figure 4). For some newborns whose respiratory distress improves, follow-up is continued
up to 20 minutes of life in the delivery room. If their respiratory signs worsen or not resolve
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after 20 minutes, infants should be admitted to the transitional care. On the other hand, if the
infants ≥34 weeks gestation and otherwise healthy whom respiratory distress improve (the
absence of clinical sign of respiratory distress, transcutaneous oxygen saturation of >90%
without oxygen, respiratory rate < 60/min) within 2 hours in the transitional care unites, they
can stay with the mother.
Figure 4. Practical AUCH approach for spontaneously breathing infants who have respiratory distress signs (tachyp‐
nea, apnea, grunting, flaring of the nostrils, retractions, cyanosis, etc.). AUCH: Ankara University Children’s Hospital;
CPAP: continuous positive airway pressure; ANS: antenatal steroid; FiO2, fraction of inspired oxygen; MV: mechanical
ventilation; NICU: neonatal intensive care unit; RDS: respiratory distress syndrome.
4.2. Treatment modalities for newborn infant’s respiratory distress in the NICU
Infants with respiratory distress may need only supplemental oxygen, whereas those with
respiratory distress and apnea require non-invasive or invasive mechanical ventilation [2].
Although the survival of infants with respiratory problems has dramatically improved with
the treatment modalities, they may also lead to harmful side effects especially for immature
infants. Avoiding lung injury and adverse effects of these treatments is the main challenge for
the modern NICUs. Flow chart for newborns with respiratory distress who need assisted
ventilation or who are in recovery period in our NICU is showed in Figure 5.
Oxygen treatment with hoods, face mask, and nasal cannulas is commonly used in the delivery
room and NICUs to achieve targeted SpO2 values or to decrease WOB. Very mild cases of
respiratory distress may be successfully managed by 21–30% ambient O2 in the incubators [2].
Optimizing oxygenation allows efficient use of respiratory muscles. Any sign of increased
WOB or increasing oxygen requirement more than 40% suggests the need for early institution
of positive pressure support. Babies should not be allowed to become significantly acidotic
(pH<7.25) without escalating support [39].
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Oxygen is a therapeutic gas, and insufficient or excessive oxygen can be harmful for all
newborns. A non-invasive monitoring device to measure oxygen saturation by pulse oximetry
should be used continuously in infants, especially in preterm ones receiving any supplemental
oxygen. Although, in preterm babies receiving oxygen, the saturation target should be between
90% and 95%, the appropriate saturation ranges remain controversial [15]. Both lower (85–
89%) and higher (91–95%) oxygen-saturation targets have been associated with severe
morbidity and mortality in preterm infants. More recently, the trial from the BOOST-II
Australia and the United Kingdom Collaborative Groups concluded that the use of an oxygen-
saturation target range of 85–89% versus 91–95% resulted in significantly increased risks of
death or disability at 2 years in infants born before 28 weeks’ gestation. In addition, fluctuations
in SpO2 should be avoided in the postnatal period for avoiding retinopathy of prematurity
(ROP) [15].
Figure 5. AUCH flow chart for newborns with respiratory distress who need assisted ventilation or who are in recov‐
ery period. NCPAP: nasal continuous positive airway pressure; BiPAP: bi-level nasal CPAP; NSIPPV: nasal synchron‐
ized intermittent positive pressure ventilation; VG PTV: volume-guarantee patient triggered ventilation; HFO: high
frequency oscillatory ventilation; ECMO: extra corporeal membrane oxygenation.
Non-invasive ventilation (NIV) support can be defined as any form of respiratory support that
is not delivered through an endotracheal tube [40]. Nasal CPAP (nCPAP) is a well-known
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useful strategy for NIV34 [15]. Among new modes of NIV, alternating nasal positive pressures
in the form of either nasal intermittent positive pressure ventilation (NIPPV) or bi-level nasal
CPAP and heated humidified high-flow nasal cannula (HHHFNC) gain increasing popularity
[41].
CPAP provides stabilization of the airway and allows alveolar recruitment. Flow for CPAP
delivery can be continuous or variable. A warmed and humidified gas is continuously
provided by ventilators and bubble CPAP devices. Infant flow CPAP system device allows
expiration, provides variable flow, and reduces WOB [2].
Nasal CPAP provides end-expiratory pressure, which reduces atelectasis, maintains higher
FRC, and improves lung function by reducing workload and minimizing ventilation/perfusion
(V/Q) mismatch. It reduces obstructive and central apnea and improves synchronization of
respiratory movements. If there is evolving signs of respiratory distress, nCPAP is best used
early rather than waiting for babies to deteriorate and has been associated with a significant
reduction in the need for intubation [39].
Recent randomized clinical trials demonstrated that, in comparison with prophylactic or early
use of surfactant, the use of CPAP decreases the need for invasive mechanical ventilation (MV)
and the combined outcome of death or BPD [42]. Although all randomized trials to date have
shown a high rate of CPAP failure in the most immature infants (24–25 weeks’ gestational age),
these infants also may benefit most from this strategy [43].
CPAP should be started from birth in babies who is lower than 30 weeks’ gestation if they do
not need MV. The interface should be short binasal prongs or mask for delivering CPAP, and
a starting pressure of 5–6 cm H2O should be applied. According to European Consensus
Guideline, CPAP with early rescue surfactant should be considered the optimal management
for babies with RDS [15].
The use of very early (prophylactic) CPAP in spontaneously breathing preterm infants is
already studied by multicenter large trials and recommended as described above. But, there
is only one trial about the role of prophylactic CPAP administration to the late preterm and
term infants who have a higher risk for TTN. It is found that prophylactic CPAP administration
decreases the rate of NICU admission without any side effect in late preterm and early term
infants delivered by elective C/S [44].
Nasal masks lead to less nasal trauma than short binasal prongs. CPAP of 5–7 cm H2O is
recommended. Babies with RDS need considerably higher PEEP than a baby with TTN or
sepsis due to the noncompliant lungs. Excessive PEEP can lead to pneumothorax and may
reduce cardiac output [2]. The increase in PEEP or O2 requirements (especially greater than
40%) may suggest the further escalation of therapy.
Clinical report from the Committee on fetus and newborn for non-invasive respiratory support
concluded that (a) synchronized NIPPV reduces the frequency of postextubation failure than
NCPAP. (b) There is no difference between nonsynchronized NIPPV and BiPAP for postex‐
tubation failure. (c) Data do not support the advantage of NIPPV/BiPAP over nCPAP for the
management of babies with RDS. (d) There is no published evidence of benefit of NIPPV or
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BiPAP for apnea of prematurity. (e) Committee suggest that further research is needed before
recommending NIPPV or BiPAP instead of nCPAP in RDS or apnea [41].
Heated humidified high flow nasal cannula devices used in preterm neonates should precon‐
dition inspiratory gases close to normal tracheal gas conditions (37°C and 100% relative
humidity) without causing the excessive airway drying, mucosal damage, bleeding, and
increased risk of infection that can complicate conventional high flow nasal oxygen. Committee
on fetus and newborn also suggested that HHHFNC devices that precondition the inspiratory
gas mixture and deliver 2–8 L/minute flow may be an effective alternative to nCPAP for
postextubation failure. Unlike CPAP, HHHFNC can cause unpredictably high nasopharyngeal
pressures and may lead to traumatic injury in the airways of the infants. An appropriate size
of the prongs, detection of an adequate air leak between the prongs and the nares, and using
air flow rates as low as possible will reduce the risk of harmful effects of HHHFNC [39, 41].
Despite its emerging popularity, the evidence that HHHFNC is as effective as nCPAP is largely
anecdotal or retrospective [39].
In our NICU, primary modes of respiratory support are nCPAP, BiPAP, or NIPPV for infants
who have spontaneous breaths. In our daily practice, infants with signs of respiratory distress
as tachypnea, grunting, retractions, or need of FiO2 greater than 21% at 20 minutes were started
nCPAP (5–7 cm H2O) in the delivery room and transferred to NICU on nCPAP. They were
kept on nCPAP unless they required nCPAP >7 cm H2O or FiO2 ≥0.4 and if so, their positive
pressure respiratory support was switched to BiPAP with the same device. BiPAP was started
as 5 and 8 cm H2O for the lower and higher CPAP levels, respectively. BiPAP pressures were
increased to maximum of 7 and 10 cm H2O for the lower and higher CPAP levels, respectively,
and the pressure exchange rate was increased to maximum of 40 per minute for clinical stability
and a blood gas analysis within normal ranges. Treatment is usually escalated to NIPPV if the
need for FiO2 of more than 0.4, or respiratory acidosis (pH ≤7.25), or insufficient respiratory
effort, or excessive work of breathing before intubation. After de-escalation of NIV support, it
was stopped when patients showed no signs of respiratory distress with nCPAP of 4 cm H2O
and BiPAP of 6–4 cm H2O and FiO2 <0.30.
The pressure gradient between the airway opening and lungs generated through mechanical
ventilation produces a flow of gas into the lung. Conventional ventilators for newborns are
either pressure or volume controlled ones [6].
Pressure-controlled ventilators deliver a preset peak inspiratory pressure (PIP), thus deliver‐
ing a variable tidal volume depending largely on lung compliance. A constant flow of gas
passes through the ventilator. Pressure is limited to the desired magnitude. This ventilation is
usually used with the technique of synchronized intermittent mandatory ventilation (SIMV),
which allows spontaneous breathing between ventilator breaths [6] and patient triggered
ventilation (PTV).
Volume-controlled ventilators deliver a preset tidal volume with a variable PIP, depending
largely on lung compliance. When this gas has been delivered by the piston, inspiration is
terminated. Infants’ tidal volume is set between 4 and 8 ml/kg. PIP may change in response to
patient’s effort, and historically, this mode of ventilation was not safe enough for neonates.
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However, in the volume-guarantee (VG) modes, the clinician sets both a maximum PIP and a
desired target volume for mechanical breaths. As recent evidence suggests that lung injury is
most likely related to volutrauma, volume guarantee modes are being accessed in the newborn
respiratory management. In addition, volume ventilation results in reductions or trend for
reductions in duration of ventilation, pneumothorax, intracranial hemorrhage, and BPD [6].
In summary, it is known that lung injury is most directly related to excessive tidal volumes
and, conversely, that an inadequate tidal volume increases work of breathing and promotes
atelectasis and V/Q mismatch [39]. Volume targeted ventilation provides an open lung strategy
and reduces the frequency of excessive tidal volumes, decreasing inadvertent hyperventila‐
tion. There has not, however, been conclusive evidence of improved long-term outcomes [39].
High-frequency ventilation (HFV) refers to various ventilator strategies and devices designed to
provide ventilation at rapid rates and very low tidal volumes. Rates during HFV are expressed
in hertz (Hz). There are two types of high frequency ventilators (high frequency jet ventilator
– HFJV and high frequency oscillatory ventilator – HFOV), which are frequently used in
neonatal medicine. Oscillatory ventilation is unique because exhalation is actively generated,
as opposed to other forms of high frequency ventilation, in which it is passive [6].
Cochrane 2015 analysis revealed that the evidence to use elective HFOV instead of conven‐
tional ventilation for reduction in the risk of BPD is small, and the evidence is weakened by
inconsistency of this effect across trials. In addition, the benefit could be counteracted by an
increased risk of acute air leak [45]. More recently, Iscan et al. suggested that HFOV with a VG
option resulted in constant tidal volume delivery and less fluctuant CO2 levels compared to
HFOV alone in premature infants with RDS [46].
One approach to minimize ventilator-induced lung injury is to tolerate higher levels of pCO2
(permissive hypercapnia), allowing the use of lower tidal volumes. Unfortunately, prospective
trials have not demonstrated a reduction in BPD. On the other hand, low pCO2 is known to
decrease cerebral blood flow. There is a proven association between hypocapnia, neonatal
brain injury, and subsequent cerebral palsy. Hypocapnia should therefore be avoided in
ventilated infants wherever possible [39].
In our NICU, preferred modes of invasive ventilatory support are volume guarantee-PTV for
preterm and term infants to maintain more stable pCO2 and to avoid over distension and
subsequent volutrauma. HFOV is preferred as a rescue strategy, but it is the primary mode for
CDH.
There are several different surfactant preparations that have been used in neonates with RDS,
including synthetic (protein-free) and natural (derived from animal lungs) products. Natural
surfactants are superior to synthetic preparations at reducing pulmonary air leaks and
mortality [15]. Natural surfactants contain the hydrophobic surfactant protein, SpB and SpC,
although at different concentrations. However, some synthetic surfactant preparations contain
only phospholipids [2]. According to Cochrane review, in a trial comparing protein containing
synthetic surfactants compared to protein-free synthetic surfactant for the prevention of RDS,
no statistically different clinical differences in death and BPD were noted [47].
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Some trials, which aim to compare the effect of poractant alfa and the beractant for rescue
therapy, demonstrated that more rapid improvement in oxygenation was achieved with
poractant alfa [15]. According to European Consensus Guideline, 200 mg/kg dose of poractant
alfa has an advantage for overall survival than 100 mg/kg of beractant or 100 mg/kg of
poractant alfa to treat RDS [15].
Infants receiving INSURE (intubate, surfactant, extubate) have less need for mechanical
ventilation, fewer pneumothorax, and less BPD, but evidence of long-term benefit is limited.
Figure 6. *FiO2 cut off <0.3 for infants born <26 weeks of gestation. Adapted and modified from Kalus & Fanaroff’s
Care of the High Risk Neonate.
According to European Consensus Guideline [15]:
1. Infants diagnosed with RDS should be given a natural surfactant preparation.
2. Extremely preterm infants in whom the mother has not had antenatal steroids and infants
who require intubation for stabilization surfactant should be administered in the delivery
room. Except these situations, early rescue surfactant should be standard.
3. Infants with RDS should be given rescue surfactant as early as possible. A suggested
protocol from European Consensus Guideline would be to treat infants <26 weeks’
gestation when FiO2 needs >0.30 and infants >26 weeks’ gestation when FiO2 needs >0.40.
4. When the initial dose of poractant alfa is 200 mg/kg, it would be better for treatment of
RDS comparing to 100 mg/kg of poractant alfa or beractant.
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5. Consideration of the INSURE technique is important. Because more mature babies can
often be extubated to NIV just after surfactant administration, and a clinical judgment
needs to be made as to whether an individual infant will tolerate this.
6. If there is evidence of ongoing RDS, a second or sometimes a third dose of surfactant can
be administered.
Management of RDS in AUCH has been summarized in Figure 6.
There are some limited data about surfactant therapy for disease other than RDS. Preliminary
reports of surfactant therapy have been noted in cases of pneumonia, pulmonary hemorrhage,
MAS, and PPHN. However, an established protocol for these situations is not present [2].
Extra corporeal membrane oxygenation (ECMO) provides oxygen delivery, carbon dioxide
removal, and cardiac support in patients who have cardiac and/or respiratory failure. ECMO
is used for critically ill term and late preterm infants (≥32–34 weeks or ≥1.6–1.8 kg) as a rescue
bridge therapy for severe but reversible respiratory and/or cardiac insufficiency in case of
failure of other conventional therapies [48].
Nitric oxide (NO) is a colorless gas with a half-life of seconds stimulates soluble guanylate
cyclase (sGC) to increase intracellular cGMP, which indirectly decreases the free cytosolic
calcium, resulting in smooth muscle relaxation. Excess iNO diffuses into the blood stream,
where it is rapidly inactivated by binding to hemoglobin and subsequent metabolism to
nitrates and nitrites. This rapid inactivation thereby limits its action to the pulmonary vascu‐
lature [49].
Inhaled NO is licensed for only term and near-term neonates with hypoxic respiratory failure
associated with clinical or echocardiographic evidence of pulmonary hypertension by the Food
and Drug Administration in the USA [50]. Inhaled NO does not improve long-term surfactant
function or markers of pulmonary inflammation and oxidative stress [51]. Although the use
of iNO has increased over the years and this increase is mostly due to off-label use in premature
infants, the treatment of preterm infants is more controversial [50].
Methylxanthines have been used as respiratory stimulants to decrease apnea of prematurity
and to facilitate successful extubation [15, 39]. Methylxanthines increase minute ventilation,
improve CO2 sensitivity, decrease hypoxic depression, enhance diaphragmatic activity, and
decrease periodic breathing [2].
The Caffeine for Apnea of Prematurity (CAP) study evaluated the issue of long-term effects
of caffeine therapy in infants who were under 1250 g birth weight. Study infants randomly
had caffeine or placebo in the first 10 days of life and continuing until the clinician decision.
Babies in caffeine group weaned off ventilation a week earlier and had significant reduction
in BPD than placebo group [15]. According to CAP study, the combined outcome of death or
neurodisability decreased in caffeine-treated babies at 18 months and also reduced rates of
cerebral palsy and cognitive delay [52]. The differences were no longer significant after 5 years
but reassuring that there were no long-term adverse effects on development. Infants who were
on MV and had started caffeine earliest appeared to provide the most benefit [52].
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Abstract
The successful transition from liquid to air breathing at birth is essential in mammali‐
an lung development and the primary biological role of the hypothalamic-pituitary-
adrenal axis. At this moment, the lung experiences a major environmental change in
oxygen tension as the fluid that filled this organ in utero (pO2 ∼26) is rapidly replaced
with ambient air during the first few breaths (pO2 ∼150). This change induces oxidant
stress in the lung which is balanced by antioxidant genes that are induced in the late
gestational fetal lung to protect against injury. These antioxidant genes impact distinct
antioxidant molecules, including glutathione, which can regulate the level of redox
stress in lung cells. Cells, such as the alveolar macrophage, are central for host defense
and surfactant homeostasis at the newly established air-liquid surface. Yet they are
prone to dysfunction with excessive oxidant stress and the newborn lung is suscepti‐
ble  to  infection.  And  yet  the  rise  in  alveolar  oxygen  tension  can  also  serve  as  a
physiologic redox signal that initiates expression of genes that regulate postnatal lung
development.  Taken  together,  birth  can  be  viewed  as  a  natural  experiment  with
hyperoxia where the birth process itself serves as an integrator for that level of redox
stress  that  limits  lung  injury  while  activating  genes  required  for  postnatal  lung
development.
Keywords: lung, perinatal, birth shock, glutathione, Kruppel-like factor 4
1. Introduction
The symbols for man (♂), woman (♀), birth (☼), death (†), and infinity (∞) were penned on a
blackboard at the opening of the 1960s medical drama “Ben Casey.” These symbols repre‐
sented a fundamental organization of life in the universe of medicine. Birth was a culmina‐
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tion of a progressive series of molecular and cellular events that began with fertilization,
progressed through gastrulation, and then embryogenesis to form the fetus and finally the
newborn child. Along the way, an ever enlarging population of cells proliferated, migrated,
differentiated, and died and a host of organs with unique functions were constructed on organ-
specific extracellular matrices connected to each other by vessels and to the external environ‐
ment by tubes. Herein, we focus on a select aspect of lung development in the perinatal period.
At that time, the fetus experienced a unique transition from a highly protected fluid-filled
uterine environment to a highly susceptible gas-filled environment that marked its independ‐
ent existence as a newborn. The role of the lung as a secretory organ came to an end and its
new role as a gas exchanger began. In so doing, the cells of the lung, more so than any other
organ, were immediately exposed to an elevated concentration of oxygen.
Decades of lung developmental research have unraveled many features about lung function
in the perinatal period. Some highlights include a primary role for hormones in regulating
lung cell maturation along with the ontogeny of a surfactant lipoglycoprotein complex to
ensure the success of this transition, particularly the hypothalamic-pituitary-adrenal axis [1].
Although some aspects of perinatal lung alveolar, cell surface differentiation is steroid-
independent [2]. Identification of regulators that control the progression of lung progenitor
cells into distinct lineages to form distal lung alveolar cells [3]. The molecular events occurring
during lung development are regulated by transcription factors, and the families involved are
extensive [3, 4]. In this review, we will focus on a particular transcription factor family known
as the Kruppel-like factors (KLF). Krüppel is a zinc-finger transcription factor described in
Drosophila melanogaster as essential for pattern formation and embryogenesis [5]. A related
family of mammalian Krüppel-like factors, Klfs, share sequence homology with the DNA-
binding domain of Krüppel and serve essential roles in mammalian embryogenesis [6]. Lung
Kruppel-like factor, Klf2, has been known to be important in lung development [7]. Another
member, Klf5, was shown more recently to play a role in perinatal lung development [8].
Interestingly, Klf5 is known to interact with Klf4, gut enriched Kruppel-like factor, which we
will highlight in this review [9].
2. The Kruppel-like family of transcription factors and the lung
Lung development is characterized by a dramatic structural and functional re-organization
from an organ of secretion in utero to one of the gas exchanges at birth. This morphologic
transition is only partially complete in the newborn murine and human lung. The process of
forming new alveoli in the lung occurs largely in the postnatal period. It involves regulation
of cell proliferation, differentiation, migration, and apoptosis and affects epithelial, endothe‐
lial, and interstitial cell populations within the lung parenchyma and airways. It also involves
complex interactions between cells and extracellular matrix proteins [10]. Previous literature
described many of the cellular components of these critical postnatal events, and contemporary
research has concentrated on the molecular regulators that drive the formation of the gas
exchange surface and the mechanical properties of the postnatal lung.
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It was known that there was a progressive decline in cell proliferation in mesenchymal cells,
including fibroblasts [11] and epithelial cells [12, 13], near the end of gestation, at birth, and
during the early postnatal period. The effect was transient as the number of proliferating cells
rose dramatically in the late postnatal period with the onset of alveolarization and continued
over the next 2–3 weeks [14]. During this time, the interstitium, which was thick and packed
with cells at birth, became progressively more thin and sparse with maturation of the alveolar
wall [15]. The relative number of interstitial cells actually declined.
Fibroblast differentiation after birth was believed to serve major function in forming alveoli
in the late postnatal lung. A population of myofibroblasts, located at the tips of developing
septa, expressed α-smooth muscle actin (α-SMA) and produced matrix proteins such as elastin.
The location of these cells denoted sites of newly forming alveoli and alveolarization extended
from postnatal day 5 through day 20 in the mouse lung. This ability to form new alveoli
appeared to be dependent upon the response of the myofibroblast to certain stimuli such as
FGF-3, FGF-4 [16], and PDGF-A [17] receptors, as well as deposited matrix protein [18, 19] and
transforming growth factor (TGF)-β activity, including a component of the TGF-β signaling
pathway, Smad3 [20, 21]. Myofibroblasts are believed to re-emerge de novo in adult lung
following tissue injury [22] and are postulated to play a role in repair. Differentiated fibroblasts
also produce matrix proteins, including elastin and collagen. The lung actually has very little
connective tissue at birth. As a result, lung elastic recoil is limited and the lung is prone to
rupture by applied pressure. Production of matrix proteins such as elastin and collagen by
interstitial fibroblasts during alveolarization contributes to elasticity and structural integrity
to the lung [23]. Interestingly, regulation of cell proliferation and cell differentiation is a role
that is reiterated in much of the Kruppel family literature.
Overall, the Kruppel-like family currently consists of over 16 members, and the originally
descriptive nomenclature is now being revised into a numerical grouping system based on
sequence homology, functional domains and transcriptional activity [24]. For instance, Klf4 is
also known as EZF (epithelial zinc finger) and gut-enriched Klf (GKLF). It activates and
represses gene transcription and has autoregulatory activity [25]. Klf2 is also known as lung
Klf. It is mainly an activator of transcription and plays a role in blood vessel and lung devel‐
opment. Table 1 summarizes selected aspects of a select Klfs and more detailed summaries
are available in recent reviews [24, 26–28].
The Klfs are a subset of a larger family that includes Sp1 and Sp1-like proteins with Sp1 being
the founding member of the family. Sp1 and Sp-1 like proteins are grouped together by
phylogenetic tree analysis of protein sequences (group I) and the Klfs divide into groups II
and III [24]. In general, Sp1 and Sp1-like members preferentially recognize the GT box in
promoters (5′-GGTGTGGGG-3′), whereas the Klf members preferentially recognize the CA
box (5′-CACCC-3′). However, competition among members for these sites and post-transla‐
tional modifications that affect DNA-binding site affinity is an active area of investigation. It
is believed that this diversity of protein members allows for a precise regulation of gene
expression under a variety of physiological conditions. The ability of the Klf family to regulate
cell proliferation, survival, and differentiation of different cell lineages suggests a potentially
broad role in normal development, response to injury, and carcinogenesis.
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Table 1. Select characteristics for some members of the Krüppel-like family.
Klf4 was initially characterized in two independent laboratories. One identified it as a novel
zinc-finger protein expressed in differentiated epithelial cells, hence named epithelial zinc
finger (EZF) [31], and transiently in certain mesenchymal cells. The other identified it as a gut-
enriched Krüppel-like factor expressed during growth arrest, hence GKLF [32]. In cultured
fibroblasts, expression was abundant in growth-arrested cells and barely detectable in rapidly
proliferating cells as the protein inhibited DNA synthesis. The message transcript was most
abundant in colon followed by testis, lung, and small intestine by Northern blot and in
epithelial cells of the colon as they migrated from the base to the top of the crypt [32]. Message
was not detectable in the mouse embryo by Northern blot until day 15.5, but was evident in
mesenchymal cells of the first branchial arch at day 11.5 and the metanephric kidney at day
12.5 by in situ hybridization. At day 15.5, the situ signal was detected in epithelial cells of the
colon and the tongue and by the newborn period in epithelial cells of the esophagus and the
stomach as well [31]. Message was also evident in skin of adult mice [31]. More recently, Klf4
expression has been defined in corneal epithelial cells [37]. This new gene was hypothesized
to play a role in epithelial cells in many organs during differentiation in development and in
mesenchymal cells during early formation of the skeleton and kidney.
These original studies demonstrated that Kl4 was an important regulator of cell proliferation
and cell differentiation. In keeping with this concept, serum deprivation, DNA damage, and
contact inhibition were associated with decreased proliferation and increased Klf4 expression
[32, 38], while GI neoplastic lesions [39, 40] and cancer cell lines [41] were associated with high
levels of proliferation but decreased levels of Klf4 expression. In tissues, Klf4 was expressed
largely in post-mitotic, terminally differentiated epithelial cells [31, 32]. Transcriptional
profiling of Klf4 confirmed this dual role in cell cycle regulation and epithelial cell differen‐
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tiation [42]. Cell cycle inhibitors were upregulated by Klf4, including the cdk inhibitor p21WAF1/
CIP1
, and cell cycle activators were downregulated, including cyclinD1 [38, 43]. Targeted
elimination of the Klf4 gene in mice revealed its critical role in terminal differentiation of
epithelial cells in the skin in the perinatal period [44]. Loss of barrier function was lethal within
24 h of birth due to the rapid loss of fluids. An independent Klf4 gene ablation experiment not
only confirmed this observation but also showed an alteration in the terminal differentiation
program of epithelial goblet cells in the colon [45].
In keeping with the known expression of Klf4 in mesenchymal cells, several studies demon‐
strated regulation of this gene in non-epithelial cell types. Human Klf4 was originally cloned
from a human umbilical vein cDNA library after the initial description of mouse Klf4 [46].
More recently, Klf4 induction was observed in a genomic analysis of immediate/early re‐
sponses to shear stress in human coronary artery endothelial cells [47]. Shear stress inhibits
endothelial cell proliferation, and Klf4 was postulated to provide a mechanism for this effect.
Studies with cardiac fibroblasts identified Klf4 induction by DNA microarray and linked its
expression with several cell cycle and differentiation-associated genes that were induced with
a sudden change from hypoxic to normoxic conditions in vitro to model “perceived hyperoxia”
of ischemia-reperfusion. Klf4 was proposed to play a role in activating pathways for growth-
arrest and fibroblast differentiation in these cells in response to oxygen-induced injury [48].
Klf4 has also been shown to mediate redox-sensitive inhibition of proliferation in vascular
smooth muscle cells [49]. Klf4 induction in response oxidant exposure was dependent on
hydroxyl radical production, intracellular calcium, p38 MAP kinase activation, and protein
synthesis, although a transcriptional mechanism for its induction was not defined. The Klf4
response was rapid, detectable within 30 min, and associated with induction of p21WAF/Cip1, p27,
and p53, known Klf4 target genes and inhibitors of cell proliferation. While Klf4 expression
was known previously to respond to changes in the cell environment, this study identified
oxidants as an additional extracellular signaling stimulus for Kl4 induction, and linked
induction was activation of the MAPK signal transduction pathway.
Prior to our investigation, little was known about a role for Klf4 in lung development.
Nonetheless, lung Klf4 expression had been reported in the lung in several different studies.
The original characterizations of Klf4 noted expression in the adult [32] and the newborn lung
[31]. Klf4 induction was also described in newborn compared to 4-week-old mice, a time of
active lung cell proliferation and differentiation [50]. Early and transient Klf4 protein induction
was described in the lung within 2 h following pneumonectomy although the cellular site was
not determined [51]. Klf4 mRNA expression was induced in the airway transcriptome in
response to cigarette smoke [52]. Klf4 mRNA was induced in alveolar epithelial type 1-like
cells in response to ozone exposure [53]. Klf4 has very recently been shown to directly regulate
TGF-β induced myofibroblast differentiation in isolated adult rat lung fibroblasts by inhibiting
expression of α-SMA [54]. In this model, a Klf4 protein–protein interaction with Smad3 blocks
Smad3 binding to a Smad3-binding element in the α-SMA promoter. This direct linkage of
Klf4 with Smad3 reveals a novel mechanism by which Klf4 regulates TGF-β-induced myofi‐
broblast gene expression in adult lung.
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With this background in mind, our finding that lung Klf4 mRNA was dramatically upregu‐
lated with birth in a normal oxygen environment and attenuation of this induction by birth in
a more hypoxic environment led us to hypothesize that Klf4 was regulated in a redox-
responsive fashion in lung mesenchymal cells and that its target genes regulated fibroblast
proliferation and differentiation events associated with postnatal lung development [55].
3. Oxygen as a regulator of Kruppel-like factor 4 in the newborn lung
This birth shock hypothesis was studied in time-pregnant mice by comparing findings in the
lung with those with those in the liver, an organ that is not exposed to the same changes in
environmental oxygen as the lung right at birth. And changes in newborn organs at 2, 6, 12,
and 24 h after birth were compared with those of the corresponding fetal organ at day 21 of
gestation, the time just before birth. Changes in gene expression at birth were examined with
microarrays, and these data revealed an acute change in the level of expression of 157 genes
within 2 h of birth in room air in the lung. The number of gene changes steadily declined at 6,
12, and 24 h thereafter. Most of the lung gene changes through 6 h involved transient induction
or repression of expression. Less than 30% of the changes involved genes in common to any
two successive time points, suggesting the presence of sequential waves of new gene expres‐
sion over time. The full implication of this pattern is yet to be fully understood. Nonetheless,
four functional categories of gene expression were overrepresented in these microarray data
at 2 h after birth in room air: transcriptional regulators, structural genes, apoptosis-related
genes, and antioxidants. Glutathione disulfide was analyzed to determine whether there was
a change in the local redox state after birth in room air. This oxidation product accumulated
fourfold within 2 h of birth and steadily decreased thereafter. Glutathione was always in excess
of glutathione disulfide at all times points indicating a surfeit of antioxidant buffering capacity.
But the lung is exposed to a transient oxidant stress and a change in the local redox state with
the rise in environmental oxygen at birth.
Contrast these lung findings with those in the liver after birth in room air. The liver exhibited
no accumulation of glutathione disulfide at the 2 h time point and no sign of oxidant stress at
any of the early time points thereafter. These data suggest that the liver may not be subjected
to the same magnitude of change in environmental oxygen tension as the lung at birth or it
may follow a very different time course. In addition, there were far fewer changes in gene
expression in the liver at 2 h after birth when compared to the lung, and no functional categories
of gene expression were found to be overrepresented in the liver gene microarray dataset.
There were a few gene expression levels that did change in common between these two organs.
These could represent a shared response to the birth process itself. But we interpreted the
majority of unique changes in the lung as a lung-specific response related to the change in
alveolar oxygen content at birth.
To explore this, we examined a group of time-pregnant mice exposed to 10% oxygen using a
glove bag at the 21st day of gestation. Some of these hypoxic mice were killed after 12 h to
harvest fetal lung and assess baseline fetal measures at the end of gestation, whereas others
were monitored and newborn lung was collected again at 2, 6, and 12 h after birth. Of note
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here, all dams, fetuses, and newborns survived in the 10% oxygen environment, and this
exposure did not significantly alter baseline gene expression in the fetal lung as determined
with microarrays. This survival pattern suggested that changes in blood flow, lung stretch,
nutrient supply, and fluid resorption were similar to that of mice birthed in room air and that
these factors were less likely to differentially impact gene expression. Birth into 10% oxygen,
however, did impact the level of redox stress in the lung at birth as well as the number of gene
expression changes. Accumulation of glutathione disulfide was attenuated by half compared
to the normal lung. And there was a 60% decrease in the number of gene changes at 2 h,
compared to that in room air with elimination of any overrepresented functional category of
gene expression. It was as if birth into an environment of hypoxia lacked any change in gene
expression at all and retained a pattern like that of the fetal lung. The transient rise and fall in
glutathione disulfide in the newborn lung in room air, despite the induction of several
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Kruppel-like factor (GKLF), a tissue-specific gene that inhibited cell proliferation and stimu‐
lated differentiation in the gut, particularly in the epithelial cells of the crypts where there is
a tight link between growth arrest and differentiation. Klf4 regulates cell proliferation by
inhibiting cell-cycle progression and inducing growth arrest [31, 32, 60]. Mesenchymal and
epithelial cell proliferation is known to progressively decline in the lung during the perinatal
period [29–31], and a transcription factor like Klf4 is a reasonable candidate to regulate this
process. Klf4 is known to induce growth arrest in cells through the cell-cycle inhibitor p21WAF/
Cip1, and the absence of Klf4 in the Klf4 knockout mouse is associated with a corresponding
decrease in the level of p21WAF/Cip1 mRNA expression in the late fetal lung and persistent cell
proliferation in fibroblasts and airway epithelial cells at birth [55].
Klf4 has previously been described in the mesenchyme during development [31]. We gener‐
ated Klf4 knockout and Klf4 expressing fibroblasts to demonstrate that smooth muscle actin,
fibronectin, tenascin C, and the alpha 1 chain of Type 1 collagen are Klf4 target genes and that
fibroblast connective tissue gene expression is down-regulated in the perinatal lung of the Klf4
knockout mouse [55]. Impaired connective tissue gene expression has at least two distinct
biological implications for postnatal lung development. First, lack of collagen synthesis
decreases the tensile strength of the postnatal lung and increases the risk for rupture under
pressure [61] and emphysema [62]. Second, lack of fibronectin, type 1 collagen, tenascin C, and
smooth muscle actin expression can impair myofibroblast differentiation and postnatal
alveogenesis [63–66]. Interestingly, Klf4 our study confirmed differential regulation of smooth
muscle actin gene expression in the myofibroblast and the vascular smooth muscle cell as Klf4
deficiency in the Klf4 knockout mouse lead to a loss of expression in the myofibroblast (positive
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regulator) but preservation of expression in the vascular smooth cell (negative regulator). This
negative regulatory function in vascular smooth muscle cells was already known [67].
Finally, cell death was also increased in the Klf4-deficient lung of the Klf4 knockout mouse at
birth. An expanding literature now describes Klf4 as an inhibitor of apoptosis [6]. Apoptosis
is present even in the normal lung at birth and may play a physiologic role in postnatal lung
development [68, 69]. We found an excess of apoptosis in the Klf4-deficient lung of the Klf4
knockout mouse, and this could well contribute to a loss of cell population and gene expression
at birth. We also noticed that apoptosis exhibited a cell-specific rather than a general nature,
as it was not increased in vascular smooth muscle cells within large blood vessels [55]. Taken
together, we found good correlation between the gene categories that were overrepresented
in the gene changes 2 h after birth and Klf4 as a potential regulator of these gene categories.
Is Klf4 expression in lung fibroblasts regulated by hyperoxia? We showed that it is and the
mechanism is transcriptional in nature and independent of protein synthesis [55]. Further
details of the mechanism await more studies. But Klf4 is known to be activated by oxidants,
heat, chemical and mechanical forces, and nutrient deprivation [6]. Lack of Klf4 induction can
be associated with stress [70] and the Klf4-deficient lung of the Klf4 knockout mouse at birth
exhibited signs of stress such as increased degree of apoptosis and p53 expression and dramatic
induction of p21CIP1//Waf1 independent of Klf4. The full implications of Klf4 expression in the
perinatal period will require further study in vitro using Klf4 deficient and sufficient cell
cultures and tissue explants, but ultimate proof will require a fibroblast-specific conditional
deletion of Klf4 in vivo [71, 72]. But our study was the first to draw attention to a physiologic
role for oxygen as a regulator of this transcription factor for fibroblast and myofibroblast
differentiation in normal postnatal lung development [55]. The role of Klf4 in regulating these
fibroblast populations during lung development is likely to be recapitulated in the adult lung
during repair of lung injury and to involve interactions with other Kruppel-like family
members. The newborn lung at birth could provide a window into the responsiveness of an
organism to changes in the environment of oxygen and oxidant stress.
4. Glutathione in perinatal lung antioxidant defense and macrophage
function
In the alveolar space, alveolar macrophage (AM) surveillance is the first line of defense in the
immune response as they ingest and clear pathogens, release cytokines and chemokines to
recruit other immune cells, serve as antigen presenting cells, and interact with other alveolar
cells to fine-tune the immune response. In order to fulfill their roles as sensors, transmitters,
and responders to inflammation, AMs respond to endogenous and exogenous danger signals
by changing their repertoire of surface receptor expression and functional phenotype to
promote either host defense, wound healing, or immune regulation. This plasticity in their
biological responses, including differentiation, phenotype, immune functions, and cellular
interactions, is determined in large part by their extracellular milieu [73]. However, the
phenotype is not permanent and pathogens or changes in the underlying microenvironment
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can promote a change between a predominance of one set of characteristics to another
phenotype. Depending on the different stimuli within the microenvironment within the
alveolar space, alveolar macrophages are activated via distinct pathways that produce
opposing effects on macrophage receptor expression, cytokine expression, and phagocytic
function [74]. In response to interferon-γ (IFN-γ) or microbial products, macrophages become
classically activated (M1) macrophages and produce inflammatory cytokines and reactive
intermediates of oxygen and nitrogen. In response to interleukin-4 or -13, macrophages become
alternatively activated (M2) and produce anti-inflammatory mediators such as the
interleukin-1 receptor antagonist and TGF-β, promote tissue repair and remodeling, and
become tolerant to stimulation by endotoxin in order to protect against overwhelming systemic
inflammation. However, this immunosuppression is associated with a decreased capacity to
clear microbes, and many diseases have abnormal shifts in the AM phenotype and immune
responses that limit the ability of the cells to become innate immune effectors. Whether
newborn AMs are skewed toward a M1 or M2 phenotype is unclear, but studies in a mouse
model suggest that AM maturation in the fetal lung may include features of both pro-
inflammatory and alternative activation paradigms [75].
Newborn infants, particularly those born preterm, face immunological challenges after birth
because of the developmental stage of their immune systems. Upon birth, there is an age-
dependent maturation of the intrapulmonary inflammatory responses with decreased AM
immune responses such as phagocytosis and secretion of inflammatory mediators with
potential immunoregulatory consequences [76, 77]. The functionally immature status of the
newborn AM is suggested to be critical in the recurrent problem of early infancy pulmonary
infections and morbidity [78]. At day 3 of life for premature newborns, the alveolar cells are
more likely to have greater numbers of mononuclear phagocytes in the airway but fewer of
these cells are functionally mature AMs [79]. This suggests that newborn AMs are functionally
immature which may lead to increased susceptibility to lung infections. Furthermore, the
degree of postnatal immune-suppression correlates with gestational age and is a predisposing
factor for late infections [80].
The growth factor GM-CSF, granulocyte-macrophage colony stimulating factor, and its
transcription factors PU.1 and Bach2 are increased after birth and necessary for AM differen‐
tiation and homeostasis making them critical to the AM immune response [81]. In newborn
mice, the pleotropic peroxisome proliferator-activated receptor-γ (PPARγ) modulates several
transcription factors and genes associated with AM differentiation and immune functions.
However, PPARγ expression in fetal lung monocytes is dependent on the GM-CSF pathway
suggesting that GM-CSF has a lung-specific role in the perinatal development of AMs through
the induction of PPARγ in fetal monocytes. Therefore, factors that suppress GM-CSF or
PPARγ expression in the newborn AM also suppress differentiation and the development of
a mature immune response as summarized I recent reviews [82–85].
In in vivo studies, ROS induces upregulation of TGF-β expression [86], which is also a charac‐
teristic of a M2 phenotype [74]. Once TGF-β is activated, it induces the GSH depletion and
increases intracellular ROS production. Children with severe asthma have significantly higher
concentration of TGF-β in the epithelial lining fluid, which is associated with increased TGF-
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β and increased oxidative stress in the AMs [87]. In a mouse model, intranasal instillation of
an adenovirus expressing constitutively active TGF-β results in suppression of the expression
of both catalytic and modifier subunits of glutamate-cysteine ligase (GCL), the rate-limiting
enzyme in de novo glutathione synthesis, decreased glutathione concentration, and increased
protein and lipid peroxidation in mouse lung [88]. Similarly, M2 macrophages have robust
increases in TGF-β1 production and secretion [74], thereby creating a vicious cycle of ROS
generation, TGF-β production and signaling, and a M2 phenotype [89]. Indeed, mounting
evidence suggests that AMs, particularly M2 AMs, are the predominant source of TGF-β in
lung fibrosis and depleting M2-polarized macrophages during the progressive phase of
fibrosis reduces TGF-β and collagen deposition [90]. In contrast, glutathione precursors induce
proteolysis of the TGF-β type II receptor and disintegration of TGF-β1 [86]. Therefore,
perturbations in glutathione availability and its redox status in the epithelial lining fluid are
important modulators of the AM phenotype and immune functions.
In addition a role for gestational development in the AM phenotype and immune response,
the role of fetal exposures and subsequent changes in the microenvironment on the AM
phenotype must also be considered. In animal models, in utero ethanol exposure also promotes
oxidant stress in the newborn lung as evidenced by decreased concentrations of the reduced
moiety and increased concentration of the oxidized glutathione moiety in the alveolus and
neonatal AM [91]. This oxidation of the glutathione redox state in the alveolar space was
associated with increased expression of TGF-β and markers of a M2 phenotype in the newborn
AM [92–94]. Impaired AM phagocytosis decreased the neonatal lung’s defense against
experimental Group B Strep as well as systemic sepsis [92]. However, addition of the gluta‐
thione precursor S-adenosyl-methionine (SAM-e) to the dam’s diet restored the AM immune
responses as well as decreased the experimental Group B Strep pneumonia and systemic sepsis
in the newborn with fetal ethanol exposure. A central role for glutathione availability in the
alveolar space in the AM immune functions was further supported by the ability of intranasal
delivery of glutathione in the newborn to reverse the immune dysfunction associated with
fetal ethanol exposure. These studies highlight the vital importance of glutathione availability
in the alveolar space for AM immune functions and the neonatal lung’s defense against
bacterial infection [92].
Studies in the adult of chronic ethanol ingestion highlight the role of the glutathione redox
state and oxidative stress in AM expression of TGF-β, GM-CSF/PU.1 signaling, PPARγ
expression, immune functions, and risk of experimental pneumonia [89, 95–98]. In addition to
GM-CSF, expression and activity of PU.1 are also dependent on Nrf2 and the antioxidant
response element which are downregulated by alcohol-induced oxidant stress [99]. Alcohol
exposure also upregulates KLF4 in AMs and treatments with GM-CSF or TGF-β enhance or
dampen KLF4 expression and binding, respectively [100]. Treatment with siRNA against KLF4
normalizes the effects on expression of GM-CSF and TGF-β as well as AM immune functions.
A potential dynamic interactive role for chronic oxidant stress on TGF-β, GM-CSF, PU.1, Nrf2,
and KLF4 on the newborn AM phenotype and immune functions remains to be determined.
The most common form of newborn chronic lung disease, bronchopulmonary dysplasia (BPD),
is thought to be caused by oxidative disruption of lung morphogenesis. Following birth,
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various risk factors, including pulmonary or systemic infections, high concentrations of
oxygen inspiration, and mechanical ventilation, may act synergistically, amplifying the
inflammation. At birth, premature newborns have significantly lower glutathione concentra‐
tions than term newborns, and the lowest glutathione levels are associated with the infants
with the most severe airways problems and required high oxygen support [101–104]. In
intubated newborns, exhaled breath condensate samples correlated with tracheal aspirate
samples in terms of reduced, oxidized, and total glutathione (GSH + GSSG) [105]. Decreased
glutathione and subsequent oxidative stress in this microenvironment of the lining fluid was
also observed in the AMs obtained from the tracheal aspirate. This glutathione deficiency and
oxidative stress associated with the immature lung are likely to promote changes in the AM
phenotype and immune functions, thereby increasing the risk of infection. This increased
oxidative stress may contribute to the significant increased expression of TGF-β in the AMs of
premature newborns [106, 107]. Further research is needed to specifically decipher the unique
and complex mechanisms underlying AM maturation and pulmonary immune regulation at
baseline and in response to oxidative stress. Pulmonary immune regulation in the premature
neonate may be similar to the adult or it may be dramatically different because of the imma‐
turity of the immune system.
5. Is birth an integrator that balances oxidant stress and antioxidant
defense?
We have presented our work and ideas about the lung at birth and its experience of a major
change in the oxygen environment. Clearly antioxidant gene induction is part of the develop‐
mental program in the late fetal lung and provides protection against oxidant stress. Other
antioxidant genes are induced at birth in response to oxidant stress as an added source of
protection. These activities are essential to a cell like the alveolar macrophage which must now
populate the gas-filled alveolar space, protect against inhaled pathogens, and regulate
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surfactant homeostasis. Nonetheless, the normal lung does not buffer all the oxidant stress it
encounters at birth. Rather a transient but measurable degree of oxidant stress persists and we
propose that this level serves a physiological function in our birth shock hypothesis. As the
local redox state of lung cells changes, this signals the lung to initiate an alternative course for
postnatal lung development. It is in effect a “natural experiment with hyperoxia” as the lung
cannot predict the magnitude of the change in the oxygen environment that will ensue. It
survives by balancing a level of redox stress that limits lung injury, while permitting activation
of genes required for postnatal lung development. Birth then may serve as an integrator of
these two competing ends. Our observations about the transcription factor Klf4 (a birth shock
protein), fibroblast and myofibroblast and macrophage cell populations and the transcrip‐
tional regulators we described affecting cell proliferation, cell differentiation, and cell apop‐
tosis in our studies are likely only the beginning of understanding this hypothesis. We believe
that study of an event such as this in the newborn lung may provide new insight and strategies
to assess, support, and manipulate the oxygen environment and oxidant stress to enable a more
normal development for the premature lung at birth and repair of oxidant-induced injury in
the developing and the mature lung.
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Abstract
Due to the developmental immaturity of the lungs and other organs, the premature
newborns are more prone to develop respiratory distress syndrome (RDS) and other
problems of prematurity. The prevention of heat and water loses improves survival.
Intolerance to excessive fluids and electrolytes in the transitional period may affect urine
and  sodium  excretion  together  with  maladaptation  of  cardiovascular  system,  the
development of heart failure, and deterioration of RDS due to patent ductus arteriosus
(PDA) and further development of bronchopulmonary dysplasia (BPD). Closure of PDA
is frequently needed. The “trophic feeding” and intensive nutrition as soon as possible
prevent weight loss and further growth restriction. Greater sensitivity to pain, short‐ and
long‐term effects of inappropriately treated pain, use of opioids and sedatives are of
concern in the short‐ and long‐term outcomes. Cardiovascular stability and adequate
perfusion of the brain both affect the neurological outcome. Delayed cord clamping and
erythropoietin help maintaining adequate levels of circulating hemoglobin which might
affect later cognitive outcomes. In the following sections, detailed descriptions of non‐
pulmonary management will be presented. We conducted electronic searches of articles
on  supportive  (non‐pulmonary)  management  of  newborns  with  RDS.  Consensus
guidelines on newborns with respiratory distress have been reviewed.
Keywords: newborns, evidence‐based therapy, antenatal steroids, transport in utero,
regionalization of maternity hospitals and neonatal intensive care units, thermoregu‐
lation, fluid, nutrition, antibiotics, pain, blood pressure, perfusion, patent ductus arte‐
riosus
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1. Introduction
Non‐pulmonary management of newborns with respiratory distress syndrome (RDS) is neither
the last nor the least important part of the management, but it is supposed to be involved and
intertwined in the whole necessary work‐up integrated for the well‐being of the tinny new‐
born. Each momentum from the prenatal care, pregnancy, and finally to the birth of the newborn
should be considered when we are aiming to improve the final outcome, that is, delivery of a
healthy newborn. Pulmonary management of newborns with RDS is only one, though very
important and lifesaving, but not sufficient and adequate part of the whole care management
of the newborns with RDS.
2. Methods
This chapter will look at the importance of prenatal care, temperature control, control of
hypoglycemia, fluid and nutritional intake, the impact of perinatal infection and the use and
misuse of antibiotics, frequency of unnecessary procedures, proper pain management, the
impact of excessive use of opiates on ventilation duration in the management of newborns
with RDS. The impact of optimal blood pressure, tissue perfusion, and patent ductus arteriosus
(PDA) with hemodynamic management in newborns with RDS is going to be reviewed. Also,
the short‐ and long‐term outcomes in respect of supportive management of newborns in the
intensive care unit will be addressed. We conducted electronic searches of articles on suppor‐
tive (non‐pulmonary) management and reviewed the consensus guidelines on management
of newborns with RDS [1].
3. Prenatal care
Every newborn can develop RDS, but the likelihood among the premature infants to be affected
with the RDS is the highest [2, 3]. Therefore, as neonatal RDS is a disease predominantly
affecting the preterm newborns, all the measures to decrease preterm delivery encompass its
management. Preconception advice starting in teenage youth to prevent pregnancy in too
young teenage girls is important, and social programs should be developed and delivered
among the youths. This is not only the problem in poor countries in the world but is even more
problematic in wealthy countries with high‐gross domestic product but also extreme social
inequalities. This preconception advice is closely related to proper protection from the sexually
transmitted diseases which may also affect the fetal and later newborn's life. Both, youth
pregnancy and sexually transmitted diseases together with under‐ or malnutrition, strongly
affect the development of the fetus and premature delivery. Publically available access to the
proper maternity care, at least in well‐developed countries, should be offered to every
pregnant woman: adequate number of visits at the obstetrician's, appropriate number of
obstetric ultrasounds, teaching programs and screening for infections, developmental malfor‐
mations, etc. Special problems are unwanted pregnancies because any termination of unwant‐
ed pregnancy brings different problems to the mother and future wanted pregnancies, but it
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is worth mentioning that illegal and criminal or nonprofessional abortion endangers the health
and lives of the women [4].
In well‐organized health systems, ultrasound measurement of cervical length in midtrimester
enables prediction of preterm labor and women with short cervix (<25 mm) should be offered
vaginal progesterone treatment [5]. Women with threatening preterm labor should be
transferred by “in utero” transport to tertiary level medical centers where better outcomes in
regards to mothers and newborns can be provided [6]. In the case of preterm premature rupture
of membranes (PPROM), after reassuring maternal and fetal wellbeing threatened preterm
delivery can be delayed by antibiotics treatment for 7 days to mothers from about 23 weeks up
to 34 weeks of gestation [7]. Antibiotics reduce the rate of chorioamnionitis, preterm birth,
infection, and respiratory insufficiency [8]. On the contrary, antibiotics have not been proved
beneficial for mothers with preterm labor and intact membranes [9]. Delaying the preterm
delivery has been also proved for magnesium sulfate which also has beneficial effects for the
brain of the preterm newborn [10]. Preterm labor is efficaciously postponed by tocolytics [11].
Antenatal steroids given to mothers from about 23 weeks up to 34 weeks of gestation decrease
the risk of neonatal death, RDS, intraventricular hemorrhage (IVH), and necrotizing entero‐
colitis (NEC) [12]. Moreover, antenatal steroids given more than 24 h and <7 days before
elective cesarean section at term also influence the RDS in the late‐preterm or term newborn
[13]. Until further studies are done, one repeated dose of antenatal steroids given a week after
the first dose is recommended [14].
Chorioamnionitis describes intrauterine inflammation of maternal and fetal tissues and
endangers both, the mother and the newborn. It has been recognized as the major risk factor
for preterm birth, prematurity‐associated mortality in morbidity of newborns: the neonatal
sepsis, RDS, cystic periventricular leukomalacia (PVL), IVH, and cerebral palsy [15, 16]. Since
guidelines for the prevention of perinatal group B streptococcal (GBS) disease have been
published, the incidence of early‐onset GBS disease in newborns has dramatically decreased.
The mayor prevention key is universal antenatal GBS screening of pregnant women and
intrapartum antibiotic prophylaxis (IAP) for women with high‐risk of infection with penicillin,
ampicillin, or cefazolin. Adequate IAP is achieved by infusion of antibiotics at least 4 h before
delivery [17].
4. Interhospital, “in utero” transport, and regionalization
Interhospital air and ground transportation of critically ill neonates, regionalization, organi‐
zation of “in utero” transportations, and new tertiary perinatal centers, which care for the most
at risk premature newborns, have greatly decreased the perinatal mortality rate over the last
30 years all over the world [6]. As an example, we present the results from the Republic of
Slovenia where we have greatly decreased the perinatal mortality rate over the last 30 years
to a rate of 3.5% for neonates weighing at least 1000 g in 2006. We have organized transportation
since 1976, and we have transport “in utero” in two Slovenian perinatal centers since 1985 [18].




From the neonatal history, we learned that misunderstanding the adverse effects of low body
temperature in the premature infants was related to higher mortality rate in hypothermic
infants. With understanding the importance of normal body temperature later together with
the invention of heated air incubators, the mortality rate dropped as much as twice immedi‐
ately [19–21]. After birth, the newborn baby is exposed to extrauterine environment with
temperature changes in relation to the environmental temperatures which are usually lower
than the body temperature. Newborns and especially preterms have increased proportion of
body surface in relation to body volume, their body has low‐temperature capacity, and their
skin is immature with increased water permeability. They also have low supplies of skin fat.
Since oxygen and energy consumption are lowest in the range of thermal neutrality, it is
important to keep newborns in those limited ambient temperature ranges to enable them to
have their body temperature ranging from 36.5 to 37.5°C. By acknowledging the importance
of thermal neutrality, this is one of the most manageable problems of non‐pulmonary man‐
agement of newborns with RDS [22].
Temperature regulation enables optimal efficiency of the metabolic processes and enzyme
activities with the lowest oxygen and calorie consumption. Newborns are unable to produce
sufficient heat by metabolic reactions, by muscle activity during motion, and by nonshivering
thermogenesis in the brown fat, which starts to evolve between 26th and 30th weeks of
gestation. Loosing heath from the body is modulated by changing the vascular tone of
peripheral vessels and by sweating, which is not fully developed by the 36th week of gestation.
There are four ways newborns may lose heat to the environment. Immediately after birth, they
are wet from the amniotic fluid and evaporation decreases their body temperature fast so all
the measures to dry their body have to be taken. Recently, to decrease evaporation from the
immature water permeable skin, very premature newborns, still wet, are immediately
wrapped into plastic wraps or bags and caps [23–27]. To lessen the evaporation, the air in the
incubators for all the preterms beyond 31 weeks of gestation should be humidified (60–80%)
and preterm newborns should not be bathed until they can maintain their body temperature.
The humidity should be decreased by 5% every day if they can maintain stable body temper‐
ature, and stopped when preterms can maintain their body temperature in 40% humidity [28].
Every object radiates—it gives or receives the heat in relation to the temperature difference.
Therefore, it is important to keep the air temperature in a defined range and also to take into
account the external temperatures, the room walls and windows and the isolation walls of the
incubators [29]. Objects can lose heat by losing or gaining heat from the object in contact by
conduction. Placing the newborn baby to the mother's abdomen allows skin to skin contact
besides parental bonding and enables conduction of the heat from the mother to the child [22,
30–32]. Resuscitation on wet basis can cause a huge heat loss from the newborn and should be
avoided. Infusing cold fluids also causes conduction loss of heat. Moving air causes heat loss
by convection.
Hypothermia may lead to hypoglycemia or acidosis and has been associated with increased
mortality, increased risk of late‐onset sepsis, IVH, pulmonary insufficiency, and hemorrhage
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[20, 21]. The vicious cycle of cooling causes norepinephrine release with pulmonary and
peripheral vasoconstriction with increased right‐to‐left shunting of blood and maintenance of
fetal circulation postnatally. To enable thermal neutrality, preterm newborns should be nursed
in preheated and humidified incubators, and in heated beds after 32nd week of gestation or
>1500 g. We provide them heated and humidified gases and clothe newborns with clothes and
caps [33, 34].
6. Perinatal infection management
After the initial care of the newborn in the delivery room with drying the newborn's skin,
providing warmth, positioning the head, and clearing the airway, the evaluation of respiration,
and consequently oxygenation of peripheral organs follows. In case transitional period is
prolonged and the signs of RDS persist, we have to obtain chest radiograph, blood gas analysis
and perform sepsis work‐up with complete blood count and cultures and start empirical
antibiotic treatment with ampicillin or penicillin and gentamicin, especially if risk factors for
early‐onset sepsis are present. Early‐onset infection with GBS typically imitates the RDS in
preterm newborns with the clinical presentation and also radiographically so usually it is
difficult to differentiate pneumonia from RDS without infection. Besides GBS congenital
pneumonia can be caused by Escherichia coli and other microorganisms [35]. A well appearing
newborn to a mother with chorioamnionitis should have a limited diagnostic evaluation and
receive empirical antibiotic therapy. Well‐appearing term newborns, born to mothers with
appropriate IAP or inappropriate IAP with rupture of membranes for <18 h, need routine care
and observation. Those term newborns whose mothers had inappropriate IAP and rupture of
membranes for more than 18 h and all preterm newborns with inadequate IAP need clinical
and laboratory evaluation and observation [17, 36]. There is no evidence to support routine
antibiotic treatment of newborns with RDS and without risk factors for early‐onset sepsis [37,
38]. In those newborns with RDS which do not have laboratory signs of sepsis and have
negative cultures, the antibiotics should be discontinued as early as feasible [37, 39].
Late‐onset sepsis occurs in one‐fifth of premature newborns and is associated with increased
mortality, prolonged hospitalization, and prolonged artificial ventilation, PDA, NEC, and BPD
[40]. Newborns that were treated for neonatal sepsis later are at risk of poor weight gain and
adverse neurodevelopmental outcome [41].
7. Fluid and electrolyte management
After birth, water and electrolyte balance is influenced by transitional and developmental
adaptations of the newborn. More preterm newborns have more total body water, and
extracellular fluid volume constitutes a greater part of total body water in comparison with
term newborns. Furthermore, after birth, renal function of preterm newborns is reduced in
comparison with term newborns and they lose more weight with diuresis which results from
Non‐Pulmonary Management of Newborns with Respiratory Distress
http://dx.doi.org/10.5772/63386
143
an isotonic reduction of extracellular fluid. Newborns, especially more preterm ones loose
water insensibly through the skin and respiratory system, especially in RDS, when respiratory
rate is increased [42, 43]. Insensible water loss is increased by radiant heaters, phototherapeutic
lights, and inappropriate water content of inspired air. Antenatal steroids besides the already
mentioned effect on lung maturation also accelerate skin and kidney maturation. Preterm
newborns whose mothers have received antenatal steroids had lower insensible water loss,
less hypernatremia, earlier diuresis and natriuresis, and less nonoliguric hyperkalemia [44,
45]. In the first postnatal days, water balance is kept in a slightly negative state. Excessive fluid
administration is associated with increased risk of PDA, NEC, and BPD [46]. Fluid balance and
volume status can be evaluated by physical examination with signs of hydration, edema, and
hemodynamic stability, body weight loss or gain, balance of fluid intake and output, and
biochemistry evaluation of electrolyte concentration in plasma of the newborns. Fluid
requirements therefore account for maintenance requirements, obligatory losses, and possible
deficits and are gestational and postnatal age, ambient temperature and humidity, renal and
respiratory function dependent. The electrolyte requirements for sodium, potassium, and
chloride are approximately 1–2 mEq/kg/day except for the first day when isotonic reduction
of extracellular fluid ensues. Diuretics cause electrolyte disturbances due to urinary loss of
sodium and potassium and loop diuretics are associated with nephrocalcinosis so we prefer
not to use them routinely [47].
8. Nutritional management
The newborn's nutritional status is influenced by his past history with genetic background,
maternal body composition, and nutrition before and during pregnancy [48]. Many preterm
newborns are born growth restricted because of inadequate intrauterine nutrient supply.
Postnatal nutrition and metabolic capacity impact postnatal growth and development and
have long‐term consequences on the lung, brain, and other organ development and cognitive
function [49]. The newborn’s brain consumes half of all the energy provided, and too little
calories mean less brain volume and worse neurocognitive outcome. Adequate volume of
fluids, the protein content, and energy balance in the newborn’s, and especially preterm’s
nutrition should cover metabolic expenditure and growth requirements, thus setting the
ground for optimal outcomes.
In newborns with RDS, early enteral feeding is frequently delayed because of concomitant
medical problems and fear of complications as the feeding intolerance and NEC. Therefore,
the parenteral nutrition is commenced as early as possible to correct prenatal, to prevent
postnatal growth failure and to improve outcomes [50, 51]. The parenteral nutrition has to
provide enough calories for energy and growth, which are met by carbohydrates, proteins,
and lipids. Carbohydrates provide glucose, proteins provide essential amino acids and
nitrogen, and lipids provide essential fatty acids. Essential nutrients needed for growth are
electrolytes, vitamins, minerals, and trace elements [52–54].
The premature newborn needs parenterally about 100 kcal/kg/day of nonprotein energy for
growing, 3/5 in the form of carbohydrates and 2/5 in the form of lipids. Glucose is the form of
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carbohydrates that we give parenterally, and it is the primary energy supply for the newborn's
brain. We start with 7 g/kg/day of glucose, which provides 4.8 mg/kg/min of glucose, and we
increase the amount by 1.5–2 g/kg/day, up to 15 g/kg/day and maximum of 18 g/kg/day (12.5 
mg/kg/min). Preterm newborns are prone to hypoglycemia because of higher glucose needs,
decreased fat stores, and higher‐energy consumption. On the other hand, for many metabolic
and nutritional reasons, they are also prone to hyperglycemia. As early as feasible, we start
with 2 g/kg/day of proteins and increase the amount by 0.5–1 to 3.5–4 g/kg/day of proteins,
which is needed to attain the intrauterine growth rate [55, 56]. It is also important to provide
the preterm 25 nonprotein kcal/1 g of proteins. Low blood urea nitrogen (BUN) is a sign of
inadequate protein intake, but a high BUN does not correlate well with a high protein intake
[57]. A preterm newborn daily loses 1 g of proteins through the kidneys, and a good caloric
input with appropriately balanced diet accumulates 2 g of proteins. Thus, improperly balanced
nutrition of a newborn can lead to a loss of 15% of protein mass in 2 days [58]. There are eight
essential amino acids in parenteral nutrition and six more for the preterm newborn. Adding
cysteine to the parenteral nutrition improved nitrogen balance [59], but the addition of
glutamine had no clinical impact [60]. Concomitantly with proteins, we administer 20% of
intravenous lipids, including essential fatty acids and long‐chain n–3 polyunsaturated fatty
acids and start with 1 g/kg/day and increase by 0.5 g/kg/day to a maximum of 3–4 g/kg/day
[61–63]. Already 0.5 g/kg/day may provide prevention of essential fatty acid deficiency, and
the tolerance is guided by triglyceride level of <200 mg/dL. The tolerance is better achieved
with the use of continuous infusion of intravenous lipids over 24 h rather than intermittent
dosing [64].
To maintain bone health, the newborns need 1.5–2 mmol/kg/day of calcium and the same
amount of phosphorus, and 0.18–0.3 mmol/kg/day of magnesium. The optimal weight ratio of
calcium and phosphorus is 1.3–1.7:1. Pediatric vitamin formulations of water‐ and fat‐soluble
vitamins and trace elements are in use, but they do not provide enough amounts of vitamin
A, D and E so we add them enterally if feasible. Vitamin A affects normal eye and lung
development, immunity, and cell differentiation. Supplementation of vitamin A in preterm
newborns was associated with reduced risk of oxygen requirement [65]. Selenium supple‐
mentation prevented short‐term morbidity in preterm newborns [66]. Although carnitine
supplementation was not associated with weight gain or apnea reduction [67, 68] there are
recommendations to add parenteral carnitine to preterm newborns needing parenteral
nutrition for more than 2 weeks [69]. Nutritional status can be evaluated by anthropometry,
body composition and biochemistry, clinical assessment and quantity, and quality dietary
evaluation. Adverse effects of parenteral nutrition include line infection and sepsis, extrava‐
sation of parenteral fluid, cholestasis, and bone disease.
To correct the intrauterine growth restriction and achieve appropriate postnatal weight gain,
the enteral feeding is also of great significance [70]. It is important to start enteral feeding as
early as feasible; in very low birth weight (VLBW) newborns 10–20 mL/kg/day is started in the
first 2–5 days, in low birth weight (LBW) newborns in first days [71]. Colostrum acts as the
immune therapy for the newborn's intestine. Feeding newborns with minimal volumes of milk
is known as trophic feeding, which has many beneficial effects for further feeding, increased
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hormone secretion, motility, and decreased permeability of the gastrointestinal tract [72]. After
a few days of gastrointestinal priming, feedings are increased by 10–20 mL/kg/day. Human
milk in comparison with formula resulted in earlier adequate energy intake [73, 74]. Fast
advancement of milk volume has no adverse outcome in comparison with slow advancement
[71]. Feeding every two hours was superior to feeding every three hours in regards to the time
to reach full enteral feeds and better weight gain [75]. Tube feeding can be bolus or continuous
and neither is superior [76]. Feeding intolerance can be determined by emesis, gastric residuals,
distended, and tender abdomen with changed bowel sounds and stool output, but most of
them have little prognostic value [77–80]. The prokinetic erythromycin has not been shown to
be effective [81–83]. When the newborn tolerates 100 mL/kg/day or has been consuming
mother's milk for 1 week, formula or mother's milk is fortified. The goal of enteral feeding of
the preterm newborn is to gain more than 15 g/kg/day.
9. Pain management
Critically ill newborn is confronted with different, more or less painful procedures every day
in the NICU. Not every procedure is painful, but the usual response from the newborn is typical
—removal of the affected part of the body and crying. The more severe the pain, the more
distressful situation is for the newborn. Brain not yet fully developed may receive too many
painful stimulations per day, and the tinny newborn may overreact even if the next stimulus
is less or even not painful. Newborn Individualized Developmental Care and Assessment
Program (NIDCAP) is a method of ensuring an adequate physical environment, reducing
overwhelming sensory stimulations, and increasing sensitive parent caregiving, for proper
brain growth and development of preterm newborns. Despite non‐convincing evidence that
NIDCAP improves long‐term neurodevelopmental or short‐term medical outcome, there is a
need for high‐quality researches using different techniques to diminish high environmental
stress on the premature infants during their treatment in the NICU [84].
Newborns with RDS experience different kinds of pain depending on their morbidities: skin
breaking procedures and tissue injury provoke acute or physiological pain, surgery, localized
inflammation, and birth trauma cause established pain and diseases like NEC, meningitis, and
scalded skin syndrome give rise to prolonged or chronic pain [85]. It has been estimated that
sick newborns experience 12–16 procedures each day which are increasingly painful:
1. Routine procedures (physical examination, diaper changes, nasogastric or orogastric
insertion, bladder catheterization) [86];
2. Moderately invasive procedures (endotracheal suction, heel lance, venipuncture, arterial
puncture, peripherally inserted central catheter placement); and
3. Severely invasive procedures (central venous line placement, chest tube insertion) [87].
Management of pain in newborns with RDS encompasses prevention with first awareness of
causing pain with different painful procedures and reduction of painful management of the
newborn. The second line includes objective assessment for the detection of pain in each
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—removal of the affected part of the body and crying. The more severe the pain, the more
distressful situation is for the newborn. Brain not yet fully developed may receive too many
painful stimulations per day, and the tinny newborn may overreact even if the next stimulus
is less or even not painful. Newborn Individualized Developmental Care and Assessment
Program (NIDCAP) is a method of ensuring an adequate physical environment, reducing
overwhelming sensory stimulations, and increasing sensitive parent caregiving, for proper
brain growth and development of preterm newborns. Despite non‐convincing evidence that
NIDCAP improves long‐term neurodevelopmental or short‐term medical outcome, there is a
need for high‐quality researches using different techniques to diminish high environmental
stress on the premature infants during their treatment in the NICU [84].
Newborns with RDS experience different kinds of pain depending on their morbidities: skin
breaking procedures and tissue injury provoke acute or physiological pain, surgery, localized
inflammation, and birth trauma cause established pain and diseases like NEC, meningitis, and
scalded skin syndrome give rise to prolonged or chronic pain [85]. It has been estimated that
sick newborns experience 12–16 procedures each day which are increasingly painful:
1. Routine procedures (physical examination, diaper changes, nasogastric or orogastric
insertion, bladder catheterization) [86];
2. Moderately invasive procedures (endotracheal suction, heel lance, venipuncture, arterial
puncture, peripherally inserted central catheter placement); and
3. Severely invasive procedures (central venous line placement, chest tube insertion) [87].
Management of pain in newborns with RDS encompasses prevention with first awareness of
causing pain with different painful procedures and reduction of painful management of the
newborn. The second line includes objective assessment for the detection of pain in each
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neonate. Thirdly, controlling the pain includes cooperation with parents to diminish pain
experience, delivering proper analgesia before expected painful medical care and combining
nonpharmacological interventions and pharmacological therapy [88–90].
An important issue in caring for a newborn with RDS is minimal handling or “do not touch”
approach. This also enables us to take in mind the possible pain we are going to cause to the
newborn with our intended handling and executed procedures. On the other hand, we have
to carefully plan the management not to compromise the well‐being of the newborn by not
performing vital examinations and investigations. By planning the handling of the newborn
in limited number of sessions per day, it is possible to disrupt the newborns less times and
perform the examinations, nursing care, and blood withdrawal at the same time. We should
use laboratory equipment that enables us to analyze several different chemical substances from
one small blood sample to reduce the volume of blood taken from the child and avoid
iatrogenic anemia. All sick newborns with RDS need intravenous line for fluid, nutritional,
antimicrobial, blood pressure, and pain management so a central venous line as soon as
possible and for newborns who need several blood investigations per day an artery line should
be placed both with appropriate analgesia. With minimally invasive approach, we can gain
many data on the well‐being of the newborn by noninvasive monitoring with the use of
transcutaneous measuring of the oxygen saturation in peripheral arteries and in different
organs by the use of near-infrared spectroscopy (NIRS), partial pressures of oxygen, and
carbon dioxide in skin capillaries or bilirubin concentrations [85, 89, 91].
For the assessment of pain, different observational scales designed for special newborn
population are in use, which encompass many physiological and behavioral variables.
Especially with observation of behavior, there is much subjectivity in the assessment proce‐
dure. The available assessment scales have proved usable in acute pain, but there is limited
applicability of the assessment scales for assessing prolonged pain, pain in extremely low birth
weight (ELBW) newborns and in those receiving paralytic agents [85].
First step on the ladder of pain management constitutes the nonpharmacological measures
which include sweet peroral solutions, breastfeeding, sucking, skin‐to‐skin contact, and
swaddling with facilitated tucking and sensorial saturation [92]. Combined use of nonphar‐
macological measures act synergistically [93–95]. Furthermore, when used with pharmaco‐
logical measures, the pharmacologic use is lesser in frequency and dosage [88, 96]. Sucrose
and glucose used before skin‐breaking procedures reduced total crying time, lessened changes
of physiological variables, and facial expressions and pain scores of multidimensional pain
assessment scales [97, 98]. Currently, it is not entirely clear how sweet solutions suppress the
responses to painful stimulation; do they only diminish the response to pain or they really
influence the pain perception. With repeated dosing, there is a concern on neurodevelopmental
outcome in the preterm newborns [99]. Sucrose alone is used for minor procedures, and
combined with other analgesics for moderately painful procedures [97]. In cases when
physically possible, breastfeeding or mother's milk is at least as effective as sweet solutions
[100]. Further on, engaging different body sensors with sensations, like non‐nutritive sucking,
swaddling, facilitated tucking, rocking, holding, kangaroo care and sensorial saturation, gives
the brain other stimuli and therefore the brain has closed door for pain reception [88, 92].
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Topical analgesia with the use of Eutectic Mixture of Local Anesthetics (EMLA) or lidocaine
alone are used with effect in venous, arterial, and lumbar punctures and also venous, arterial
catheter placement, and circumcision. With reasonable dosing, methemoglobinemia is not a
significant problem [101].
Systemic analgesia can be provided by nonopioid, nonsteroidal anti‐inflammatory agents,
opioid analgesics, and sedatives. Paracetamol (acetaminophen) does not diminish pain
perception after assisted vaginal birth, heel lance, or eye examination. Paracetamol may
diminish the need for morphine after surgical procedures in newborns [102]. We use nonster‐
oidal anti‐inflammatory agents for closing PDA in preterm newborns, but because of their
serious adverse effects, like gastrointestinal bleeding, platelet dysfunction and decreased
glomerular filtration rate, we do not use them as analgesics in newborns. The most powerful
analgesics are opioids, and morphine is the most frequently used, either intermittently for
acute pain with invasive procedures or continuously for established pain during artificial
ventilation or after surgery. Morphine reduces acute pain after some invasive procedures:
central line, tracheal, and chest tube insertion [103, 104], but not heelstick [105] or tracheal
suctioning [106, 107]. The NEOPAIN study showed no difference in mortality rate, severe IVH
and PVL between ventilated preterm newborns receiving continuous morphine or placebo.
The preterm newborns treated with morphine had less pain, but more hypotension, longer
duration of artificial ventilation and longer time to full volume feeds [103]. Morphine is safe
and effective for treating established pain after surgery in newborns [108, 109]. In extremely
preterm newborns, opioid analgesics should be used cautiously [110, 111].
More rapid analgesia with fewer hemodynamic adverse effects is achieved by fentanyl and
shorter‐acting derivatives, which is suitable for acute invasive procedures in controlled clinical
setting like tracheal tube and central line placement [112, 113]. There was no favorable effect
on established pain during artificial ventilation of premature newborns using fentanyl [114].
Furthermore, premature newborns treated with continuous fentanyl had prolonged time of
artificial ventilation and of meconium passage. Fentanyl is used for treating established pain
after surgery and in newborns with pulmonary hypertension.
Ketamine causes analgesia with sedation and amnesia with no effect on respiration and
increasing blood pressure and heart rate [115]. It is used in newborns with hemodynamic
instability for acute pain with invasive procedures and for established pain during and after
surgery [116]. Among sedatives midazolam which can cause prolonged sedation in sick
preterm newborns is not recommended for use in preterm newborns [117].
Painful experiences in early childhood may have unfavorable consequences for neurodevel‐
opment [118, 119]. Although there are some data indicating that prolonged use of analgesics
in newborns does not influence long‐term neurodevelopmental and behavioral outcome [120–
122], more recent studies have shown some adverse long‐term effects on growth, neurological,
and behavioral outcome [123]. A positive autonomic nervous system's stability to pain in
neonates with kangaroo care or skin to skin care can be proved by measuring heart rate
variability [124, 125].
Respiratory Management of Newborns148
Topical analgesia with the use of Eutectic Mixture of Local Anesthetics (EMLA) or lidocaine
alone are used with effect in venous, arterial, and lumbar punctures and also venous, arterial
catheter placement, and circumcision. With reasonable dosing, methemoglobinemia is not a
significant problem [101].
Systemic analgesia can be provided by nonopioid, nonsteroidal anti‐inflammatory agents,
opioid analgesics, and sedatives. Paracetamol (acetaminophen) does not diminish pain
perception after assisted vaginal birth, heel lance, or eye examination. Paracetamol may
diminish the need for morphine after surgical procedures in newborns [102]. We use nonster‐
oidal anti‐inflammatory agents for closing PDA in preterm newborns, but because of their
serious adverse effects, like gastrointestinal bleeding, platelet dysfunction and decreased
glomerular filtration rate, we do not use them as analgesics in newborns. The most powerful
analgesics are opioids, and morphine is the most frequently used, either intermittently for
acute pain with invasive procedures or continuously for established pain during artificial
ventilation or after surgery. Morphine reduces acute pain after some invasive procedures:
central line, tracheal, and chest tube insertion [103, 104], but not heelstick [105] or tracheal
suctioning [106, 107]. The NEOPAIN study showed no difference in mortality rate, severe IVH
and PVL between ventilated preterm newborns receiving continuous morphine or placebo.
The preterm newborns treated with morphine had less pain, but more hypotension, longer
duration of artificial ventilation and longer time to full volume feeds [103]. Morphine is safe
and effective for treating established pain after surgery in newborns [108, 109]. In extremely
preterm newborns, opioid analgesics should be used cautiously [110, 111].
More rapid analgesia with fewer hemodynamic adverse effects is achieved by fentanyl and
shorter‐acting derivatives, which is suitable for acute invasive procedures in controlled clinical
setting like tracheal tube and central line placement [112, 113]. There was no favorable effect
on established pain during artificial ventilation of premature newborns using fentanyl [114].
Furthermore, premature newborns treated with continuous fentanyl had prolonged time of
artificial ventilation and of meconium passage. Fentanyl is used for treating established pain
after surgery and in newborns with pulmonary hypertension.
Ketamine causes analgesia with sedation and amnesia with no effect on respiration and
increasing blood pressure and heart rate [115]. It is used in newborns with hemodynamic
instability for acute pain with invasive procedures and for established pain during and after
surgery [116]. Among sedatives midazolam which can cause prolonged sedation in sick
preterm newborns is not recommended for use in preterm newborns [117].
Painful experiences in early childhood may have unfavorable consequences for neurodevel‐
opment [118, 119]. Although there are some data indicating that prolonged use of analgesics
in newborns does not influence long‐term neurodevelopmental and behavioral outcome [120–
122], more recent studies have shown some adverse long‐term effects on growth, neurological,
and behavioral outcome [123]. A positive autonomic nervous system's stability to pain in
neonates with kangaroo care or skin to skin care can be proved by measuring heart rate
variability [124, 125].
Respiratory Management of Newborns148
10. Blood pressure and perfusion management
Systemic blood pressure is dependent on systemic blood flow with cardiac output and systemic
vascular resistance. Hypotension ensues in cases of decreased cardiac output as a result of
cardiac dysfunction or hypovolemia with inadequate compensation with vasomotor tone, or,
decreased vasomotor tone with inadequate compensatory increase in cardiac output. Hypo‐
tension, especially in preterms, is difficult to define unequivocally; population‐based norma‐
tive blood pressure data show the increment of blood pressure with increasing gestational and
postnatal age, but normal gestational and postnatal age dependent blood pressure range is not
known [126]. The physiological principles of blood pressure define autoregulatory threshold
where there is loss of autoregulation of blood flow to vital organs, functional threshold where
there is loss of cellular function, and ischemic threshold where there is loss of functional
integrity [127]. Blood pressure correlates poorly with systemic and cerebral blood flow;
therefore, different measurement approaches combined with clinical assessment of adequate
perfusion have been investigated for the purpose of better hemodynamic monitoring. Systemic
blood flow can be measured by clinician performed ultrasound of the heart and blood vessels
with the pressure wave‐form analysis and by magnetic resonance imaging (MRI) [128, 129].
Systemic resistance is evaluated by Laser‐Doppler technique and by NIRS [130]. Noninva‐
sively, NIRS gives us information about oxygenation of organs, inferring about oxygen
delivery, and oxygen demand of certain tissues. The brain activity can continuously be
monitored by concomitant use of NIRS and amplitude integrated electroencephalography
(EEG) [131, 132].
The blood flow is regulated by cardiac output, carbon dioxide tension, local neuronal and
chemical activity, changes in cerebrospinal fluid hydrogen ion concentration, arterial oxygen
content, hemoglobin, and blood glucose [133–135]. Accordingly, systemic blood flow can be
improved by inotropes or volume, and systemic resistance can be improved by vasopressors
and lusitropes. Treatment of neonatal hypotension improves blood pressure, cardiac output,
organ blood flow, lactic acidosis, peripheral perfusion, and urine output. Neonatal hypoten‐
sion endangers cerebral autoregulation and increases morbidity and mortality in preterm
newborns [136, 137].
Low systemic blood pressure frequently occurs in the early stages of RDS. Therefore, blood
pressure should frequently be measured, either noninvasively or invasively with intravascular
line. For volume expansion, after hypovolemia crystalloid or colloid solutions are used [138,
139]. For decreased cardiac output because of cardiac dysfunction, the initial agent is dopa‐
mine, later dobutamine, and epinephrine are added [140, 141]. In newborns with refractory
hypotension or high‐dose inotropic therapy, glucocorticoid therapy increases blood pressure
[142, 143]. Different developmental factors affect hemodynamic response to sympathomimetic
amines in newborns [144]. Before deciding on a specific therapy of hypotension, potentially
reversible causes have to be taken in mind and corrected if possible (measurement error, blood
loss, pneumothorax, sepsis, adrenocortical insufficiency).
There is conflicting evidence on the management of hypotension improving clinically mean‐
ingful longer‐term outcome measures in VLBW newborns, but there are many confounding
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factors influencing the outcome of management of preterm newborns and studies are weak to
show the impact [145–148].
Besides cardiac output, the oxygen supply to the tissues depends also on the content of oxygen
in the arteries, which is in the biggest part a function of concentration of hemoglobin. Target
values of hemoglobin or hematocrit differ with regards to the gestational and postnatal age of
the newborn, the rate of evolution of anemia, the presence of clinical signs of anemia, and the
degree of respiratory support [149]. Targeting to lower concentrations of hemoglobin in ELBW
newborns might have no effect on short‐term outcomes, but may have a negative impact on
the longer‐tem neurodevelopmental outcome [150, 151]. Anemia can be avoided or postponed
by delayed cord clamping or cord milking and also by applications of erythropoietin. Delayed
cord clamping and cord milking in preterm newborns was associated with higher hematocrit,
fewer transfusions, less IVH, NEC, and no increased need for phototherapy because of jaundice
[152–156]. Also, preterm newborns who were receiving erythropoietin received fewer
transfusions and had higher cognitive scores at 18–22 months of corrected age [157, 158].
11. PDA management
Shunting blood from the aorta to the pulmonary artery means decreased blood flow in the
systemic circulation and low perfusion of peripheral organs and increased blood flow in the
pulmonary circulation with RDS, pulmonary edema, BPD, IVH, NEC, and heart failure.
Newborns with PDA have higher mortality rate and increased risk of pulmonary edema,
hemorrhage, and BPD. The field of management of the PDA is an area in neonatal practice
which has, perhaps, changed the most in the last decades and many questions still remain
unanswered. The uses of antenatal steroids, postnatal surfactant, and the gentler modes of
ventilation with lower oxygen saturation targets may have lowered the incidence and the
impact of clinically significant PDA shunt. In VLBV newborns with RDS, PDA is present in
30% [159, 160]. Current management of the PDA generally includes three approaches.
Supportive care for newborns with PDA encompasses providing thermal neutrality, using
PEEP, keeping hematocrit between 35 and 40%, fluid restriction of 110–130 ml/kg/day,
permissive hypercapnia, low oxygen saturation targets and, in case of diuretic need, thiazide
diuretics over loop diuretics. If the newborn has poor perfusion, a large left‐to‐right shunt and
remains artificially ventilated for a longer time a course of cyclooxygenase (COX) inhibitors is
administered, favoring ibuprofen over indomethacin, because the latter is reducing blood flow
to the brain, gastrointestinal tract, and kidneys [161, 162]. Ibuprofen is efficacious for closing
PDA given either intravenously or orally [163]. Newborns, who remain artificially ventilated
and have failed to respond to COX inhibitor, are candidates for surgical ligation, which has
been associated with adverse long‐term outcomes [164].
The prophylactic therapy to reduce the incidence of PDA has not been proved to be of benefit.
The prophylactic indomethacin has been shown to have no impact on mortality, neurologic
impairment, BPD, or NEC although it was associated with reduction of hemodynamically
important PDA and severe IVH [165]. The prophylactic ibuprofen has been linked with adverse
effects [166, 167].
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12. Postnatal supplemental management of respiratory support
Apnea of prematurity is a developmental consequence of immature respiratory center in
premature newborns. Besides mechanical ventilation with oxygen supplementation the
management of apnea of prematurity encompasses supportive measures like assuring the
temperature stability, proper positioning of the newborn's head and neck and ensuring the
nasal patency. Methylxanthines stimulate the respiratory drive by increasing the responsive‐
ness of respiratory center to carbon dioxide and decreasing its hypoxic depression. The
medicines also have inotropic effects on respiratory muscles [168]. Caffeine is being preferred
over theophylline and other agents [169]. Caffeine therapy has been proved to shorten the
duration of mechanical ventilation and supplemental oxygen and also reducing the risk of
BPD and PDA ligation [170, 171]. The same effects have been shown for prophylactic use of
caffeine in very preterm newborns [172, 173]. There have been some positive neurodevelop‐
mental effects of caffeine therapy proved during follow‐up of children treated with caffeine
during neonatal period [174–176].
The duration of mechanical ventilation can be shortened and the risk of BPD diminished by
the use of postnatal tapering course of low‐ (<0.2 mg/kg/day) or even very low‐dose
dexamethasone (0.05 mg/kg/day) [177, 178]. Hydrocortisone has been proved to have the same
beneficial effects on earlier extubating of mechanically ventilated preterm newborns [179].
13. Conclusion
For the best outcomes of newborns with RDS, besides optimal pulmonary management, it is
of extreme importance to have optimal supportive care (Table 1) starting prenatally and
aiming at newborns being delivered in highly specialized tertiary centers with timing of birth
after completion of a course of prenatal steroids. Body temperature should be maintained
between 36.5 and 37.5°C. Preterm newborns should be nursed in incubators with high relative
humidity (60–80%) and started on intravenous fluids of 70–80 ml/kg/day, later managed
individually, based on weight change and serum electrolyte concentrations. Both parenteral
and minimal enteral nutrition should be started as early as possible—from day 1—and quickly
increased to 3.5 g/kg/day of proteins and 3 g/kg/day of lipids. Proper infection control starts
prenatally with administering antibiotics to women with preterm prelabor rupture of mem‐
branes, and before labor to those with risk factors for early‐onset sepsis. Furthermore,
antibiotics are given to newborns with RDS until early‐onset sepsis is ruled out. Adequate
treatment of pain may be associated with decreased complications and mortality. Sedatives
do not provide pain relief and may mask newborn's response to pain. Additionally, proper
management of the PDA and hemodynamic support of the circulation with good systemic
perfusion and oxygenation are also of utmost importance for the best outcomes of newborns
with RDS.
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Prenatal care All the measures to prevent preterm delivery should be taken (counseling, progesterone, antibiotic,
magnesium sulfate, tocolysis)
If possible, birth should be delayed to allow effect of antenatal steroid therapy to the mother
Timely and safe transport of the expectant mother to specialized tertiary centers
Appropriate intrapartum antibiotic prophylaxis
Delivery room
stabilization
Delayed cord clamping or cord milking at birth
Collecting cord blood for diagnostic purposes (hemogram, hemoculture, blood group, virology)
Stabilization of the preterm newborn in a plastic bag under a radiant warmer
Drying the newborn's skin, providing warmth, positioning the head and clearing the airway,
evaluation of respiration and oxygenation of peripheral organs
Supportive
care
Nursing the newborn in incubators with heated and humidified air
In cases with risk factors for early-onset sepsis and/or clinical and laboratory signs of sepsis antibiotics
should be started
Insertion of central lines to enable blood withdrawal for diagnostic purposes and parenteral nutrition
Careful fluid and electrolyte therapy
Early parenteral nutrition and early trophic feeding
Minimal handling with clustered care of examination, blood withdrawal and nursing care at the same
time but not to overburden the neonate
Regular use of appropriate pain assessment scales and proper analgesia before planned procedures
Regular measurement of blood pressure and assessment of peripheral perfusion to decide on possible
hemodynamic therapy
Targeting hemoglobin or hematocrit values in regards to the gestational and postnatal age, the rate of
evolution of anemia, the presence of clinical signs of anemia and the degree of respiratory support
needed
Consideration on the presence and clinical significance of patent ductus arteriosus to decide on
possible therapies
Caffeine therapy to minimize the need for and duration of ventilation
Consideration on postnatal tapering course of low- or very low-dose dexamethasone or
hydrocortisone
Adapted from Sweet et al. [1].
Table 1. Summary of recommendations for non-pulmonary management of newborns with respiratory distress.
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